TOXICOLOGICAL PROFILE FOR
1,2-DIBROMOETHANE

Agency for Toxic Substances and Disease Registry
U.S. Public Health Service

July 1992
DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.
The Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) extended and amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous substances which are most commonly found at facilities on the CERCLA National Priorities List and which pose the most significant potential threat to human health, as determined by ATSDR and the Environmental Protection Agency (EPA). The lists of the 250 most significant hazardous substances were published in the Federal Register on April 17, 1987; on October 20, 1988; on October 26, 1989; and on October 17, 1990. A revised list of 275 substances was published on October 17, 1991.

Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the lists. Each profile must include the following content:

(A) An examination, summary, and interpretation of available toxicological information and epidemiological evaluations on the hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure which present a significant risk to human health of acute, subacute, and chronic health effects.

(C) Where appropriate, an identification of toxicological testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile is intended to characterize succinctly the toxicological and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicological properties. Other pertinent literature is also presented but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.
Foreword

Each toxicological profile begins with a public health statement, which describes in nontechnical language a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health will be identified by ATSDR, the National Toxicology Program (NTP) of the Public Health Service, and EPA. The focus of the profiles is on health and toxicological information; therefore, we have included this information in the beginning of the document.

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

This profile reflects our assessment of all relevant toxicological testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control, the NTP, and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

William L. Roper, M.D., M.P.H.
Administrator
Agency for Toxic Substances and Disease Registry
CONTENTS

FOREWORD ................................................................. iii

LIST OF FIGURES ......................................................... ix

LIST OF TABLES .......................................................... xi

1. PUBLIC HEALTH STATEMENT ........................................ 1
   1.1 WHAT IS 1,2-DIBROMOETHANE? .................................. 1
   1.2 HOW MIGHT I BE EXPOSED TO 1,2-DIBROMOETHANE? .......... 2
   1.3 HOW CAN 1,2-DIBROMOETHANE ENTER AND LEAVE MY BODY?  2
   1.4 HOW CAN 1,2-DIBROMOETHANE AFFECT MY HEALTH? .......... 3
   1.5 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 1,2-DIBROMOETHANE? .......... 3
   1.6 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? .................. 4
   1.7 WHERE CAN I GET MORE INFORMATION? ....................... 4

2. HEALTH EFFECTS ..................................................... 5
   2.1 INTRODUCTION .................................................... 5
   2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE .... 5
      2.2.1 Inhalation Exposure ......................................... 6
         2.2.1.1 Death .................................................. 6
         2.2.1.2 Systemic Effects ...................................... 15
         2.2.1.3 Immunological Effects ................................ 19
         2.2.1.4 Neurological Effects .................................. 20
         2.2.1.5 Developmental Effects ................................ 20
         2.2.1.6 Reproductive Effects .................................. 21
         2.2.1.7 Genotoxic Effects ...................................... 23
         2.2.1.8 Cancer .................................................. 23
      2.2.2 Oral Exposure ................................................ 26
         2.2.2.1 Death .................................................. 26
         2.2.2.2 Systemic Effects ...................................... 31
         2.2.2.3 Immunological Effects ................................ 33
         2.2.2.4 Neurological Effects .................................. 33
         2.2.2.5 Developmental Effects ................................ 33
         2.2.2.6 Reproductive Effects .................................. 33
         2.2.2.7 Genotoxic Effects ...................................... 34
         2.2.2.8 Cancer .................................................. 35
      2.2.3 Dermal Exposure .............................................. 37
         2.2.3.1 Death .................................................. 37
         2.2.3.2 Systemic Effects ...................................... 37
         2.2.3.3 Immunological Effects ................................ 40
         2.2.3.4 Neurological Effects .................................. 40
         2.2.3.5 Developmental Effects ................................ 41
         2.2.3.6 Reproductive Effects .................................. 41
         2.2.3.7 Genotoxic Effects ...................................... 41
         2.2.3.8 Cancer .................................................. 41
2.3 TOXICOKINETICS  ................................................. 42
  2.3.1 Absorption ................................................. 42
    2.3.1.1 Inhalation Exposure ...................................... 42
    2.3.1.2 Oral Exposure ........................................... 42
    2.3.1.3 Dermal Exposure ......................................... 42
  2.3.2 Distribution .................................................. 43
    2.3.2.1 Inhalation Exposure ...................................... 43
    2.3.2.2 Oral Exposure ........................................... 43
    2.3.2.3 Dermal Exposure ......................................... 43
    2.3.2.4 Other Routes of Exposure ................................ 45
  2.3.3 Metabolism .................................................... 45
  2.3.4 Excretion ..................................................... 50
    2.3.4.1 Inhalation Exposure ...................................... 50
    2.3.4.2 Oral Exposure ........................................... 51
    2.3.4.3 Dermal Exposure ......................................... 51
    2.3.4.4 Other Routes of Exposure ................................ 51

2.4 RELEVANCE TO PUBLIC HEALTH  .................................. 51

2.5 BIOMARKERS OF EXPOSURE AND EFFECT  ......................... 63
  2.5.1 Biomarkers Used to Identify and/or Quantify Exposure to
       1,2-Dibromoethane .............................................. 64
  2.5.2 Biomarkers Used to Characterize Effects Caused by
       1,2-Dibromoethane .............................................. 65

2.6 INTERACTIONS WITH OTHER CHEMICALS  ........................ 66

2.7 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE ............... 67

2.8 MITIGATION OF EFFECTS ........................................ 67

2.9 ADEQUACY OF THE DATABASE .................................... 68
  2.9.1 Existing Information on Health Effects of
       1,2-Dibromoethane .............................................. 69
  2.9.2 Data Needs .................................................. 71
  2.9.3 On-going Studies ............................................ 76

3. CHEMICAL AND PHYSICAL INFORMATION  ............................ 77
  3.1 CHEMICAL IDENTITY ............................................. 77
  3.2 PHYSICAL AND CHEMICAL PROPERTIES  .......................... 77

4. PRODUCTION, IMPORT, USE, AND DISPOSAL  ..................... 81
  4.1 PRODUCTION .................................................... 81
  4.2 IMPORT/EXPORT ................................................ 81
  4.3 USE ............................................................ 81
  4.4 DISPOSAL ....................................................... 84

5. POTENTIAL FOR HUMAN EXPOSURE .................................. 85
  5.1 OVERVIEW ....................................................... 85
  5.2 RELEASES TO THE ENVIRONMENT ................................ 85
    5.2.1 Air ........................................................ 90
    5.2.2 Water ....................................................... 90
    5.2.3 Soil ........................................................ 90
  5.3 ENVIRONMENTAL FATE ............................................ 91
    5.3.1 Transport and Partitioning ................................ 91
    5.3.2 Transformation and Degradation .......................... 91
      5.3.2.1 Air ..................................................... 91
5.3.2.2 Water ........................................ 91
5.3.2.3 Soil ........................................ 92
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT .......... 92
5.4.1 Air .......................................... 92
5.4.2 Water ....................................... 93
5.4.3 Soil ......................................... 94
5.4.4 Other Environmental Media .................................. 94
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE ............. 94
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES ............... 95
5.7 ADEQUACY OF THE DATABASE ................................ 95
5.7.1 Data Needs .................................... 96
5.7.2 On-going Studies .................................... 98

6. ANALYTICAL METHODS .................................. 99
6.1 BIOLOGICAL MATERIALS ................................ 99
6.2 ENVIRONMENTAL SAMPLES ................................ 99
6.3 ADEQUACY OF THE DATABASE ................................ 104
6.3.1 Data Needs .................................... 104
6.3.2 On-going Studies .................................... 105

7. REGULATIONS AND ADVISORIES ............................... 107

8. REFERENCES .......................................... 111

9. GLOSSARY ............................................. 145

APPENDICES

A. USER'S GUIDE ........................................ A-1
B. ACRONYMS, ABBREVIATIONS, AND SYMBOLS ...................... B-1
C. PEER REVIEW ........................................ C-1
LIST OF FIGURES

2-1 Levels of Significant Exposure to 1,2-Dibromoethane - Inhalation  . .  12
2-2 Levels of Significant Exposure to 1,2-Dibromoethane - Oral  . . . .  30
2-3 Proposed Metabolic Pathways for 1,2-Dibromoethane  . . . . . . .  48
2-4 Existing Information on Health Effects of 1,2-Dibromoethane  . . .  70
5-1 Frequency of NPL Sites with 1,2-Dibromoethane Contamination  . . .  89
LIST OF TABLES

2-1 Levels of Significant Exposure to 1,2-Dibromoethane - Inhalation .................. 7
2-2 Levels of Significant Exposure to 1,2-Dibromoethane - Oral .......................... 27
2-3 Levels of Significant Exposure to 1,2-Dibromoethane - Dermal ....................... 38
2-4 Distribution of $^{14}$C in Selected Tissues and Body Fluids of Male Rats 24 and 48 Hours After a Single Oral Dose of 15 mg/kg [U-$^{14}$C]-1,2-Dibromoethane .............................................. 44
2-5 Distribution of 1,2-Dibromoethane in Mice .............................................. 46
2-6 Percentage of Administered $^{14}$C in Selected Tissues and Body Fluids of Male Guinea Pigs at Various Time Intervals Following Intraperitoneal Administration of 30 mg/kg of $^{14}$C-1,2-Dibromoethane .......................... 47
2-7 Genotoxicity of 1,2-Dibromoethane In Vivo .............................................. 59
2-8 Genotoxicity of 1,2-Dibromoethane In Vitro ............................................ 60
3-1 Chemical Identity of 1,2-Dibromoethane ................................................. 78
3-2 Physical and Chemical Properties of 1,2-Dibromoethane ............................... 80
4-1 Facilities That Manufacture or Process 1,2-Dibromoethane ......................... 82
5-1 Releases to the Environmental from Facilities That Manufacture or Process 1,2-Dibromoethane ................................................................. 86
6-1 Analytical Methods for Determining 1,2-Dibromoethane in Biological Materials ................................................. 100
6-2 Analytical Methods for Determining 1,2-Dibromoethane in Environmental Samples ................................................. 102
7-1 Regulations and Guidelines Applicable to 1,2-Dibromoethane ........................ 108
1. PUBLIC HEALTH STATEMENT

This Statement was prepared to give you information about 1,2-dibromoethane (ethylene dibromide, EDB) and to emphasize the human health effects that may result from exposure to it. The Environmental Protection Agency (EPA) has identified 1,177 sites on its National Priorities List (NPL). 1,2-Dibromoethane has been found at 9 of these sites. However, we do not know how many of the 1,177 NPL sites have been evaluated for 1,2-dibromo-ethane. As EPA evaluates more sites, the number of sites at which 1,2-dibromoethane is found may change. The information is important to you because 1,2-dibromoethane may cause harmful health effects and because these sites are potential or actual sources of human exposure to 1,2-dibromoethane.

When a chemical is released from a large area such as an industrial plant, or from a container, such as a drum or bottle, it enters the environment as a chemical emission. This emission, which is also called a release, does not always lead to exposure. You can be exposed to a chemical only when you come into contact with the chemical. You may be exposed to it in the environment by breathing, eating, or drinking substances containing the chemical or from skin contact with the chemical.

If you are exposed to a hazardous substance such as 1,2-dibromoethane, several factors will determine whether harmful health effects will occur and what the type and severity of those health effects will be. These factors include the dose (how much), the duration (how long), the route or pathway by which you are exposed (breathing, eating, drinking, or skin contact), the other chemicals to which you are exposed, and your individual characteristics such as age, sex, nutritional status, family traits, life style, and state of health.

1.1 WHAT IS 1,2-DIBROMOEthane?

1,2-Dibromoethane is a pesticide and gasoline additive. It is mostly man-made, but it may occur naturally in the ocean in very small amounts. In the 1970s and early 1980s, it was used in soil to kill insects and worms that get on fruits, vegetables, and grain crops. It was also used in soil to protect grass, such as on golf courses. Another use was to kill fruit flies on citrus fruits, mangoes, and papayas after they were picked. EPA stopped most of these uses in 1984. 1,2-Dibromoethane is added to leaded gasoline to produce better fuel efficiency. Because use of leaded gasoline has fallen, less 1,2-dibromoethane is made for this use. The chemical is a colorless liquid with a mild, sweet odor. It evaporates easily and can dissolve in water. 1,2-Dibromoethane stays in groundwater and in soil for a long time but breaks down quickly in the air. More information on the chemical and physical properties of 1,2-dibromoethane can be found in Chapter 3 and on its occurrence and fate in the environment in Chapter 5.
1. PUBLIC HEALTH STATEMENT

1.2 HOW MIGHT I BE EXPOSED TO 1,2-DIBROMOETHANE?

You can be exposed to low levels of 1,2-dibromoethane in drinking water (especially well water) and in air. Before EPA stopped the use of 1,2-dibromoethane as a pesticide, the most common way you would have been exposed was by eating food that had very small amounts of this chemical in it. You could still be exposed to low levels of 1,2-dibromoethane, particularly from groundwater (well water), in areas where the chemical was used in farming or from hazardous waste sites. Most of the 1,2-dibromoethane that enters the soil will get into the groundwater or evaporate into the air. Small amounts can remain in very tiny particles in soil near hazardous waste sites or in areas once used as farmland. The compound may be released from these particles slowly over time or if the soil is crushed or disturbed. You can be exposed to 1,2-dibromoethane in the air near production plants. Background levels in the environment are very low. The air most people breathe contains between 0.01-0.06 parts of 1,2-dibromoethane per billion parts of air (ppb). Because 1,2-dibromoethane easily evaporates, most surface waters do not contain detectable amounts. Groundwater is more likely to contain 1,2-dibromoethane with an average concentration of about 0.9 ppb. In foods, 1,2-dibromoethane has recently been found in 2 out of 549 samples at concentrations of 2 and 11 ppb. There is no information on background levels in surface water or soil. If you applied 1,2-dibromoethane on a farm or golf course, if you worked to pack fruits gassed with 1,2-dibromoethane, or if you worked in a factory that made 1,2-dibromoethane, you could be exposed to much higher than background levels. For more information on human exposure to 1,2-dibromoethane, see Chapter 5.

1.3 HOW CAN 1,2-DIBROMOETHANE ENTER AND LEAVE MY BODY?

1,2-Dibromoethane can enter your body after you eat or drink contaminated food and water. It can also enter your body through your skin when you bathe or swim in contaminated water. The 1,2-dibromoethane inside tiny soil particles may enter your body if you crush or eat contaminated soil. The chemical can enter your nose and lungs when you breathe air that contains 1,2-dibromoethane or when you shower with water that is contaminated. Near hazardous waste sites or near areas that once were farmed, the most likely way that you will be exposed is by drinking contaminated groundwater. 1,2-Dibromoethane will be rapidly taken into your bloodstream by any method of exposure. Most of it builds up in your liver and kidneys where it is rapidly broken down to different substances. These substances leave your body quickly in the urine, and smaller amounts are passed in liver bile into the stool. Small amounts of 1,2-dibromoethane that are not broken down can be breathed out of your lungs. Chapter 2 has more information on how 1,2-dibromoethane enters and leaves the body.
1. PUBLIC HEALTH STATEMENT

1.4 HOW CAN 1,2-DIBROMOETHANE AFFECT MY HEALTH?

The effects of breathing high levels of 1,2-dibromoethane in humans are unknown. Studies in animals show that they can die from breathing high concentrations of 1,2-dibromoethane for a short time while lower concentrations can cause liver and kidney damage. You can die if you swallow or have skin contact with large quantities of 1,2-dibromoethane. A woman who drank 40 milliliters (mL) of pure liquid 1,2-dibromoethane died within a day. Changes in the liver and kidney are reported in humans that died of ingestion of 1,2-dibromoethane. People who tried to commit suicide by swallowing concentrated 1,2-dibromoethane got ulcers inside their mouth and stomach. Laboratory rats and mice fed less-concentrated 1,2-dibromoethane for as little as 2 weeks had damage to the lining of their stomach. If you spill liquid 1,2-dibromoethane on your skin, you can get blisters.

Breathing 1,2-dibromoethane for moderately long periods damages the lining of the nose in rats. This effect has not been seen in humans. Animals that breathed or ate food containing 1,2-dibromoethane for short or long periods were less fertile or had abnormal sperms. Changes in the brain and behavior have occurred in young rats whose male parents had breathed 1,2-dibromoethane.

A worker who breathed 1,2-dibromoethane for several years developed bronchitis, headache, and depression, but his health improved after he stopped breathing air contaminated with 1,2-dibromoethane. 1,2-Dibromoethane is not known to cause birth defects in people. It can impair reproduction in males by damaging sperms in testicles. This type of damage has been seen in workers exposed to 1,2-dibromoethane for several years. Pregnant animals that are sick from exposure to 1,2-dibromoethane have had pups with birth defects. There are no reports of cancer in workers or other people exposed to 1,2-dibromoethane for several years. Rats and mice that repeatedly breathed, swallowed, or had skin contact with 1,2-dibromoethane for long periods had cancer in many organs. The Department of Health and Human Services has determined that 1,2-dibromoethane may reasonably be anticipated to be a carcinogen.

1.5 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 1,2-DIBROMOETHANE?

There is no known reliable medical test to determine whether you have been exposed to 1,2-dibromoethane. For more information, see Chapters 2 and 6.
1. PUBLIC HEALTH STATEMENT

1.6 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?

The federal government has set standards and guidelines to protect people from the potential health effects of 1,2-dibromoethane in drinking water, food, and air. EPA recommends that no more than 0.008 ppm of 1,2-dibromoethane should be present in drinking water that is consumed for up to 10 days. EPA does not allow any 1,2-dibromoethane to be in food. Companies must report to EPA if they spill 1,000 pounds or more of 1,2-dibromoethane.

The Occupational Health and Safety Administration (OSHA) has limited workers' exposure to 1,2-dibromoethane in air to an average of 20 ppm for an 8-hour workday. According to OSHA, short-term exposure of 15 minutes to 1,2-dibromoethane should not be more than 0.5 ppm. The National Institute for Occupational Safety and Health (NIOSH) has set an average limit for 1,2-dibromoethane of 0.045 ppm in workroom air during an 8-hour day. According to NIOSH, short-term exposure of 15 minutes to 1,2-dibromoethane should not be more than 0.13 ppm.

For more information on guidelines and standards for 1,2-dibromoethane exposure, see Chapter 7.

1.7 WHERE CAN I GET MORE INFORMATION?

If you have any more questions or concerns not covered here, please contact your state health or environmental department or:

Agency for Toxic Substances and Disease Registry
Division of Toxicology
1600 Clifton Road, E-29
Atlanta, Georgia 30333

This agency can also provide you with information on the location of the nearest occupational and environmental health clinic. Such clinics specialize in recognizing, evaluating, and treating illness that result from exposure to hazardous substances.
2. HEALTH EFFECTS

2.1 INTRODUCTION

The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and other interested individuals and groups with an overall perspective of the toxicology of 1,2-dibromoethane and a depiction of significant exposure levels associated with various adverse health effects. It contains descriptions and evaluations of studies and presents levels of significant exposure for 1,2-dibromoethane based on toxicological studies and epidemiological investigations.

2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE

To help public health professionals address the needs of persons living or working near hazardous waste sites, the information in this section is organized first by route of exposure—inhalation, oral, and dermal—and then by health effect—death, systemic, immunological, neurological, developmental, reproductive, genotoxic, and carcinogenic effects. These data are discussed in terms of three exposure periods—acute (less than 15 days), intermediate (15-364 days), and chronic (365 days or more).

Levels of significant exposure for each route and duration are presented in tables and illustrated in figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. LOAELs have been classified into "less serious" or "serious" effects. These distinctions are intended to help the users of the document identify the levels of exposure at which adverse health effects start to appear. They should also help to determine whether or not the effects vary with dose and/or duration, and place into perspective the possible significance of these effects to human health.

The significance of the exposure levels shown in the tables and figures may differ depending on the user's perspective. For example, physicians concerned with the interpretation of clinical findings in exposed persons may be interested in levels of exposure associated with "serious" effects. Public health officials and project managers concerned with appropriate actions to take at hazardous waste sites may want information on levels of exposure associated with more subtle effects in humans or animals (LOAEL) or exposure levels below which no adverse effects (NOAEL) have been observed. Estimates of levels posing minimal risk to humans (Minimal Risk Levels, MRLs) may be of interest to health professionals and citizens alike.

Levels of exposure associated with the carcinogenic effects of 1,2-dibromoethane are indicated in Figures 2-1 and 2-2. Because cancer effects could occur at lower exposure levels, the figures also show a range for the upper bound of estimated excess risks, ranging from a risk of one in 10,000 to one in 10,000,000 (10^{-4} to 10^{-7}) as developed by EPA.
2. HEALTH EFFECTS

Estimates of exposure levels posing minimal risk to humans (MRLs) have been made, where data were believed reliable, for the most sensitive noncancer effect for each exposure duration. MRLs include adjustments to reflect human variability and to extrapolate from laboratory animal data to humans.

Although methods have been established to derive these levels (Barnes et al. 1988; EPA 1989a), uncertainties are associated with these techniques. Furthermore, ATSDR acknowledges additional uncertainties inherent in the application of the procedures to derive less than lifetime MRLs. As an example, acute inhalation MRLs may not be protective for health effects that are delayed in development or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic bronchitis. As these kinds of health effects data become available and methods to assess levels of significant human exposure improve, these MRLs will be revised.

2.2.1 Inhalation Exposure

2.2.1.1 Death

No studies were located regarding death in humans after inhalation exposure to 1,2-dibromoethane. However, inhalation exposure as well as dermal exposure may have played a role in the deaths of two pesticide workers exposed to 1,2-dibromoethane. For a discussion of this report by Letz et al. (1984), see Section 2.2.3.1.

Older studies have established lethal concentrations of inhalation exposure to 1,2-dibromoethane for experimental animals. Groups of rats were exposed to 1,2-dibromoethane at concentrations of 100-10,000 ppm and durations of 0.02-16 hours (Rowe et al. 1952). For each exposure concentration tested, several exposure durations were selected that were expected to encompass 0%-100% mortality. A total of 40 combinations of exposure concentration and duration were tested, using a total of 711 rats. Plots were constructed of concentration versus exposure duration expected to produce 99.99%, 50%, and 0.01% mortality. Selected points from the 50% plot are illustrated in Figure 2-1 and recorded in Table 2-1.

Deaths in rats resulting from single-exposure concentration/duration combinations expected to produce 50%-90% mortality usually occurred within 24 hours. These deaths were attributed to cardiac or respiratory failure and were probably a direct effect of 1,2-dibromoethane toxicity. Deaths resulting from exposure concentration/duration combinations expected to produce 0.01%-50% mortality occurred as long as 12 days after exposure and were due to pneumonia. The authors attributed pneumonia to 1,2-dibromoethane-induced lung injury, but this lesion could also have been due to intercurrent bacterial or mycoplasmal pulmonary infection. Rats free of enzootic respiratory infections were not available in 1952. More contemporary inhalation studies of
<table>
<thead>
<tr>
<th>Key to figure*</th>
<th>Species</th>
<th>Exposure frequency/duration</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Death</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td>1</td>
<td>Rat</td>
<td>1 d 12.0 hr</td>
<td></td>
<td>200 (LC₅₀)</td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td>2</td>
<td>Rat</td>
<td>1 d 2.0 hr</td>
<td></td>
<td>400 (16/25 died)</td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td>3</td>
<td>Rat</td>
<td>1 d 0.1 hr</td>
<td></td>
<td>5,000 (9/10 died)</td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td>4</td>
<td>Rat</td>
<td>1 d 0.05 hr</td>
<td></td>
<td>10,000 (LC₅₀)</td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td>5</td>
<td>Rat</td>
<td>9 d 7hr/d</td>
<td></td>
<td>100 (3/10 died)</td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td>6</td>
<td>Rabbit</td>
<td>4 d 7 hr/d</td>
<td></td>
<td>100 (3/4 died)</td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td>7</td>
<td>Gn pig</td>
<td>1d 7hr/d</td>
<td></td>
<td>200</td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td>8</td>
<td>Gn pig</td>
<td>1 d 2hr/d</td>
<td></td>
<td>400</td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td>9</td>
<td>Mouse</td>
<td>10 d 23hr/d Gd6-15</td>
<td></td>
<td>38 (10/17 died)</td>
<td></td>
<td>Short et al. 1978</td>
</tr>
<tr>
<td>10</td>
<td>Rat</td>
<td>10 d 23hr/d Gd6-15</td>
<td></td>
<td>80 (LC₅₀)</td>
<td></td>
<td>Short et al. 1978</td>
</tr>
<tr>
<td></td>
<td>Systemic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td>11</td>
<td>Rat</td>
<td>7 hr Hepatic</td>
<td></td>
<td>50</td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4 hr Hepatic</td>
<td></td>
<td>100 (histopathological changes)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to figure</td>
<td>Species</td>
<td>Exposure frequency/duration</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL (effect)</td>
<td>Reference</td>
</tr>
<tr>
<td>--------------</td>
<td>---------</td>
<td>----------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>----------------</td>
<td>-----------</td>
</tr>
<tr>
<td>12</td>
<td>Rat</td>
<td>7d/9d 7hr/d</td>
<td>Resp</td>
<td>100 (leukocyte infiltration)</td>
<td>Rowe et al. 1952</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>100 (cloudy swelling)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>100 (increased weight)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>100 (spleen congestion)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Rabbit</td>
<td>4 d 7hr/d</td>
<td>Hepatic</td>
<td>100 (fatty degeneration, necrosis)</td>
<td>Rowe et al. 1952</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>100</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Developmental

| 14           | Rat     | 10 d 23hr/d Gd6-15         |        | 20 (skeletal anomalies)   | Short et al. 1978 |
| 15           | Mouse   | 10 d 23hr/d Gd6-15         |        | 20 (skeletal anomalies)   | Short et al. 1978 |

INTERMEDIATE EXPOSURE

Death

| 16           | Rat     | 3 wk 7d/wk 7hr/d           |        | 80 (10/50 females died)   | Short et al. 1979 |
| 17           | Rat     | 10 wk 5d/wk 7hr/d          |        | 89 (7/33 males died)      | Short et al. 1979 |

Systemic

<p>| 18           | Rat     | 13 wk 5d/wk 6hr/d          | Resp   | 3 10 (hyperplasia)        | Nitschke et al. 1981 |</p>
<table>
<thead>
<tr>
<th>Key to figure&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Species</th>
<th>Exposure frequency/duration</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL (effect)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>19 Rat</td>
<td>13 wk 5d/wk 6hr/d</td>
<td>Resp</td>
<td>3</td>
<td>15 (hyperplasia)</td>
<td>Reznik et al. 1980</td>
</tr>
<tr>
<td></td>
<td>20 Rat</td>
<td>13 wk 5d/wk 6hr/d</td>
<td>Other</td>
<td>15</td>
<td>75 (vacuolization of cells)</td>
<td>NTP 1982</td>
</tr>
<tr>
<td></td>
<td>21 Rat</td>
<td>91 d 5d/wk 7hr/d</td>
<td>Hemato</td>
<td>50</td>
<td>50 (increased weight)</td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td></td>
<td>50 (increased weight)</td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td></td>
<td>50 (decreased spleen weight)</td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td></td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td></td>
<td>22 Rabbit</td>
<td>84 d 5d/wk 7hr/d</td>
<td>Hepatic</td>
<td>50</td>
<td>50</td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td></td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td></td>
<td>23 Rabbit</td>
<td>214 d 5d/wk 7hr/d</td>
<td>Other</td>
<td>25</td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td></td>
<td>24 On pig</td>
<td>80 d 5d/wk 7hr/d</td>
<td>Resp</td>
<td>25</td>
<td>50 (increased weight)</td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>25</td>
<td>50 (fatty degeneration)</td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>25</td>
<td>50 (tubular degeneration)</td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td></td>
<td>25 Mouse</td>
<td>13 wk 5d/wk 6hr/d</td>
<td>Resp</td>
<td>15</td>
<td>75 (megalocytic cells)</td>
<td>NTP 1982</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Derm/oc</td>
<td>15</td>
<td>75 (eye irritation)</td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td></td>
<td>26 Monkey</td>
<td>70 d 5d/wk 7hr/d</td>
<td>Hepatic</td>
<td>50</td>
<td>50 (fatty degeneration)</td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>50</td>
<td>50 (increased weight)</td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td></td>
<td>27 Monkey</td>
<td>220 d 5d/wk 1hr/d</td>
<td>Other</td>
<td>25</td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td>Key to figure</td>
<td>Species</td>
<td>Exposure frequency/duration</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL (effect)</td>
<td>Serious (ppm)</td>
</tr>
<tr>
<td>--------------</td>
<td>---------</td>
<td>-----------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Reproductive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>89 (infertility)</td>
</tr>
<tr>
<td>28 Rat</td>
<td>10 wk</td>
<td>5d/wk</td>
<td>39</td>
<td></td>
<td></td>
<td>89 (infertility)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7hr/d</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29 Rat</td>
<td>3 wk</td>
<td>7d/wk</td>
<td>39</td>
<td></td>
<td>80 (reduced fertility)</td>
<td>Short et al. 1979</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7hr/d</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20 (CEL, lung tumors)</td>
</tr>
<tr>
<td>30 Mouse</td>
<td>6 mo</td>
<td>5d/wk</td>
<td>39</td>
<td></td>
<td></td>
<td>20 (CEL, lung tumors)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6hr/d</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHRONIC EXPOSURE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20 (43/48 males died; 37/48 females died)</td>
</tr>
<tr>
<td>Death</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20 (43/48 males died; 37/48 females died)</td>
</tr>
<tr>
<td>31 Rat</td>
<td>18 mo</td>
<td>5d/wk</td>
<td>39</td>
<td></td>
<td></td>
<td>20 (43/48 males died; 37/48 females died)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7hr/d</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>32 Rat</td>
<td>89-104 wk</td>
<td>5d/wk</td>
<td>39</td>
<td></td>
<td>40 (45/50 males died; 42/50 females died)</td>
<td>NTP 1982</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6hr/d</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>33 Mouse</td>
<td>79-103 wk</td>
<td>5d/wk</td>
<td>39</td>
<td></td>
<td>10 (31/50 females died)</td>
<td>NTP 1982</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6hr/d</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>40 (nephropathy)</td>
</tr>
<tr>
<td>34 Rat</td>
<td>89-104 wk</td>
<td>Renal</td>
<td>10</td>
<td></td>
<td>40 (nephropathy)</td>
<td>NTP 1982</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5d/wk</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hepatic</td>
<td>10</td>
<td></td>
<td>40 (nephropathy)</td>
<td>NTP 1982</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6hr/d</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other</td>
<td>10</td>
<td></td>
<td>40 (nephropathy)</td>
<td>NTP 1982</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to figure</td>
<td>Species</td>
<td>Exposure frequency/duration</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL (effect)</td>
<td>Reference</td>
</tr>
<tr>
<td>---------------</td>
<td>---------</td>
<td>---------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>----------------</td>
<td>-----------</td>
</tr>
<tr>
<td>35 Rat</td>
<td>18 mo</td>
<td>Hemato</td>
<td>20 (splenic atrophy)</td>
<td>Wong et al. 1982</td>
<td></td>
<td></td>
</tr>
<tr>
<td>36 Mouse</td>
<td>79-103 wk</td>
<td>Resp</td>
<td>10 (hyperplasia in females)</td>
<td>NTP 1982</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5d/wk</td>
<td>Hepatic</td>
<td>40</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6hr/d</td>
<td>Other</td>
<td>10 (decreased body weight)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Reproductive

| 37 Rat        | 89-104 wk | 10 (testicular degeneration) | NTP 1982 |
|---------------| 5d/wk     |                           |          |
|               | 6hr/d     |                           |          |

Cancer

| 38 Rat        | 18 mo   | 20 (CEL, multiple organs) | Wong et al. 1982 |
|---------------| 5d/wk   |                            |              |
|               | 7hr/d   |                            |              |

| 39 Rat        | 89-104 wk | 10 (CEL, lung tumors, NTP 1982 nasal tumors) |              |
|---------------| 5d/wk     |                                              |              |
|               | 6hr/d     |                                              |              |

| 40 Mouse      | 79-103 wk | 10 (CEL, lung tumors, NTP 1982 hemangiosarcomas) | |
|---------------| 5d/wk     |                                                |              |
|               | 6hr/d     |                                                |              |

*The number corresponds to entries in Figure 2-1.

CEL = cancer effect level; d = day; Derm/oc = dermal/ocular; Gd = gestation day; Gn pig = guinea pig; Hemato = hematological; hr = hour; LOAEL = lowest-observed-adverse-effect level; LC₅₀ = lethal concentration, 50% kill; mo = month; NOAEL = no-observed-adverse-effect level; Resp = respiratory; wk = week
FIGURE 2-1. Levels of Significant Exposure to 1,2-Dibromoethane - Inhalation

ACUTE
(≤14 Days)

Systemic

Death
Respiratory
Hepatic
Renal
Other
Developmental

(ppm)
10,000
1,000
100
10
1
0.1
0.01
0.001
0.0001
0.00001

Key
- Rat
- Mouse
- Rabbit
- Guinea pig
- LC50
- LOAEL for serious effects (animals)
- LOAEL for less serious effects (animals)
- NOAEL (animals)

The number next to each point corresponds to entries in Table 2-1.
FIGURE 2-1 (Continued)

INTERMEDIATE
(15-364 Days)

Systemic

Death  Respiratory  Neurological  Hepatic  Reproductive  Oncologic  Oral  Cancer

Key

- Rat
- Mouse
- Rabbit
- Guinea pig
- Monkey

LOAEL for serious effects (animals)
LOAEL for less serious effects (animals)
NOAEL (animals)
CELE - Cancer Effect Level

The number next to each point corresponds to entries in Table 2-1.

Doses represent the lowest dose tested per study that produced a tumorigenic response and do not imply the existence of a threshold for the cancer end point.
FIGURE 2-1 (Continued)

CHRONIC
(≥365 Days)

Systemic

(ppm)

10,000
1,000
100
10
1
0.1
0.01
0.001
0.0001
0.00001
10⁻7
10⁻6
10⁻5
10⁻4

Key

r Rat
m Mouse

- LOAEL for serious effects (animals)
- LOAEL for less serious effects (animals)
- NOAEL (animals)
- CEL - Cancer Effect Level

The number next to each point corresponds to entries in Table 2-1.

* Dose represents the lowest dose tested per study that produced a tumorigenic response and do not imply the existence of a threshold for the cancer end point.

2. HEALTH EFFECTS
1,2-dibromoethane using commercially produced rats (Nitschke et al. 1981; NTP 1982) did not report pneumonic lesions or pneumonia-related mortality.

As the duration of exposure of the rats increased, the LC₅₀ (lethal concentration, 50% kill) value decreased. Maximum nonfatal single exposures for rats were 1.2 minutes at 10,000 ppm, 2.4 minutes at 5,000 ppm, 6 minutes at 3,000 ppm, 12 minutes at 1,600 ppm, 36 minutes at 400 ppm, 2 hours at 200 ppm, and 16 hours at 100 ppm, the longest exposure tested. In other species exposed to 1,2-dibromoethane by Rowe et al. (1952), maximum nonfatal single exposures for guinea pigs were 2 hours at 400 ppm and 7 hours at 200 ppm, the longest exposure tested.

A group of albino rats heterogenous for weight (range of 190-604 grams) was exposed in a fumigation chamber to 1,040 ppm of 1,2-dibromoethane until death occurred (Akamine 1952). Clinical signs of toxicity were reddened nasal mucous membranes, epistaxis, ptyalism, anorexia, weight loss, and weakness. The lethal exposure times ranged from 5 to 165 minutes.

Deaths occurred in pregnant female Crl:CD rats and CD mice exposed to 1,2-dibromoethane for 23 hours per day over a 10-day period. Female rats and mice had increased mortality when exposed to 80 ppm of 1,2-dibromoethane while female mice also had significant mortality when exposed to concentrations of 38 ppm 1,2-dibromoethane (Short et al. 1978). Twenty percent mortality occurred in female Crl:CD rats exposed to 80 ppm 1,2-dibromoethane over a 3-week period; mortality did not occur at lower concentrations of 20 or 39 ppm. Male rats exposed to 89 ppm 1,2-dibromoethane over a 10-week period had 21% mortality but mortality did not occur at lower concentrations of 19 or 39 ppm (Short et al. 1979). There was no gross necropsy or histopathologic examination to establish the cause of death as related to chemical toxicity in either of these studies, which were focused primarily on development and reproduction.

Rats and mice exposed chronically to 1,2-dibromoethane by inhalation had high mortality (NTP 1982; Wong et al. 1982). The majority of deaths were related to cancer rather than direct toxic effects of 1,2-dibromoethane. Both studies are discussed further in Section 2.2.1.8.

The highest NOAEL value and the reliable lethal concentrations for each species for the acute-duration category, in rats for the intermediate-duration category and in rats and mice for the chronic-duration/category are recorded in Table 2-1 and plotted in Figure 2-1.

2.2.1.2 Systemic Effects

The highest NOAEL values and all reliable LOAEL values for systemic effects in each species and duration category are recorded in Table 2-1 and plotted in Figure 2-1.
2. HEALTH EFFECTS

No studies were located regarding cardiovascular, gastrointestinal, or musculoskeletal effects in humans or animals after inhalation exposure to 1,2-dibromoethane.

**Respiratory Effects.** The respiratory tract, particularly the nasal cavity, is the point-of-contact target organ affected by inhalation of 1,2-dibromoethane.

A possible case of chronic intoxication by 1,2-dibromoethane occurred in a worker involved in 1,2-dibromoethane production (Kochmann 1928). Symptoms were nonspecific. Upper respiratory symptoms consisted of pharyngitis and bronchitis; other symptoms were lymphadenopathy, conjunctivitis, anorexia, headache, and depression. The worker's condition improved upon cessation of exposure. No other studies were located regarding respiratory effects in humans after inhalation exposure to 1,2-dibromoethane.

Rats were exposed repeatedly to inhalation of 1,2-dibromoethane (Rowe et al. 1952). Of 10 female rats exposed to 100 ppm of 1,2-dibromoethane over a 9-day period, 30% did not survive. Survivors had increased lung weights and increased number of leukocytes in pulmonary septa. There was no description of nasal lesions; therefore, it is likely that the nasal cavity was not examined microscopically.

There have been several subchronic studies of 1,2-dibromoethane. In one, rats and guinea pigs were exposed to 50 ppm of 1,2-dibromoethane daily for as many as 63 (rats) or 57 (guinea pigs) exposures (Rowe et al. 1952). Experimental findings were complicated by upper respiratory infection and pneumonia.

To determine doses to be used in chronic inhalation studies, F344 rats and B6C3F1 mice of both sexes were exposed to 0, 3, 15, or 75 ppm 1,2-dibromoethane for 13 weeks (NTP 1982; Reznik et al. 1980). Lesions occurred in respiratory turbinates in the dorsal portion of the nasal cavity of rats and mice exposed to 75 ppm. Respiratory epithelium was affected with cytomegaly of basal cells, focal hyperplasia, loss of cilia, and squamous metaplasia. Rats exposed to 15 ppm 1,2-dibromoethane had similar lesions but at lower incidence and with less severity; mice exposed to 15 ppm had no nasal lesions. Lung lesions were not described for rats; mice exposed to 75 ppm developed megalocytic bronchiolar epithelial cells (NTP 1982).

A study was conducted to examine proliferative nasal epithelial lesions in F344 rats following subchronic inhalation of 1,2-dibromoethane at concentrations of 0, 3, 10, or 40 ppm (Nitschke et al. 1981). The study incorporated serial sacrifices and sacrifices after an 88-89-day postexposure period. Rats in the mid- and high-dose groups had hyperplasia of nasal turbinate epithelium; rats at the highest dose also exhibited nonkeratinizing squamous metaplasia of respiratory epithelium of the nasal turbinates.
2. HEALTH EFFECTS

Lesions in both dose groups reverted to normal after the postexposure interval. Although lesions did not progress and were essentially reversible during the recovery period, it is possible that such effects could progress in severity and result in neoplasia following long-term inhalation of 1,2-dibromoethane.

In a chronic inhalation study conducted by NTP (1982), carcinogenic end points were nasal tumors in rats and mice and pulmonary tumors in mice (see Section 2.2.1.8). A nonneoplastic lesion of epithelial hyperplasia occurring throughout the respiratory tract was a prominent histologic feature in the 1,2-dibromoethane-exposed mice.

**Hematological Effects.** No studies were located regarding hematologic effects in humans after inhalation exposure to 1,2-dibromoethane. Female rats exposed acutely to 100 ppm 1,2-dibromoethane for up to seven exposures (see Section 2.2.1.1) had splenic congestion and hemosiderosis; no changes in hematopoietic or lymphoid elements were described (Rowe et al. 1952).

Hematologic evaluation was performed on Sprague-Dawley rats that received 20 ppm 1,2-dibromoethane by inhalation and were fed either a control diet or a diet containing 0.05% disulfiram for 18 months (Wong et al. 1982). Hematologic evaluation of control rats with no exposure to 1,2-dibromoethane was not done. This study is discussed in Section 2.2.1.8. Moribund animals (males and females) that had exposure to the inhalation and dietary regimens for 10-12 months were evaluated. Rats exposed to 1,2-dibromoethane and fed a control diet had hematologic parameters within normal ranges. Atrophy of the spleen occurred in male rats. Both sexes of rats exposed to 1,2-dibromoethane and fed the 0.05% disulfiram diet had total erythrocyte counts, hematocrit, and hemoglobin values significantly lower than rats exposed to 1,2-dibromoethane and fed the control diet, with females most severely affected. Both sexes of rats on this latter regimen had splenic atrophy. Because there was no description of this splenic lesion, it is unclear whether atrophy referred to decreased extramedullary hematopoiesis in the red pulp, lymphoid depletion of the white pulp, or both changes.

**Hepatic Effects.** Two workers collapsed after entering a pesticide storage tank containing residues of 1,2-dibromoethane (Letz et al. 1984). Clinical chemistry prior to death for both men revealed acute hepatic failure along with other symptoms of toxicity. As with dermal exposure, inhalation exposure was also postulated to play a potentially important role. However, the exposure levels were not quantified. The liver is a target organ for toxic effects of 1,2-dibromoethane in experimental animals following exposure by a variety of routes.
2. HEALTH EFFECTS

Acute toxic hepatic effects of 1,2-dibromoethane consisting of hepatocellular cloudy swelling, centrilobular fatty change, and patchy necrosis were reported in animals after a single inhalation exposure (Rowe et al. 1952). Repeated inhalation exposures of rats and rabbits to 100 ppm 1,2-dibromoethane induced diffuse hepatocellular cloudy swelling in rats and centrilobular hepatocellular fatty change and necrosis in rabbits.

Rats in a subchronic inhalation study exposed to 50 ppm 1,2-dibromoethane had intercurrent infectious disease that severely complicated experimental results (see the discussion in this section on Respiratory Effects). No liver lesions were reported in surviving rats (Rowe et al. 1952). Guinea pigs exposed to 50 ppm 1,2-dibromoethane did not develop respiratory disease. Their liver lesions consisted of minimal centrilobular hepatocellular fatty change (Rowe et al. 1952). Liver lesions were not induced in F344 rats or B6C3F1 mice following subchronic exposure to any concentrations of 1,2-dibromoethane used including the highest dose (75 ppm.) (NTP 1982).

In the chronic inhalation bioassay of 1,2-dibromoethane conducted by NTP (1982) (discussed in Section 2.2.1.8), increased incidence of focal and centrilobular hepatocellular necrosis occurred in male and female F344 rats exposed to the highest dose (40 ppm) of 1,2-dibromoethane. Compound-related degenerative or necrotizing hepatocellular lesions did not occur in B6C3F1 mice following exposure to any concentration used. Liver lesions were not reported in rats after chronic inhalation exposure to 20 ppm 1,2-dibromoethane with or without 0.05% disulfiram in the diet; however, hepatocellular tumors (not otherwise classified) were induced in exposed rats fed dietary disulfiram (Wong et al. 1982). Also see Section 2.2.1.8.

Renal Effects. The clinical chemistry prior to death of two men who entered a pesticide tank that contained residues of 1,2-dibromoethane revealed acute renal failure (Letz et al. 1984). The exposure levels were not reported.

Renal effects have been reported in laboratory animals. Slight renal congestion, edema, and cloudy swelling of tubular epithelium (mild and nonspecific lesions) occurred in rats exposed acutely by inhalation (single exposure) to toxic concentrations greater than 100 ppm. Rats receiving several inhalation exposures to 100 ppm 1,2-dibromoethane had elevated kidney weights but no renal lesions. No evidence of kidney damage occurred in rabbits on a somewhat similar exposure regimen (Rowe et al. 1952). Blood urea nitrogen levels were not elevated in either species, indicating that renal function was not compromised.

Rats exposed subchronically to 50 ppm 1,2-dibromoethane had increased kidney weights but unremarkable kidney histology (Rowe et al. 1952). Guinea pigs similarly exposed had elevated absolute and relative kidney weights.
2. HEALTH EFFECTS

Histologically, the guinea pig kidneys had slight congestion, edema, and tubular epithelial degeneration (Rowe et al. 1952). Neither species exposed to 1,2-dibromoethane had elevated blood urea nitrogen levels.

Renal lesions did not occur in rats or mice exposed by inhalation to 0., 3, 15, or 75 ppm of 1,2-dibromoethane in a subchronic study to determine concentrations to be used for the chronic inhalation bioassay (NTP 1982).

Renal changes were not reported in rats, guinea pigs, or rabbits exposed to 25 ppm 1,2-dibromoethane over 205-214 days (Rowe et al. 1952). In the NTP chronic inhalation study (NTP 1982), toxic nephropathy (not otherwise characterized) was present in 4 low-dose (10 ppm) and 28 high-dose (40 ppm) male and 8 high-dose female F344 rats but was not present in any of the control animals. Compound-related renal lesions were not found in B6C3F1 mice, although ascending suppurative urinary tract infections may have masked renal lesions as a result of early mortality and/or pyelonephritis.

Because neoplastic changes were emphasized in the study of Wong et al. (1982), (see Section 2.2.1.8), it is unclear whether nonneoplastic lesions were recognized by the investigators.

Dermal/Ocular Effects. No studies were located regarding dermal or ocular effects in humans after inhalation exposure to 1,2-dibromoethane:

No studies were located regarding dermal effects in animals after inhalation exposure to 1,2-dibromoethane.

In the subchronic inhalation study of 1,2-dibromoethane in rodents conducted by NTP (1982), eye irritation was noted at study conclusion (weeks 12 and 13) in mice receiving the highest concentration (75 ppm).

Other Systemic Effects. Mild nonspecific endocrine lesions were observed after inhalation exposure to 1,2-dibromoethane. After subchronic exposure to 75 ppm, rats had adrenal lesions consisting of swelling and/or cytoplasmic vacuolization of cells in the zona fasciculata of the cortex and thyroid lesions consisting of slight decreases in follicular size. Degenerative changes in the adrenal cortex occurred at elevated incidence in female Fischer 344 rats after chronic exposure to 40 ppm 1,2-dibromoethane. This may represent a secondary, stress-related effect because there was poor survival at this high dose with the majority of rats dying or sacrificed when moribund during the study (NTP 1982).

2.2.1.3 Immunological Effects

No studies were located regarding immunologic effects in humans after inhalation exposure to 1,2-dibromoethane. Lymphoid neoplasia putatively
2. HEALTH EFFECTS

associated with exposure of grain milling workers to various chemicals including 1,2-dibromoethane is discussed in Section 2.9.3.

As discussed in Section 2.2.1.2, splenic atrophy occurred in rats exposed by inhalation to 20 ppm 1,2-dibromoethane and fed diets with or without 0.05% disulfiram. Whether atrophy referred to lymphoid or hematopoietic tissue was not specified (Wong et al. 1982).

2.2.1.4 Neurological Effects

In an old case report by Kochmann (1928), a worker exposed by inhalation during 1,2-dibromoethane production had nonspecific neurologic signs of headache and depression; these signs resolved after cessation of exposure. Also, see Section 2.2.1.2.

There are no studies in animals focusing specifically on the nervous system. In the lethality studies of Rowe et al. (1952) discussed in Section 2.2.1.1, rats and guinea pigs exposed by inhalation to higher concentrations of 1,2-dibromoethane had central nervous system depression (exact clinical signs not specified). Brain tissue apparently was not examined histologically.

2.2.1.5 Developmental Effects

No studies were located regarding developmental effects in humans after inhalation exposure to 1,2-dibromoethane.

1,2-Dibromoethane can induce developmental effects in rodents (Short et al. 1978, 1979; Smith and Goldman 1983). The results of these studies indicate that 1,2-dibromoethane is more toxic to pregnant mice than pregnant rats (Short et al. 1978). It produces maternal toxicity as evidenced by decreases in food consumption, body weight gain, and survival (Short et al. 1978, 1979). Developmental effects observed include anatomical and skeletal defects and reduced survival of fetuses. However, these adverse developmental effects have been observed in animals at doses that induce maternal toxicity.

Inhalation exposure of pregnant Sprague-Dawley (Crl:CD) rats to 1,2-dibromoethane for 10 days during gestation resulted in significant reduction in food consumption at 20 ppm, weight loss at 32, 38, and 80 ppm, and 50% mortality at 80 ppm (Short et al. 1978). A significant reduction in the viability of embryos and fetuses was also evident at 80 ppm. Skeletal anomalies, primarily incomplete ossification, were common in the fetuses at concentrations as low as 20 ppm. Using the same protocol, the authors reported similar observations in CD-1 mice, although the maternal effects were more pronounced (Short et al. 1978). The maternal mortality was 100% in the 80-ppm exposure group. Reduction in food consumption and maternal body weight were noted at concentrations as low as 20 ppm. Fetotoxic effects consisted of
2. HEALTH EFFECTS

significantly increased resorptions and reduced fetal body weight. The skeletal anomalies, primarily incomplete ossification, observed in fetuses may have been the result of malnourishment rather than the direct effect of 1,2-dibromoethane-induced toxicity. However, the number of fetal mice was insufficient to draw this conclusion.

The reliable LOAEL values for developmental effects in rats and mice for the acute-duration category are reported in Table 2-1 and plotted in Figure 2-1.

2.2.1.6 Reproductive Effects

Antispermatic effects of 1,2-dibromoethane have been observed in humans occupationally exposed to 1,2-dibromoethane (Ratcliffe et al. 1987; Takahashi et al. 1981; Ter Haar 1980). These effects include changes in sperm velocity and count. Whether or not these effects are associated with reduced fertility in humans cannot be totally addressed, since the epidemiologic study (Wong et al. 1979) was not capable of detecting such a sensitive effect. Although this study had several limitations, it indicates a potential for adverse effects of 1,2-dibromoethane on fertility.

Two types of human studies have been reported in the literature: one that assessed fertility differences between groups of workers (Wong et al. 1979) and others that assessed the potential antispermatic effects in male workers (Ratcliffe et al. 1987; Ter Haar 1980). These studies provided little or equivocal evidence that 1,2-dibromoethane exposure was associated with adverse fertility or antispermatic effects in exposed workers. All studies lacked sufficient statistical power to detect an association due to small sample size, inadequate exposure assessment or histories, inappropriate control groups, and a general methodological weakness in assessing fertility status and antispermatic effects. Nevertheless, they do provide some indication of potential adverse effects of 1,2-dibromoethane on fertility and sperm production.

A decrease in male fertility to 49% below expected values (significant at p=0.05) was reported in one of four 1,2-dibromoethane manufacturing plants (Wong et al. 1979). After adjustment for workers who had vasectomies and one whose wife had a hysterectomy, the reduction in fertility was 29% and no longer significant at that level.

Occupational exposure to 1,2-dibromoethane has been reported to produce adverse effects both on spermatogenesis (sperm concentration) and seminal fluid production (semen volume) in human males (Ratcliffe et al. 1987; Takahashi et al. 1981, Ter Haar 1980).

The study by Ter Haar (1980) examined the relationship between sperm count and 1,2-dibromoethane exposure of 59 men employed at a production plant for antiknock compounds in Arkansas. In the low-exposure group (less than
2. HEALTH EFFECTS

0.5 ppm 1,2-dibromoethane in air), 20% of the individuals had sperm counts below 40 million while 42% of the high-exposure group (between 0.5 and 5 ppm 1,2-dibromoethane in the air) had sperm counts below 40 million. As discussed by Dobbins (1987), there was no concurrent unexposed control group; sperm counts were compared to several published values for the U.S. population. While the differences between the low- and high-exposure groups were significant, the absence of a control group was a serious defect.

The semen quality of 46 papaya workers with chronic exposure to 1,2-dibromoethane was examined (Ratcliffe et al. 1987). These men were employed for an average of 5 years and worked in six plants as sorters, packers, forklift drivers, and fumigators. The time-weighted average 1,2-dibromoethane exposure level was estimated at 0.088 ppm, with peak exposures as high as 0.226 ppm. After adjusting data for several variables, statistically significant decreases in sperm count, decreases in the percentages of viable and motile sperm, and increases in sperm abnormalities were evident when compared with a control population of unexposed sugar refinery workers. Chronic exposure to 1,2-dibromoethane affected sperm motility, but not velocity.

A significant reduction in sperm count of agricultural workers was also reported in earlier studies by Takahashi et al. (1981). They examined sperm counts, volume, morphology, and motility in a small sample of agricultural workers in Molokai, Hawaii. Agricultural worker exposure to 1,2-dibromoethane could not be estimated. A significant reduction in sperm count occurred in the workers as compared to reference controls and to fertile controls. Confounding factors were additional worker exposure to dibromochloropropane and marijuana use.

The direct effect of inhalation exposure to 1,2-dibromoethane on spermatogenesis in animals has not been studied. Nonetheless, the available data from animal studies indicate that the male reproductive system in rats is affected by exposure to 1,2-dibromoethane at high doses. In all studies discussed below, however, rats had high mortality associated with chemical toxicity and/or chemically-induced neoplasia. It is therefore difficult to attribute effects on the reproductive organs to a direct result of 1,2-dibromoethane toxicity. Male Sprague-Dawley (Crl:CD) rats exposed by inhalation to 1,2-dibromoethane at concentrations as high as 89 ppm in air for 10 weeks developed atrophy of the testis, epididymis, prostate, and seminal vesicles (Short et al. 1979). None of the rats from the 89-ppm exposure group were able to impregnate female rats during a 2-week mating period following termination of exposure. Mortality and morbidity also occurred among rats exposed at the high concentration. Testicular degeneration and testicular atrophy in dosed F344 rats in NTP's chronic inhalation study (NTP 1982) occurred in association with spontaneous interstitial cell tumors and chemically-induced mesotheliomas. In the study by Wong et al. (1982), testicular atrophy occurred in Sprague-Dawley rats exposed to
2. HEALTH EFFECTS

1,2-dibromoethane (20 ppm) in combination with disulfiram in the diet, a regimen that resulted in 100% mortality by 14 months.

The highest NOAEL and reliable LOAEL values for reproductive effects in rats for intermediate durations and a LOAEL value for chronic duration are recorded in Table 2-1 and plotted in Figure 2-1.

2.2.1.7 Genotoxic Effects

The incidence of sister chromatid exchange and chromosomal aberrations in lymphocytes from workers occupationally exposed to 1,2-dibromoethane was investigated by Steenland et al. (1985, 1986). Neither study revealed any genotoxic effect. In a study conducted on workers involved in spraying 1,2-dibromoethane on fallen pine trees, the estimated average exposure level of 1,2-dibromoethane was 0.06 ppm (Steenland et al. 1985). The rates of sister chromatid exchange measured in vitro in lymphocytes obtained from these workers soon after 1,2-dibromoethane exposure were not higher than those observed in lymphocytes taken from the same individuals before the exposures. In a subsequent study (Steenland et al. 1986), lymphocytes were taken from 60 workers in a papaya processing plant where 1,2-dibromoethane was used to fumigate fruit. The estimated average exposure level was 0.088 ppm 1,2-dibromoethane for an average of 5 years. This study did not detect an increase in the rate of sister chromatid exchange or the frequency of chromosomal aberrations in vitro in lymphocytes obtained from these workers. 1,2-Dibromoethane did not induce dominant-lethal mutations in rats exposed by inhalation to 1,2-dibromoethane vapor at exposure levels as high as 39 ppm (Short et al. 1979).

Other genotoxicity studies are discussed in Section 2.4.

2.2.1.8 Cancer

There have been two epidemiological studies regarding carcinogenic effects in workers exposed occupationally to 1,2-dibromoethane, primarily by the respiratory route (Ott et al. 1980; Turner and Barry 1979).

Cancer mortality and mortality due to respiratory disease were studied in 161 male employees exposed to 1,2-dibromoethane in two 1,2-dibromoethane manufacturing plants located in Texas and Michigan (Ott et al. 1980). Because the Texas and Michigan plants ceased operations in 1969 and 1976, respectively, environmental assessments were based on existing records and discussions with workers formerly associated with the plants. No statistically significant increase in deaths was observed when data were examined in terms of duration of exposure or interval since first exposure. Although there was an increase in cancer mortality among employees with more than 6 years of exposure to 1,2-dibromoethane in both plants, this increase was not statistically significant. The authors suggested that the observed incidence of cancer in the study population was lower than that which would be
2. HEALTH EFFECTS

predicted from animal studies. They concluded that there was a need for continued surveillance of the cohort of 161 employees and an industry-wide study of mortality among workers in 1,2-dibromoethane manufacturing plants. Although this study has a number of limitations, results of the study neither confirm nor refute the possibility that 1,2-dibromoethane is a human carcinogen. Study limitations include not controlling for confounding factors such as smoking, incomplete identification of exposure levels of 1,2-dibromoethane, concomitant exposure of workers to other chemicals, lack of a matched control group, and lack of completeness of report data.

In another epidemiological study, the mortality of workers exposed to 1,2-dibromoethane in two manufacturing plants in Britain was evaluated (Turner and Barry 1979). The manufacturing operation of each plant involved the extraction of bromine from sea water and its subsequent reaction with ethylene to form 1,2-dibromoethane. Although the size of the group studied was too small to analyze mortality rates on a year-by-year basis, a comparison of rates was done by grouping person-years of follow-up into four age ranges over the period of the study (23 years). No increase in mortality from any cause, including neoplasia, was identified in the 1,2-dibromoethane workers.

Chronic inhalation exposure of rodents to 1,2-dibromoethane has been associated with neoplasms in the respiratory tract, as well as in other organ systems. Two studies have examined the carcinogenic potential of 1,2-dibromoethane in rodents after inhalation exposure (NTP 1982; Wong et al. 1982). There was also an A strain mouse assay (Adkins et al. 1986).

A chronic inhalation study (18 months) in Sprague-Dawley (Crl:CD) rats examined the carcinogenicity of 20 ppm 1,2-dibromoethane alone and with simultaneous exposure to 0.05% disulfiram in the diet (Wong et al. 1982). Male rats exposed to 1,2-dibromoethane had significantly higher incidences of splenic hemangiosarcomas and subcutaneous mesenchymal tumors. Female rats exposed to 1,2-dibromoethane had significantly higher incidences of splenic hemangiosarcomas and mammary tumors (combined adenoma, fibroadenoma, carcinoma, or adenocarcinoma). In both sexes of rats, the combination of 1,2-dibromoethane and disulfiram resulted in significantly higher incidences of hepatocellular tumors (percentage of adenoma or carcinoma not identified); splenic hemangiosarcoma; kidney adenoma and adenocarcinoma; thyroid follicular epithelial adenoma; and hemangiosarcoma of the omentum or mesentery. It was unclear whether hemangiosarcoma of the mesentery (omentum) and of the lung were primary sites or metastatic from spleen. Female rats had increased incidence of mammary gland tumors.

Because the nasal cavity of the animals was not examined histologically, it cannot be determined whether nasal cavity tumors were induced. Also, because the authors tested animals at only one concentration, the doseresponse cannot be characterized.
2. HEALTH EFFECTS

The carcinogenicity of 1,2-dibromoethane in F344 rats and B6C3F1 mice was examined in an inhalation bioassay (NTP 1982). Doses tested were 0, 10, and 40 ppm; study duration was 79–103 weeks. Mortality related to chemically-induced malignant tumors and to toxic lesions was high in high-dose rats of both sexes. Both sexes of rats had significant compound-related increases in nasal epithelial tumors. EPA (IRIS 1991) has derived a unit risk value of $2.2 \times 10^{-4}$ µg/m$^3$ for cancer risk associated with inhalation exposure to 1,2-dibromoethane from this study based on the incidence of nasal tumors in male rats. EPA also estimated that 1,2-dibromoethane concentrations of $5 \times 10^{-1}$, $5 \times 10^{-2}$, and $5 \times 10^{-3}$ µg/m$^3$ ($6.5 \times 10^{-5}$, $6.5 \times 10^{-6}$, and $6.5 \times 10^{-7}$ ppm) in air are associated in humans with excess lifetime cancer risks of $10^{-4}$, $10^{-5}$, and $10^{-6}$, respectively. These values correspond to 1 excess cancer death in 10,000, 100,000, or 1 million persons exposed continuously for their lifetime (estimated as 70 years) to these respective levels of 1,2-dibromoethane by inhalation. These estimated concentrations associated with cancer risk were converted into ppm and plotted in Figure 2-1.

Exposed rats also had elevated incidences of splenic hemangiosarcomas (both sexes), mesothelioma of the tunica vaginalis (males), pulmonary alveolar/bronchiolar adenoma or carcinoma (females), and fibroadenoma of the mammary gland (females).

Exposed female mice had significant compound-related increases in nasal carcinomas (NTP 1982; Stinson et al. 1981). The incidences of combined alveolar/bronchiolar carcinoma and adenoma were significantly increased in the lungs of high-dose male and female mice as compared with control animals. In addition to these tumors, adenomatous polyps were present in tracheal, bronchial, and bronchiolar lumens (NTP 1982).

There was a statistically significant compound-related increase in incidence of several other tumors in female mice: hemangiosarcoma of the abdominal retroperitoneum, particularly involving the area of the ovaries, uterus, kidneys, and adrenal; subcutaneous fibrosarcomas; and mammary adenocarcinoma (NTP 1982). A limitation of the study was poor survival in male mice from ascending suppurative urinary tract infections.

A/J strain mice exposed by inhalation to 20 and 50 ppm 1,2-dibromoethane for 6 months had a significant increase in the frequency and incidence of alveolar- bronchiolar adenomas (Adkins et al. 1986).

In summary, two epidemiological studies have not identified an increased risk of cancer in people occupationally exposed by inhalation to 1,2-dibromoethane. In experimental animals exposed by the inhalation route, 1,2-dibromoethane is a potent carcinogen, producing cancer at the point-of-contact—the upper respiratory tract—as well as in numerous organs and tissues throughout the body.
2. HEALTH EFFECTS

2.2 Oral Exposure

2.2.2 Death

There are two case reports of death in humans following oral administration of 1,2-dibromoethane in suicide attempts.

A white 43-year-old female died 54 hours after ingestion of 9 "Fumisoil" capsules each containing 4.5 mL 1,2-dibromoethane (140 mg/kg/day) (Olmstead 1960). Clinical signs prior to death were emesis, diarrhea, oliguria progressing to anuria, tachypnea, and agitation. Pathologic findings were in liver and kidney. The liver had extensive centrilobular hepatocellular necrosis with sinusoidal dilatation and a minimal cellular reaction. The kidney had patchy areas of either acute tubular necrosis or autolysis, mild cytoplasmic vacuolization of proximal cortical tubules, and proteinaceous casts in tubules near the cortico-medullary junction.

Ingestion of one ampule of commercial 1,2-dibromoethane occurred in six additional human cases of attempted suicide (Saraswat et al. 1986). The patients were all teenagers or young adults; two out of six died. One female patient was admitted in a moribund condition and died approximately 36 hours after admission. Pathologic findings were oropharyngeal ulceration, gastric mucosal erosions, massive hepatocellular necrosis, icterus, and renal lesions (hemorrhage, tubular swelling, and occasional necrosis). A second female was admitted with nausea, emesis, and a burning sensation in her throat. She became hypotensive, unconscious, and died approximately 15 hours after admission. Pathologic findings were oropharyngeal ulcers, gastric hyperemia, and centrilobular hepatocellular necrosis. Four other patients who survived after ingesting 1,2-dibromoethane (three female, one male) had nausea and emesis and three out of four had labial and oral erosions and ulcers.

In a study using large domestic animals because of concern over soil nematocide residues in treated forage, 1,2-dibromoethane was administered orally in a gelatin capsule to a small number of animals (Schlinke 1969). 1,2-Dibromoethane at 50 mg/kg body weight caused mortality in one calf, while one calf given 25 mg/kg body weight and one calf given 10 mg/kg body weight survived. Sheep were similarly treated; one given 50 mg/kg body weight died, one out of two given 25 mg/kg died, and one given 10 mg/kg survived. Interpretation of these studies was complicated by use of a ruminant species, a very small number of animals, and lack of necropsy data.

Single-dose oral LD₅₀ values in rats, guinea pigs, rabbits, and mice were determined by Rowe et al. (1952) in a gavage study using 1,2-dibromoethane in olive oil. All reliable LD₅₀ values (lethal dose, 50% kill) for each species for the acute-duration category are recorded in Table 2-2 and plotted in
<table>
<thead>
<tr>
<th>Key to figure</th>
<th>Species</th>
<th>Route</th>
<th>Duration</th>
<th>Exposure frequency</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL (effect)</th>
<th>Less serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Rat</td>
<td>(GO)</td>
<td>1 d</td>
<td>1x/d</td>
<td></td>
<td>117 (LD₅₀: female)</td>
<td></td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td>2</td>
<td>Rat</td>
<td>(GO)</td>
<td>1 d</td>
<td>1x/d</td>
<td></td>
<td>146 (LD₅₀: males)</td>
<td></td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td>3</td>
<td>Rabbit</td>
<td>(GO)</td>
<td>1 d</td>
<td>1x/d</td>
<td></td>
<td>55 (LD₅₀: female)</td>
<td></td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td>4</td>
<td>Gn pig</td>
<td>(GO)</td>
<td>1 d</td>
<td>1x/d</td>
<td></td>
<td>110 (LD₅₀)</td>
<td></td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td>5</td>
<td>Mouse</td>
<td>(GO)</td>
<td>1 d</td>
<td>1x/d</td>
<td></td>
<td>420 (LD₅₀: female)</td>
<td></td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Rat</td>
<td>(GO)</td>
<td>1 d</td>
<td>1x/d</td>
<td>Hepatic</td>
<td>100</td>
<td></td>
<td></td>
<td>Short et al. 1979</td>
</tr>
<tr>
<td>7</td>
<td>Rat</td>
<td>(GO)</td>
<td>1 d</td>
<td>1x/d</td>
<td>Hepatic</td>
<td>110 (necrosis)</td>
<td></td>
<td></td>
<td>Broda et al. 1976</td>
</tr>
<tr>
<td>8</td>
<td>Rat</td>
<td>(G)</td>
<td>2 wk</td>
<td>5d/wk</td>
<td>Gastro</td>
<td>40</td>
<td>80 (forestomach cell proliferation and hyperkeratosis)</td>
<td></td>
<td>Ghanayem et al. 1986</td>
</tr>
<tr>
<td>9</td>
<td>Rat</td>
<td>(GO)</td>
<td>1 d</td>
<td>1x/d</td>
<td>Hepatic</td>
<td>107 (fat degeneration)</td>
<td></td>
<td></td>
<td>Botti et al. 1986</td>
</tr>
</tbody>
</table>
### TABLE 2-2 (Continued)

<table>
<thead>
<tr>
<th>Key to figure*</th>
<th>Species</th>
<th>Exposure frequency/Route duration</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL (effect)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Rat</td>
<td>(GO) 5 d 1x/d</td>
<td>30</td>
<td></td>
<td>Teramoto et al. 1980</td>
</tr>
<tr>
<td>11</td>
<td>Mouse</td>
<td>(GO) 5 d 1x/d</td>
<td>150</td>
<td></td>
<td>Teramoto et al. 1980</td>
</tr>
</tbody>
</table>

### INTERMEDIATE EXPOSURE

**Reproductive**

| 12 | Bull | (C) 20 d 1x/2d | 4 (transient sperm anomalies) | Amir 1975 |
| 13 | Bull | (GO) 20 d 1x/2d | 4 (transient sperm anomalies) | Amir et al. 1977 |

### CHRONIC EXPOSURE

**Cancer**

<p>| 14 | Rat   | (GO) 49-61 wk 5d/wk 1x/d | 38 (CEL; stomach tumor male) | NCI 1978 |
| 15 | Mouse | (W) 15-18 mo 7d/wk 1x/d  | 103 (CEL, forestomach tumor female) | Van Duuren et al. 1985 |
| 16 | Mouse | (W) 18 mo 7d/wk 24h/d     | 116 (CEL, forestomach tumor male) |         |
|    |       |                         | 50 (CEL, gastrointestinal tumors male) | Van Duuren et al. 1986 |</p>
<table>
<thead>
<tr>
<th>Key to figure</th>
<th>Species</th>
<th>Route duration</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>Mouse (GO)</td>
<td>53-78 wk</td>
<td></td>
<td></td>
<td>62 (CEL, forestomach, lung tumors)</td>
<td></td>
<td>NCI 1978</td>
</tr>
<tr>
<td></td>
<td>Mouse (GO)</td>
<td>5d/wk</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mouse (GO)</td>
<td>1x/d</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The number corresponds to entries in Figure 2-2.

(C) = capsule; CEL = cancer effect level; CNS = central nervous system; d = day; (G) = gavage; Gastro = gastrointestinal; Gp. pig = guinea pig; (GO) = oral by gavage; LOAEL = lowest-observed-adverse-effect level; LD50 = lethal dose, 50% kill; mo = month; NOAEL = no-observed-adverse-effect level; (W) = water; wk = week; (x) = times.
FIGURE 2-2. Levels of Significant Exposure to 1,2-Dibromoethane - Oral

**ACUTE**
(≤14 Days)

**INTERMEDIATE**
(15-364 Days)

**CHRONIC**
(≥365 Days)

Key:
- r: Rat
- m: Mouse
- h: Rabbit
- g: Guinea pig
- o: Other
- LD50
- LOAEL for serious effects (animals)
- LOAEL for less serious effects (animals)
- NOAEL (animals)
- CEL: Cancer Effect Level

The number next to each point corresponds to entries in Table 2-2.

* Doses represent the lowest dose tested per study that produced a tumorigenic response and do not imply the existence of a threshold for the cancer end point.
2. HEALTH EFFECTS

2.2.2.2 Systemic Effects

No studies were located regarding respiratory, cardiovascular, hematological, musculoskeletal, or dermal/ocular effects in humans or animals after oral exposure to 1,2-dibromoethane.

The highest NOAEL and all reliable LOAEL values for systemic effects in each species and duration category are recorded in Table 2-2 and plotted in Figure 2-2.

Gastrointestinal Effects. Oral and/or pharyngeal ulceration occurred in five out of six humans who ingested commercial 1,2-dibromoethane ampules (Saraswat et al. 1986). This report was discussed in detail in Section 2.2.2.1.

Because 1,2-dibromoethane given chronically by gavage induced a high incidence of squamous cell tumors of the forestomach of rodents, a short-term study was conducted to identify forestomach lesions following 2-week repeated gavage administration of 40 or 80 mg/kg/day 1,2-dibromoethane to F344 rats (Ghanayem et al. 1986). A significant increase in forestomach mucosal cell proliferation and hyperkeratosis occurred in rats exposed to 80 mg/kg/day. These proliferative lesions, which in themselves are not preneoplastic, could suggest the potential for development of neoplastic lesions. The authors concluded that forestomach mucosal hyperplasia resulting from chronic gavage of 1,2-dibromoethane may provide a favorable environment for tumor development.

Nonneoplastic proliferative lesions of the forestomach were observed in high-dose Osborne-Mendel rats in the chronic gavage study of 1,2-dibromoethane conducted by the National Cancer Institute (NCI 1978). These consisted of acanthosis and hyperkeratosis of forestomach squamous epithelium. Similar lesions occurred in high-dose B6C3F1 mice. These dose levels are not plotted and recorded in Figure 2-2 and Table 2-2, respectively, since these doses also caused forestomach squamous cell tumors.

Hepatic Effects. Severe liver necrosis occurred in three humans who ingested commercial 1,2-dibromoethane in order to commit suicide (Olmstead 1960; Saraswat et al. 1986). Necrosis was massive in one of these individuals; the other two had centrilobular hepatocellular necrosis.

1,2-Dibromoethane is considered to be a weak hepatotoxin in animals. Hepatocellular fatty change (degeneration) is one of the common lesions in experimental animals associated with acute oral exposure to 1,2-dibromoethane (Botti et al. 1986). When administered to rats by gavage at a dosage of 110 mg/kg/day, this lesion is corroborated by an increase in liver
2. HEALTH EFFECTS

triglyceride levels that begins within 8 hours of treatment (Nachtomi and Alumot 1972).

Using light microscopy, Broda et al. (1976) did not observe hepatocellular fatty change in livers of rats exposed by gavage to 110 mg/kg 1,2-dibromoethane in olive oil. Rats developed centrilobular dilatation within 8 hours after exposure, hepatocellular degeneration within 17 hours after exposure, and frank centrilobular necrosis 22 hours after 1,2-dibromoethane exposure.

Following gavage administration of 107 mg/kg 1,2-dibromoethane to rats, 1,2-dibromoethane depleted both cytosolic and mitochondrial glutathione; ultrastructurally, some mitochondria had abnormal shapes (Botti et al. 1986). When rats were pretreated 30 minutes prior to 1,2-dibromoethane administration with diethylmaleate, a cytoplasmic glutathione-depleting agent, hepatocytes had generalized vacuolization due to mitochondria with severe ultrastructural abnormalities and swelling. These findings demonstrated the importance of glutathione in maintenance of mitochondrial membrane integrity. With reduced glutathione levels and the concomitant formation of glutathione disulfides, the mitochondrial membrane became altered and permeable to calcium ions (Botti et al. 1986).

Liver was not examined histologically in the subchronic study used to set concentrations for the NCI chronic gavage bioassay of 1,2-dibromoethane (NCI 1978). In the NCI (1978) gavage bioassay (discussed in detail in Section 2.2.2.8), a nonneoplastic hepatic lesion, peliosis hepatis, occurred in a small number of treated male and female Osborne-Mendel rats and had an equivocal relationship to 1,2-dibromoethane exposure.

**Renal Effects.** Renal lesions have been reported in humans dying acutely after acute oral exposure to 1,2-dibromoethane. In the case report by Olmstead (1960), the patient's kidneys had equivocal necrotizing tubular lesions, proximal convoluted tubular cytoplasmic vacuolization, and proteinaceous casts in tubules near the corticomedullary junction. In the report of Saraswat et al. (1986), one of two fatalities had renal hemorrhage, tubular swelling, and occasional necrotic tubular cells.

Cell proliferation, predominantly in the proximal tubules, occurred in Wistar rats following a single oral dose of 100 mg/kg 1,2-dibromoethane in corn oil. Mitotic activity peaked at 30 hours. Lack of any histologic evidence of tubular necrosis between 8-48 hours after treatment indicates that such proliferation was not a regenerative response (Ledda-Columbano et al. 1987b).

Toxic nephropathy of the type seen after inhalation exposure of rats (see Section 2.2.1.2) was not identified in rats or mice in the NCI (1978) gavage bioassay of 1,2-dibromoethane.
2. HEALTH EFFECTS

Other Systemic Effects. Endocrine lesions related to 1,2-dibromoethane exposure were reported in the NCI (1978) gavage bioassay. These consisted of adrenal cortical cell degeneration in a small number of exposed male and female Osborne-Mendel rats. The possibility exists that this adrenal change represents a secondary (stress-related) effect rather than a primary effect of 1,2-dibromoethane exposure.

2.2.2.3 Immunological Effects

No studies were located regarding immunologic effects in humans or animals after oral exposure to 1,2-dibromoethane.

2.2.2.4 Neurological Effects

No clinical signs specific to primary neurologic effects were described in humans following ingestion of 1,2-dibromoethane (Saraswat et al. 1986) (see Section 2.2.2.1). One of the patients who became unconscious and died after ingestion of 1,2-dibromoethane had nonspecific brain lesions--meningeal congestion and interstitial cortical edema. Of the four patients who survived, three had symptoms of confusion upon admission although they were conscious.

Sheep and calves dying after toxic oral doses of 1,2-dibromoethane (Schlinke 1969) had nonspecific clinical signs of stiffness, prostration, and anorexia.

2.2.2.5 Developmental Effects

No studies were located regarding developmental effects in humans and animals after oral exposure to 1,2-dibromoethane.

2.2.2.6 Reproductive Effects

No studies were located regarding reproductive effects in humans, although oral exposure via drinking water and contaminated food has been documented in the literature.

Reproductive effects from oral exposure to 1,2-dibromoethane have been investigated in various animals including bulls, rats, and mice over intermediate and chronic exposure durations (Amir 1973; Amir and Ben-David 1973; Amir and Lavon 1976; Amir and Volcani 1965; Amir et al. 1983; NCI 1978). These studies indicate species differences in sperm damage resulting from exposure to 1,2-dibromoethane.

A high percentage (up to 79%) of abnormal spermatozoa in bull ejaculates was reported as early as two weeks following oral administration of 10 doses of 4 mg/kg 1,2-dibromoethane on alternate days (Amir and Ben-David 1973).
Radioactivity (\(^3\)H or \(^{14}\)C-1,2-dibromoethane) was detected in spermatozoa collected approximately 1 week following the initial oral dose (Amir 1973). These results indicate that 1,2-dibromoethane exerts spermicidal action during the process of spermiogenesis and sperm maturation. This conclusion was supported by the evidence that the percentage of sperm abnormalities was highest when little 1,2-dibromoethane radioactivity could be detected in sperm. In addition, reduction in sperm concentration was more pronounced in adult bulls than in young bulls, and the period of recovery was longer in adult animals (Amir 1975). In another study, bulls were fed 2 mg/kg/day 1,2-dibromoethane for 12 months followed by 4 mg/kg 1,2-dibromoethane every other day, until they reached the age of 14-16 months. The semen samples examined revealed low sperm density, structural abnormalities, and low mobility (Amir and Volcani 1965). Sperm production returned to normal as early as 10 days postexposure (Amir and Lavon 1976; Amir et al. 1977).

In the chronic gavage study of 1,2-dibromoethane conducted by NCI (1978), high-dose male Osborne-Mendel rats and B6C3F1 mice developed testicular atrophy. Because study animals had high compound- and gavagerelated mortality and early onset of forestomach squamous cell carcinomas, it is difficult to determine from these results whether testicular atrophy (degeneration) was a primary (compound-induced) or secondary (nonspecific) event.

The highest NOAEL values for reproductive effects in rats and mice for acute exposure duration and a reliable LOAEL in bulls for the intermediate-duration category are recorded in Table 2-2 and plotted in Figure 2-2.

### 2.2.2.7 Genotoxic Effects

No studies were located regarding genotoxic effects in humans after oral exposure to 1,2-dibromoethane. Repeated oral administration of 1,2-dibromoethane to rats at 100 mg/kg/day (Epstein et al. 1972) and to mice at doses as high as 150 mg/kg/day (Teramoto et al. 1980) did not induce dominant lethal mutations. Females mated to these males did not show a significant increase in the number of dead implants, indicating a lack of genotoxic effect. Liver and sperm cells from rats gavaged once with 1,2-dibromoethane at doses ranging from 10 to 100 mg/kg were not found to have higher rates of unscheduled DNA synthesis than those from untreated rats (Working et al. 1986). In contrast, oral administration of approximately 3 mg/kg to rats resulted in the formation of DNA adducts in all tissues examined (kidney, liver, spleen, intestine, stomach, testes, heart, brain, and muscle, listed in decreasing order of amount detected) (Hill et al. 1978). 1,2-Dibromoethane induced DNA damage in rat liver cells when administered as a single dose by gavage at doses ranging from 75-220 mg/kg (Nachtmann and Sarma 1977). Hepatocellular DNA damage caused at the 75-mg/kg dose level was completely repaired 96 hours after administration.

Other genotoxicity studies are discussed in Section 2.4.
2. HEALTH EFFECTS

2.2.2.8 Cancer

No studies were located regarding carcinogenic effects in humans following oral exposure to 1,2-dibromoethane.

The rat liver foci assay is a short-term in vivo test to predict carcinogenic potential of a chemical. In this assay, 1,2-dibromoethane has both initiating and promoting activity, which correlates well with its carcinogenic effects in animals.

1,2-Dibromoethane was administered orally in corn oil to Sprague-Dawley rats in doses up to 120 mg/kg body weight in an initiation protocol that included partial hepatectomy (Milks et al. 1982). This treatment did not cause an increase in γ-glutamyl transpeptidase (GGT) positive foci after 2 months. When 1,2-dibromoethane was orally administered in corn oil at doses of 10 or 30 mg/kg in a promotion protocol with N-nitrosodiethylamine as an initiator, there was a significant increase in production of GGT positive foci after 2 months. Based on their results, the authors speculated that 1,2-dibromoethane had epigenetic (promoter) activity, which could contribute to the compound's carcinogenic effect. Promotion effects may have been related to hepatocellular mitogenesis. Such a promotional effect was not detected when 1,2-dibromoethane was used to induce hepatocellular mitogenesis in the absence of partial hepatectomy following initiation by diethylnitrosamine (Ledda-Colwnbano et al. 1987a).

In another liver foci study using Sprague-Dawley (Crl:CD) rats, 1,2-dibromoethane in corn oil given by gavage was used as an initiator. Two dose regimens were used: 75 mg/kg 1,2-dibromoethane at 0 and 24 hours or corn oil at 0 hours and 75 mg/kg 1,2-dibromoethane at 24 hours. Partial hepatectomies and phenobarbital in drinking water also were part of the protocol. With this system, at 16 months, 1,2-dibromoethane-exposed rats had increased numbers of foci of hepatic cellular alteration. Rats that received the two doses of 1,2-dibromoethane had increased numbers of nodules on hematoxylin and eosin-stained sections as well as increased number and size of GGT positive foci (Moslen 1984). These results indicate that 1,2-dibromoethane can act as an initiator.

Oral exposure of rodents to 1,2-dibromoethane either via gavage or drinking water has resulted in neoplasms of the forestomach and other organs.

The carcinogenicity of 1,2-dibromoethane by the oral route has been examined in a chronic bioassay conducted by NCI (1978). The chemical was administered by gavage in corn oil to rats and mice. Because of dose adjustments during the study, doses were expressed as time-weighted average (TWA) as follows: high doses for rats were 41 mg/kg/day (males) and 39 mg/kg/day (females); low doses for rats were 38 mg/kg/day (males) and 37 mg/kg/day (females); the high dose for male and female mice was 107 mg/kg/day; and the low dose for male and female mice was 62 mg/kg/day.
2. HEALTH EFFECTS

Under test conditions, 1,2-dibromoethane was carcinogenic to Osborne-Mendel rats and B6C3F1 mice resulting in squamous cell carcinomas of the forestomach in rats and mice of both sexes and lung adenomas in male and female mice. There were also two equivocal endpoints in rats: hepatocellular tumors in females and hemangiosarcomas in males. It should be noted that there were a number of problems associated with this study. High mortality as a result of incorrect determination of the maximum tolerated dose necessitated discontinuation of dosing from weeks 17 to 30 in the high-dose rats. Periodic adjustments of dose were made for male and female mice. There may have been errors in laboratory gavage procedures. Finally, the rat and mouse studies were terminated early. However, these limitations do not diminish the conclusion that 1,2-dibromoethane is carcinogenic to rats and mice following chronic gastric intubation exposure.

EPA (1987a) has derived a \( q^* \) value of 85 (mg/kg/day)\(^{-1}\) for cancer risk associated with oral exposure to 1,2-dibromoethane based on the study by NCI (1978) in rats. IRIS (1991) also estimated that 1,2-dibromoethane concentrations of \( 4 \times 10^{-3} \), \( 4 \times 10^{-4} \), and \( 4 \times 10^{-5} \) µg/L (\( 5 \times 10^{-7} \), \( 5 \times 10^{-8} \), and \( 5 \times 10^{-9} \) mg/kg/day) in water are associated in humans with excess lifetime cancer risks of \( 10^{-4} \), \( 10^{-5} \), and \( 10^{-6} \), respectively. These values correspond to 1 excess cancer death in 10,000, 100,000, or 1 million persons, exposed continuously for their lifetime (estimated as 70 years) to these respective levels of 1,2-dibromoethane by ingestion. These estimated concentrations associated with cancer risk were converted into mg/kg/day and plotted in Figure 2-2.

There are two drinking water studies of 1,2-dibromoethane that further support the conclusion that oral exposure to 1,2-dibromoethane results in forestomach tumors in mice.

A dose of 103 mg/kg/day for females and 116 mg/kg/day for males of 1,2-dibromoethane in drinking water induced squamous cell tumors (primarily carcinomas) of the forestomach in male and female B6C3F1 mice (Van Duuren et al. 1985). It should be noted that the male and female mice were sacrificed before the completion of the chronic study because of excessive morbidity. Because only one dose of 1,2-dibromoethane was used, a dose-response could not be characterized.

In another drinking water study, 50 mg/kg/day 1,2-dibromoethane was used as a positive control for a study on humic acids (Van Duuren et al. 1986). Both sexes of B6C3F1 mice exposed to 1,2-dibromoethane had statistically significant increases in squamous cell tumors of the forestomach: squamous cell carcinomas in males and papillomas or carcinomas in females. Male 1,2-dibromoethane-treated mice also had a significant increase over control animals in the incidence of papilloma and squamous carcinoma of the esophagus. Animals were tested at only one dose; therefore, dose-response could not be characterized.
2. HEALTH EFFECTS

2.2.3 Dermal Exposure

2.2.3.1 Death

Two fatal cases of occupational exposure to 1,2-dibromoethane were reported by Letz et al. (1984). A worker collapsed shortly after entering a pesticide storage tank containing residues of 1,2-dibromoethane; he remained in the tank for 45 minutes. A supervisor attempting to rescue the worker also collapsed and was exposed for 20-30 minutes prior to rescue. Both men died 12 and 64 hours after collapse, respectively. The primary route of exposure was postulated to be dermal, with inhalation also playing a potentially important role. Neither worker had been wearing protective clothing or respirators.

Clinical chemistry prior to death for both men revealed metabolic acidosis, acute renal and hepatic failure, skeletal muscle necrosis, and damage to other organ systems. Autolysis of viscera prevented complete characterization of lesions associated with mortality from these 1,2-dibromoethane exposures.

Lethal amounts of topically applied 1,2-dibromoethane were rapidly absorbed through the intact skin of rabbits. When evaporation was prevented for 24 hours by occlusive dressing, mortality occurred within 4 days (Rowe et al. 1952).

The reliable LOAEL for death in rabbits from acute dermal exposure to 1,2-dibromoethane is recorded in Table 2-3.

2.2.3.2 Systemic Effects

No studies were located regarding hematologic effects in humans or animals after dermal exposure to 1,2-dibromoethane.

Respiratory Effects. In the case report of Letz et al. (1984) (see Section 2.2.3.1), one patient had bilateral pulmonary edema and cyanosis at necropsy. These lesions, however, are nonspecific and can occur with any type of agonal death. No studies were located regarding respiratory effects in animals after dermal exposure to 1,2-dibromoethane.

Cardiovascular Effects. One of the patients described by Letz et al. (1984) (see Section 2.2.3.1) who had a terminal cardiopulmonary arrest had acute myocardial interstitial edema, myocardial inflammation, and Grampositive sporulating rods at necropsy. The second patient initially had a
<table>
<thead>
<tr>
<th>Species</th>
<th>Exposure frequency/duration</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL (effect)</th>
<th>Serious (mg/kg/day)</th>
<th>Less serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACUTE EXPOSURE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rabbit</td>
<td>24 hr</td>
<td></td>
<td>300 (approximate LD&lt;sub&gt;50&lt;/sub&gt;)</td>
<td></td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td>Systemic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rabbit</td>
<td>24 hr</td>
<td>Derm/oc</td>
<td>210 (erythema, necrosis)</td>
<td></td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td>Neurological</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rabbit</td>
<td>24 hr</td>
<td></td>
<td>210 (CNS depression)</td>
<td></td>
<td></td>
<td>Rowe et al. 1952</td>
</tr>
<tr>
<td><strong>CHRONIC EXPOSURE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse</td>
<td>440-594 d</td>
<td></td>
<td>833 (CEL, lung adenoma)</td>
<td></td>
<td></td>
<td>Van Duuren et al. 1979</td>
</tr>
<tr>
<td>3d/wk</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1x/d</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CEL = cancer effect level; CNS = central nervous system; d = day; Derm/oc = dermal/ocular; hr = hour; LD<sub>50</sub> = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level; wk = week
2. HEALTH EFFECTS

normal electrocardiogram, but as his renal and hepatic function deteriorated, eventually developed supraventricular tachycardia and asystole.

No studies were located regarding cardiovascular effects in animals after dermal exposure to 1,2-dibromoethane.

**Gastrointestinal Effects.** Both patients described by Letz et al. (1984) (see Section 2.2.3.1) vomited shortly after removal from the tank; one complained of a burning throat. Both patients later developed diarrhea.

No studies were located regarding gastrointestinal effects in animals after dermal exposure to 1,2-dibromoethane.

**Musculoskeletal Effects.** Both patients described by Letz et al. (1984) (see Section 2.2.3.1) had greatly elevated levels of serum creatinine phosphokinase after 1,2-dibromoethane exposure; this enzyme increases in the event of skeletal muscle necrosis. There was no report of skeletal muscle being examined at necropsy or histologically in either individual.

No studies were located regarding musculoskeletal effects in animals after dermal exposure to 1,2-dibromoethane.

**Hepatic Effects.** Both patients described by Letz et al. (1984) (see Section 2.2.3.1) had elevated serum aspartate aminotransferase and lactic dehydrogenase, indicating severe hepatic damage. These enzymes were elevated 5 hours after exposure in one man who died 12 hours after exposure and 24 hours after exposure in the second patient who died 64 hours following exposure. Liver from the patient dying first had intrasinusoidal nuclear fragmentation consistent with Kupffer cell damage; autolysis precluded examination of the second patient's liver.

No studies were located regarding hepatic effects in animals after dermal exposure to 1,2-dibromoethane.

**Renal Effects.** The patient described by Letz et al. (1984) (see Section 2.2.3.1) who lived for 64 hours after exposure to toxic levels of 1,2-dibromoethane had acute renal failure as evidenced by severe oliguria 24 hours after exposure and abnormal clinical chemistry values (blood urea nitrogen, creatinine, and serum uric acid). Severe metabolic acidosis was present despite two hemodialysis procedures.

No studies were located regarding renal effects in animals after dermal exposure to 1,2-dibromoethane.

**Dermal/Ocular Effects.** Volunteers including the report's author were exposed topically to liquid from a remote water gauge; this liquid contained 1,2-dibromoethane as well as other chemicals (Pfleiser 1938). Follow-up tests
2. HEALTH EFFECTS

were formed with 1,2-dibromoethane. No dermal changes occurred when the liquid or 0.5 cc of 1,2-dibromoethane was applied to uncovered skin. A burning sensation, inflammation and vesiculation occurred when a cloth dressing saturated with the liquid was applied for 1-2 hours. Skin lesions resolved with treatment after 7-13 days.

Erythema and blisters developed within 24 hours on the trunk and legs of a worker exposed to residues of 1,2-dibromoethane in a pesticide tank (Letz et al. 1984). This patient, immediately after rescue, complained of burning eyes, but ocular lesions did not develop.

When rabbits were exposed topically to 1,2-dibromoethane, all animals with occlusive dressings, irrespective of concentration, had moderate to severe cutaneous erythema, edema, and necrosis with sloughing (Rowe et al. 1952). When evaporation was not inhibited, slight erythema but no additional damage occurred. Lethality associated with this exposure was discussed in Section 2.2.3.1.

Undiluted 1,2-dibromoethane applied topically to rabbit eyes caused pain, conjunctival irritation, and superficial corneal necrosis. A 10% solution of 1,2-dibromoethane in propylene glycol applied topically produced more ocular damage to rabbit eyes than undiluted 1,2-dibromoethane. Conjunctival irritation and corneal damage were more pronounced and persistent. Healing was complete 2 and 12 days after exposure to the undiluted 1,2-dibromoethane and the 10% solution, respectively (Rowe et al. 1952).

The LOAEL for dermal effects in rabbits from acute dermal exposure to 1,2-dibromoethane is recorded in Table 2-3.

2.2.3.3 Immunological Effects

No studies were located regarding immunologic effects in humans or animals after dermal exposure to 1,2-dibromoethane.

2.2.3.4 Neurological Effects

Two male workers collapsed very shortly after entering a storage tank that contained toxic 1,2-dibromoethane residues (Letz et al. 1984). After 45 minutes of exposure prior to rescue, one patient was comatose then became combative and incoherent in the ambulance. One hour later, he was lethargic; as metabolic acidosis developed, he became semicomatose. When the second patient was rescued from the tank after 20-30 minutes of exposure; he became delirious and combative. His neurological symptoms then ameliorated until he developed hepatorenal failure.
2. HEALTH EFFECTS

In the study of Rowe et al. (1952) discussed in Section 2.2.3.1, rabbits exposed dermally to 1,2-dibromoethane at all dosage levels had central nervous system depression (not otherwise specified).

The reliable LOAEL for neurological effects in rabbits from acute dermal exposure is recorded in Table 2-3.

No studies were located regarding the following health effects in humans or animals after dermal exposure to 1,2-dibromoethane:

2.2.3.5 Developmental Effects
2.2.3.6 Reproductive Effects
2.2.3.7 Genotoxic Effects

Genotoxicity studies are discussed in Section 2.4.

2.2.3.8 Cancer

No studies were located regarding carcinogenic effects in humans following exposure to 1,2-dibromoethane by the dermal route alone. However, occupational exposures to 1,2-dibromoethane are likely to involve dermal as well as respiratory exposure. Two epidemiologic studies concerning occupational exposure are discussed in Section 2.2.1.8 and an abstract is discussed in Section 2.9.3.

Dermal exposure of mice to 1,2-dibromoethane has resulted in cutaneous neoplasms and increased incidences of primary lung tumors.

Repeated topical application of 1,2-dibromoethane (0, 833, or 1,666 mg/kg/day) to Ha:ICR Swiss mice resulted in a statistically significant increase in skin papillomas at the high dose (Van Duuren et al. 1979). In addition, the number of mice with distant tumors (lung tumors) was significantly higher at both doses applied. Because the mice in the study were housed six to a cage with no restraining collars to prevent licking the application site, aspiration to the lungs could have occurred during grooming. 1,2-Dibromoethane did not initiate skin tumors after a single topical application, even when treatment by phorbol myristate (a potent tumor promoter) followed the dermal application of 1,2-dibromoethane (Van Duuren et al. 1979). The cancer effect level causing lung tumors in mice from chronic dermal exposure is reported in Table 2-3.
2. HEALTH EFFECTS

2.3 TOXICOkinetics

2.3.1 Absorption

2.3.1.1 Inhalation Exposure

No studies were located in humans regarding the inhalation absorption of 1,2-dibromoethane. The available animal toxicity data (see Section 2.2.1) indicate that absorption of 1,2-dibromoethane occurs in rats, mice, rabbits, guinea pigs, and monkeys exposed via inhalation for acute, intermediate, and chronic durations (Rowe et al. 1952; Stott and McKenna 1984). Based on the findings in animal studies, 1,2-dibromoethane is expected to be absorbed in humans exposed via the inhalation route.

2.3.1.2 Oral Exposure

No studies were located in humans regarding the oral absorption of 1,2-dibromoethane. However, there is evidence to suggest that oral absorption occurs in humans. Death and poisoning resulting from suicide attempts (Olmstead 1960; Saraswat et al. 1986) and from consumption of contaminated fruits, grains, and drinking water (EPA 1983), indicate that absorption occurred.

Uptake of 1,2-dibromoethane readily occurs in rats following oral intubation (Botti et al. 1982; Nachtomi 1981; Plotnick et al. 1979; Van Bladeren et al. 1980). The presence of 1,2-dibromoethane residues in the kidney, liver, and spleen of rats following ingestion is also evidence of its absorption (Plotnick et al. 1979). It may be inferred that uptake from the gastrointestinal tract of rats is extensive, since 73% of a radiolabeled $^{14}$C-1,2-dibromoethane dose was excreted in the urine (Plotnick et al. 1979; Van Bladeren et al. 1980) and about 2% was excreted in the feces by 24-48 hours (Plotnick et al. 1979).

2.3.1.3 Dermal Exposure

No studies were located regarding the dermal absorption of 1,2-dibromoethane in humans. However, two occupational case reports suggest that dermal absorption of 1,2-dibromoethane was the major route of exposure to 1,2-dibromoethane that resulted in death (Letz et al. 1984). Dermal absorption does occur in animals but has not been quantified. Absorption of 1,2-dibromoethane was demonstrated in guinea pigs whose blood levels were monitored during dermal exposure to 1 mL of 1,2-dibromoethane (Jakobson et al. 1982). Following dermal application, the blood level of 1,2-dibromoethane increased rapidly, reaching a maximum level of approximately 2.1 µg/mL at 1 hour and 1.8 µg/mL at 6 hours.
2. HEALTH EFFECTS

The available data suggest that 1,2-dibromoethane may be absorbed dermally by humans. Thus, contact with water contaminated with 1,2-dibromoethane may result in absorption.

2.3.2 Distribution

2.3.2.1 Inhalation Exposure

No studies were located in humans or animals regarding the distribution of 1,2-dibromoethane after inhalation exposure. Although occupational cases of inhalation exposure of humans have been reported (Letz et al. 1984), there were no data on 1,2-dibromoethane levels in tissues.

2.3.2.2 Oral Exposure

No studies were located in humans regarding the distribution of 1,2-dibromoethane after oral exposure. In humans intentionally ingesting 1,2-dibromoethane, kidney lesions and centrilobular necrosis of the liver were found (Olmstead 1960; Saraswat et al. 1986). This is indirect evidence of distribution of 1,2-dibromoethane. The tissue distribution of 1,2-dibromoethane has been studied in rats following exposure by the oral route. Although retention was limited, the kidneys, liver, and spleen appear to retain the highest amounts of the administered dose (Plotnick et al. 1979) as illustrated in Table 2-4. Rats received an oral dose of 15 mg/kg/day of labeled 1,2-dibromoethane in corn oil. Twenty-four hours later 3% of radioactivity was detected in fat, brain, kidney, liver, spleen, testes, blood, and plasma, 72.38% in the urine, and 1.65% in the feces (Plotnick et al. 1979). By 48 hours after administration, 73% of the radiolabeled dose was accounted for in the urine, 1.1% in the liver, and 2.4% in the feces. Total recovery was 77.8% of the administered radioactivity. 1,2-Dibromoethane in the expired air was not measured.

The retention of 1,2-dibromoethane in tissues and body fluids can be altered by concurrent exposure to modifiers of enzyme activity, such as disulfiram (Plotnick et al. 1979). The concentration of radiolabeled 1,2-dibromoethane in the liver, kidneys, spleen, testes, and brain increased significantly in rats fed disulfiram in the diet for 12 days before an oral dose of 15 mg $^{14}$C-1,2-dibromoethane/kg compared with rats not fed disulfiram. Disulfiram, an inhibitor of P-450 metabolism (via action on acetaldehyde dehydrogenase), was found to increase the uptake of $^{14}$C into liver nuclei. These observations correlate well with the results of chronic studies (Wong et al. 1982) that demonstrated enhanced tumorigenic effects in the liver and testes following combined 1,2-dibromoethane and disulfiram exposure.

2.3.2.3 Dermal Exposure

No studies were available in humans or animals regarding the distribution of 1,2-dibromoethane following dermal exposure. However, toxic
## 2. HEALTH EFFECTS

### TABLE 2-4. Distribution of $^{14}$C in Selected Tissues and Body Fluids of Male Rats 24 and 48 Hours After a Single Oral Dose of 15 mg/kg [U-$^{14}$C]-1,2-Dibromoethane

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Tissue concentration$^b$</th>
<th>Percentage of dose$^c$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>24 Hours</td>
<td>48 Hours</td>
</tr>
<tr>
<td>Liver</td>
<td>4.78 ± 0.24</td>
<td>2.87 ± 0.33</td>
</tr>
<tr>
<td>Kidneys</td>
<td>3.32 ± 0.42</td>
<td>1.06 ± 0.16</td>
</tr>
<tr>
<td>Spleen</td>
<td>1.00 ± 0.03</td>
<td>0.66 ± 0.03</td>
</tr>
<tr>
<td>Testes</td>
<td>0.49 ± 0.05</td>
<td>0.19 ± 0.02</td>
</tr>
<tr>
<td>Brain</td>
<td>0.41 ± 0.04</td>
<td>0.17 ± 0.02</td>
</tr>
<tr>
<td>Fat$^d$</td>
<td>0.35 ± 0.04</td>
<td>0.44 ± 0.06</td>
</tr>
<tr>
<td>Blood$^e$</td>
<td>0.90 ± 0.05</td>
<td>0.64 ± 0.07</td>
</tr>
<tr>
<td>Plasma</td>
<td>0.46 ± 0.04</td>
<td>0.22 ± 0.02</td>
</tr>
<tr>
<td>Urine</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Feces</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Total recovery</td>
<td>No data</td>
<td>No data</td>
</tr>
</tbody>
</table>

$^a$Source: Plotnick et al. 1979

$^b$Values represent mean concentration in μg/g or μg/mL (expressed as parent compound) plus or minus the standard error of the mean of duplicate determinations on six animals.

$^c$Values represent the mean percentage of the administered radioactivity plus or minus the standard error of the mean of duplicate determinations on six animals.

$^d$Assumed 6% of body weight

$^e$Assumed 9% of body weight

$^f$n = 12 (includes 24-hour samples obtained from rats killed 48 hours after compound administration)

$^g$Cumulative 48-hour excretion
effects observed in humans and animals after dermal exposure indicate that the compound is widely distributed throughout the body.

2.3.2.4 Other Routes of Exposure

Tissue distribution of 1,2-dibromoethane following intraperitoneal administration was studied in mice (Edwards et al. 1970) and guinea pigs (Plotnick and Conner 1976). The kidney, liver, and stomach retained the highest amounts of the administered 1,2-dibromoethane dose across all the observation periods (see Tables 2-5 and 2-6). Autoradiographic studies of mice injected intraperitoneally with $^{14}$C-1,2-dibromoethane (40 mg/kg) revealed radioactivity primarily in the intestines, kidneys, liver, blood, fat, and spleen. Only 1% of the administered dose (per gram of wet tissue) was detected in the kidney and in the stomach tissue, 6.2% in whole blood, and 2.6% in plasma 24 hours posttreatment (Edwards et al. 1970). Following a single intraperitoneal injection of 30 mg/kg $^{14}$C-1,2-dibromoethane in corn oil to guinea pigs, the majority of the dose was accounted for in the urine (65.9%), liver (2.16%), and feces (3%) by the end of the 72-hour period. Approximately 10%-12% of the administered dose was excreted via the lungs (Plotnick and Conner 1976). Plotnick and Conner (1976) investigated tissue distribution of 1,2-dibromoethane in guinea pigs because they found similarities in metabolism and biotransformation pathways between guinea pigs and humans. The authors reported that target organs for tissue distribution in guinea pigs were the same as those in rats, although the percentage of dose recovered was higher in guinea pig tissues.

These results are similar to those after oral administration and suggest that 1,2-dibromoethane is rapidly absorbed and distributed but retained to only a limited extent mainly in the kidneys, liver, and stomach, regardless of the route of exposure and the species tested.

2.3.3 Metabolism

1,2-Dibromoethane is metabolized to active forms capable of inducing toxic effects by either of two systems— the microsomal monooxygenase system (cytochrome P-450 oxidation) and the cytosolic activation system (glutathione conjugation). Figure 2-3 provides an overview of the metabolism of 1,2-dibromoethane by the two systems. The pathway of biotransformation for 1,2-dibromoethane appears to be the controlling factor for its biological activity. Two reactive intermediates, 2-bromoacetaldehyde and S-(2-bromoethyl) glutathione, are formed. The 2-bromoacetaldehyde is responsible for tissue damage caused by covalent binding to cellular macromolecules. S-(2-bromoethyl) glutathione is responsible for 1,2-dibromoethane's proven genotoxic effect and, perhaps, its carcinogenic effect observed in laboratory animals. These two systems and their relative importance are discussed in detail below.
2. HEALTH EFFECTS

TABLE 2-5. Distribution of 1,2-Dibromoethane in Mice

<table>
<thead>
<tr>
<th>Organ</th>
<th>1 Hour</th>
<th>3 Hours</th>
<th>24 Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Small intestine</td>
<td>34.0</td>
<td>5.8</td>
<td>0.39</td>
</tr>
<tr>
<td>Kidney</td>
<td>13.0</td>
<td>12.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Liver</td>
<td>12.0</td>
<td>6.6</td>
<td>0.42</td>
</tr>
<tr>
<td>Lung</td>
<td>0.9</td>
<td>1.0</td>
<td>0.14</td>
</tr>
<tr>
<td>Spleen</td>
<td>4.1</td>
<td>4.7</td>
<td>0.61</td>
</tr>
<tr>
<td>Plasma</td>
<td>12.0</td>
<td>12.0</td>
<td>2.6</td>
</tr>
</tbody>
</table>

*aSource: Edwards et al. 1970
*bIntraperitoneal injection of 40 mg/kg body weight
TABLE 2-6. Percentage of Administered $^{14}$C in Selected Tissues and Body Fluids of Male Guinea Pigs at Various Time Intervals Following Intraperitoneal Administration of 30 mg/kg of $^{14}$C-1,2-Dibromoethane$^{a,b}$

<table>
<thead>
<tr>
<th>Organ</th>
<th>4 Hours</th>
<th>8 Hours</th>
<th>12 Hours</th>
<th>24 Hours</th>
<th>48 Hours</th>
<th>72 Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td>16.29 ± 2.42</td>
<td>13.65 ± 0.39</td>
<td>10.50 ± 2.13</td>
<td>4.72 ± 0.21</td>
<td>2.12 ± 0.07</td>
<td>2.16 ± 0.21</td>
</tr>
<tr>
<td>Kidneys</td>
<td>6.00 ± 0.42</td>
<td>5.69 ± 0.43</td>
<td>3.31 ± 0.17</td>
<td>1.64 ± 0.45</td>
<td>0.31 ± 0.01</td>
<td>0.24 ± 0.02</td>
</tr>
<tr>
<td>Stomach$^c$</td>
<td>1.14 ± 0.44</td>
<td>0.52 ± 0.20</td>
<td>0.62 ± 0.08</td>
<td>0.18 ± 0.02</td>
<td>0.18 ± 0.02</td>
<td>0.18 ± 0.04</td>
</tr>
<tr>
<td>Lungs</td>
<td>0.35 ± 0.06</td>
<td>0.38 ± 0.09</td>
<td>0.37 ± 0.01</td>
<td>0.24 ± 0.01</td>
<td>0.12 ± 0.01</td>
<td>0.10 ± 0.01</td>
</tr>
<tr>
<td>Pancreas</td>
<td>0.31 ± 0.10</td>
<td>0.36 ± 0.06</td>
<td>0.33 ± 0.02</td>
<td>0.20 ± 0.03</td>
<td>0.07 ± 0.01</td>
<td>0.06 ± 0.01</td>
</tr>
<tr>
<td>Testes</td>
<td>0.16 ± 0.04</td>
<td>0.17 ± 0.01</td>
<td>0.12 ± 0.01</td>
<td>0.12 ± 0.01</td>
<td>0.07 ± 0.01</td>
<td>0.06 ± 0.01</td>
</tr>
<tr>
<td>Heart</td>
<td>0.13 ± 0.02</td>
<td>0.16 ± 0.02</td>
<td>0.12 ± 0.01</td>
<td>0.10 ± 0.01</td>
<td>0.04 ± 0.01</td>
<td>0.03 ± 0.01</td>
</tr>
<tr>
<td>Brain</td>
<td>0.12 ± 0.02</td>
<td>0.16 ± 0.02</td>
<td>0.14 ± 0.01</td>
<td>0.13 ± 0.01</td>
<td>0.07 ± 0.01</td>
<td>0.05 ± 0.00</td>
</tr>
<tr>
<td>Adrenals</td>
<td>0.08 ± 0.02</td>
<td>0.10 ± 0.04</td>
<td>0.04 ± 0.01</td>
<td>0.03 ± 0.01</td>
<td>0.01 ± 0.01</td>
<td>0.02 ± 0.01</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.07 ± 0.01</td>
<td>0.06 ± 0.01</td>
<td>0.07 ± 0.01</td>
<td>0.08 ± 0.02</td>
<td>0.03 ± 0.00</td>
<td>0.02 ± 0.01</td>
</tr>
<tr>
<td>Urine$^d$</td>
<td>14.9 ± 1.0</td>
<td>26.3 ± 10.1</td>
<td>43.2 ± 8.1</td>
<td>46.0 ± 4.8</td>
<td>54.3 ± 3.4</td>
<td>65.9 ± 4.6</td>
</tr>
</tbody>
</table>

$^a$Source: Plotnick and Conner 1976

$^b$Values represent the mean plus or minus the standard error of the mean of duplicate determinations on three animals at each time interval.

$^c$Including stomach contents

$^d$Cumulative excretion
FIGURE 2-3. Proposed Metabolic Pathways for 1,2-Dibromoethane*

*Adapted from Lawrence and Michaels 1984
2. HEALTH EFFECTS

1,2-Dibromoethane is metabolized in various tissues through microsomal oxidation by cytochrome P-450 to form 2-bromoacetaldehyde (Tamura et al. 1986; Van Duuren et al. 1985). This metabolite can produce histopathological changes such as liver damage, by binding to cellular proteins (Hill et al. 1978). 2-Bromoacetaldehyde can be metabolized further by aldehyde dehydrogenase in the presence of nicotinamide adenine dinucleotide dehydrogenase to 2-bromoethanol which is highly toxic and causes genotoxicity. 2-Bromoacetaldehyde can also be metabolized by aldehyde dehydrogenase in the presence of nicotinamide adenine dinucleotide to bromoacetic acid which is excreted in the urine. In addition, 2-bromoacetaldehyde can also be conjugated with glutathione. The conjugated metabolite is reduced to S-carboxymethylglutathione. This compound can form S-carboxymethylcysteine which may be metabolized to thiglycolic acid and excreted in the urine or can be metabolized to S-(β-hydroxyethyl) cysteine. The latter is excreted in the urine following action by N-acetyl transferase in the presence of acetyl CoA enzyme and subsequent sulfoxidation to form mercapturic acids (Nachtomi et al. 1966; Van Bladeren 1983). Mercapturic acids are the primary urinary metabolites of 1,2-dibromoethane. Tomasi et al. (1983) demonstrated that 1,2-dibromoethane can form a free radical intermediate under a hypoxic condition suggesting a new metabolic pathway for 1,2-dibromoethane.

As shown in Figure 2-3, 1,2-dibromoethane can be conjugated with glutathione through the action of glutathione transferases to form S-(2-bromoethyl) glutathione (Peterson et al. 1988). This reactive intermediate can react to form ethylene and glutathione disulfide through further action of glutathione transferases. These are detoxification products. The ethylene is exhaled, and the glutathione disulfide is eliminated in the feces via the bile.

S-(2-bromoethyl)glutathione is considered to be the genotoxic, and probably the carcinogenic, intermediate of 1,2-dibromoethane metabolism (Van Bladeren et al. 1981). This ion is a highly reactive alkylating agent that can bind to DNA either through direct nucleophilic substitution (Van Bladeren 1983) or substitution through the ethylene-S-glutathionyl-episulfonium ion to form S-[2-(N'-guanyl)ethyl]glutathione (Ozawa and Guengerich 1983; Koga et al. 1986; Peterson et al. 1988). A recent study suggests that S-(2-bromoethyl) glutathione is the main genotoxic metabolite that binds to DNA to form the complex S-[2-(N'-guanyl)ethyl]cysteine (Bolt et al. 1986). The ethylene-S-glutathionyl-episulfonium ion can also react with water and be detoxified to form S-(β-hydroxyethyl)glutathione, or react with glutathione to form S,S'-ethylene-bis-(glutathione). The latter is excreted in the feces via the bile. S-(β-hydroxyethyl)glutathione can form S-(β-hydroxyethyl)-glutathione-S-oxide by sulfoxidation or react with peptidases to form S-(β-hydroxyethyl)cysteine. The former is excreted in the feces via the bile. The latter forms S-(β-hydroxyethyl)mercapturic acid by the action of N-acetyl transferase and is excreted in the urine (EPA 1985; Nachtomi 1970; Van Bladeren 1983).
2. HEALTH EFFECTS

In animals, 1,2-dibromoethane is rapidly metabolized after oral administration and is converted into mercapturic acid derivatives that appear in urine (Kirby et al. 1980; Nachtomi 1970; Nachtomi et al. 1965). The principal mercapturic acid derivative, N-acetyl-S-(2-hydroxyethyl)-L-cysteine, and other related metabolites are derived from the conjugation reaction of 1,2-dibromoethane with glutathione, a molecule present in mammalian cells. This suggests that the primary pathway of 1,2-dibromoethane metabolism (i.e., activation and detoxification) in rats is via the microsomal monooxygenase system. An in vivo study (Van Duuren et al. 1985) provides evidence that microsomal oxidation of 1,2-dibromoethane in rodents can produce adducts that bind preferentially to protein. In a study using tetradeutero-1,2-dibromoethane, only about 20% of the mercapturic acid excreted was formed via direct glutathione conjugation (Van Bladeren 1983). The reactive metabolites formed by these two systems may bind to protein (2-bromoacetaldehyde) or DNA (S-[2-bromoethyl]glutathione) producing either cytotoxicity or genotoxicity, respectively. Adducts formed via cytosolic glutathione conjugation—identified as S-[2-(N'-guanyl)ethyl]glutathione by Ozawa and Guengerich (1983)—have been associated with genotoxic, and perhaps carcinogenic, effects (Van Bladeren et al. 1982; White et al. 1983). Edwards et al. (1970) also identified metabolites after oral administration.

Evidence from animal bioassays supports the hypothesis that it is the cytosolic system and not the microsomal oxidative system that is responsible for the carcinogenicity of 1,2-dibromoethane. Metabolism of 1,2-dibromoethane by glutathione conjugation was demonstrated in vitro in rat hepatocytes (Sundheimer et al. 1982). In the long-term drinking water study of Van Duuren et al. (1985), mice were administered equimolar concentrations of 1,2-dibromoethane, bromoethanol, and bromoacetaldehyde. Bromoethanol and bromoacetaldehyde, which are microsomal metabolites of 1,2-dibromoethane, were far less potent carcinogens than 1,2-dibromoethane. The cytosol-induced binding to isolated DNA was 5-10 times greater than that found in microsomal oxidation in isolated rat hepatocytes. The preferential binding of 1,2-dibromoethane metabolites to DNA in tissues of the forestomach, nasal mucosa, oral epithelium, and testis of mice and rats demonstrates the ability of these tissues to metabolize 1,2-dibromoethane by conjugation with glutathione (Kowalski et al. 1985a; Sipes et al. 1986a; Wiersma and Sipes 1983).

2.3.4 Excretion

2.3.4.1 Inhalation Exposure

No studies were located-in humans or animals regarding the excretion of 1,2-dibromoethane after inhalation exposure.
2. HEALTH EFFECTS

2.3.4.2 Oral Exposure

No studies were available in humans regarding the excretion of 1,2-dibromoethane after oral exposure. Oral administration of 1,2-dibromoethane to rats primarily results in mercapturic acid derivatives excreted in the urine (approximately 74% of the administered dose) (Plotnick et al. 1979) as shown in Table 2-4. Unmetabolized 1,2-dibromoethane may be excreted via the lungs; fecal excretion of metabolites accounts for approximately 3% of the administered dose (Plotnick et al. 1979).

Based on the rapid and extensive metabolism seen in all animals, the fate of 1,2-dibromoethane in humans would be expected to be similar. Seventy percent of the administered parent compound is excreted in the urine and feces by 48 hours. The lack of persistence of metabolites in the tissues indicate that 1,2-dibromoethane is readily removed from the body. Low-level exposure would not be expected to result in accumulation of 1,2-dibromoethane or its metabolites in human tissue. However, theoretically, acute high-level exposure may saturate metabolic pathways and consequently allow 1,2-dibromoethane to accumulate in the tissues for a longer period of time.

2.3.4.3 Dermal Exposure

No studies were found regarding the excretion of 1,2-dibromoethane in humans or animals after dermal exposure.

2.3.4.4 Other Routes of Exposure

Plotnick and Conner (1976) reported that 10%-12% of a dose is excreted via the lungs 72 hours after intraperitoneal injection of 30 mg/kg \(^{14}\)C-1,2-dibromoethane to guinea pigs. The majority of the dose was accounted for in the urine (65.9%), liver (2.16%), and feces (3%).

Intraperitoneal administration of 37.6, 75, or 113 mg 1,2-dibromoethane/kg/day (0.2, 0.4, or 0.6 mmol/kg) to rats resulted in metabolic biotransformation into mercapturic acid which was strongly indicative of saturable metabolism (Goyal et al. 1989). Administration of L-2-oxothiazolidine-4-carboxylic acid (OTCA) (4±5 mmol/kg) enhanced glutathione availability and increased excretion of urinary mercapturic acid at the higher doses. These results suggest that OTCA increases the capacity for detoxification via the glutathione pathway.

2.4 RELEVANCE TO PUBLIC HEALTH

No MRLs were derived for 1,2-dibromoethane because of a lack of quantitative exposure data.

Humans are susceptible to the acute toxic effects of 1,2-dibromoethane from various routes of exposure. Except for adverse reproductive effects in
2. HEALTH EFFECTS

Men after occupational exposure, chronic effects of 1,2-dibromoethane exposure have not been documented in humans. Based on data derived from animal studies, mechanisms of action of 1,2-dibromoethane at a cellular level, toxicokinetics, and genotoxicity tests, there is a potential for certain adverse health effects in humans exposed chronically to low environmental levels of 1,2-dibromoethane that could exist near hazardous waste sites or areas of former agricultural use.

Clinical signs in humans and animals related to acute toxic exposure to 1,2-dibromoethane are depression and collapse, indicative of neurologic effects, and erythema and necrosis of tissue at the point of contact (oral and pharyngeal ulcers for ingestion, skin blisters and sloughing for dermal exposure). Neurologic signs are not seen in animals exposed to nonlethal doses.

Target organs of 1,2-dibromoethane are of two types. The first is the point of contact with the chemical, i.e., skin for dermal exposure (humans and animals), oropharynx for ingestion (humans), stomach for gavage administration (rodents), and upper respiratory tract for inhalation exposure (humans, rodents). Although there is little information on toxicity of 1,2-dibromoethane in humans after inhalation, the testis was a target organ in exposed workers; the liver and kidney have been identified as target organs after dermal and oral exposure in humans. The liver, kidney, and testis are target organs in experimental animals irrespective of the exposure route.

**Death.** 1,2-Dibromoethane can be fatal to humans after oral or dermal exposure. Acute deaths following toxic doses are related to cardiopulmonary arrest or, if affected individuals survive for a period of time, to hepatic and renal failure. These results are supported by animal studies in which acute death occurred after oral, dermal, and inhalation exposure.

Doses that cause acute death in humans and animals are relatively large. For humans, reports of death following oral exposure were a result of intentional ingestion of a high concentration of 1,2-dibromoethane. Human death following dermal and inhalation exposure occurred in two accidentally-exposed workers. It is therefore highly unlikely that there would be a risk to humans of death under conditions of low-level, long-term exposure from contaminated food or water.
2. HEALTH EFFECTS

Systemic Effects

Respiratory Effects. Nonspecific respiratory symptoms were reported in a worker involved in 1,2-dibromoethane production and presumably chronically exposed by inhalation (Kochmann 1928). One of the workers exposed in a storage tank by dermal and inhalation routes to 1,2-dibromoethane had bilateral pulmonary edema, a nonspecific agonal finding, at necropsy (Letz et al. 1984). Similar results occurred in rats exposed acutely to toxic concentrations by inhalation (Rowe et al. 1952). Abnormal respiratory effects have been well documented in experimental animals after inhalation exposure; respiratory effects did not occur after dermal or oral exposure. Many of the respiratory tract lesions in animal inhalation studies consist of proliferation, particularly in the upper respiratory tract. Animal studies also identify the upper respiratory tract as a site for 1,2-dibromoethane binding and metabolism. These animal studies are relevant to humans because they suggest a possibility for adverse effects in the human respiratory system following low-level exposure to 1,2-dibromoethane by inhalation.

Cardiovascular Effects. Cardiovascular effects as terminal events were reported in patients dying after dermal and inhalation exposure to 1,2-dibromoethane. One individual also had acute myocardial lesions (Letz et al. 1984). Cardiovascular effects were not identified in humans who died after 1,2-dibromoethane ingestion. These findings in humans were not supported by studies in experimental animals exposed by inhalation, oral, or dermal routes. It is unlikely that humans exposed to low levels of 1,2-dibromoethane will experience adverse cardiovascular effects.

Gastrointestinal Effects. Gastrointestinal effects of labial, oral, and pharyngeal ulcers occurred in humans intentionally ingesting high concentrations of 1,2-dibromoethane (Saraswat et al. 1986). Nausea and emesis occurred in humans exposed to high concentrations by the oral or dermal and inhalation routes; the latter patients also developed diarrhea (Letz et al. 1984). Results of adverse gastrointestinal effects in humans were supported by animal studies using the oral route of exposure (Ghanayem et al. 1986; NCI 1978). No gastrointestinal effects were present in animals exposed dermally or by inhalation. While adverse gastrointestinal effects are not likely in humans exposed orally to low levels of 1,2-dibromoethane, the upper gastrointestinal tract is a potential site of 1,2-dibromoethane binding and metabolism (Kowalski et al. 1985a).

Hematologic Effects. Effects of 1,2-dibromoethane on the hematopoietic system of humans exposed by inhalation, oral, or dermal routes have not been described. Results of animal studies are equivocal except that, based on a study in rats, individuals taking disulfiram for alcoholism might be a susceptible human subpopulation at higher risk for adverse hematopoietic effects (Wong et al. 1982) (See Sections 2.6 and 2.7).
2. HEALTH EFFECTS

Musculoskeletal Effects. Dramatic musculoskeletal effects as evidenced by elevated muscle enzymes in serum occurred in two patients exposed by the dermal and inhalation routes (Letz et al. 1984). No musculoskeletal effects were reported in humans exposed by other routes or in experimental animals. Risks appear to be negligible for adverse musculoskeletal effects in humans exposed to low levels of 1,2-dibromoethane.

Hepatic Effects. Hepatic effects have been reported in humans exposed orally or by the dermal and inhalation routes to toxic doses of 1,2-dibromoethane (Letz et al. 1984; Olmstead 1960; Saraswat et al. 1986). These effects consist of hepatocellular and Kupffer cell necrosis. Results in humans are supported by animal studies in which the liver is also a target organ for toxic effects of 1,2-dibromoethane following exposure by a variety of routes (Botti et al. 1986; Brandt et al. 1987; Broda 1976; NTP 1982; Rowe et al. 1952). 1,2-Dibromoethane, as well as inducing necrosis, can also act as a hepatocellular mitogen in rats (Ledda-Columbano et al. 1987a).

Liver toxicity related to 1,2-dibromoethane depends on the metabolic pathway utilized and the amount of damage induced in cellular protein and membrane structures. Humans exposed to low levels of 1,2-dibromoethane are at potential risk of having toxic events occurring within hepatocytes; whether these effects will be subcellular or result in cell necrosis may depend on internal dose and a variety of factors. Liver damage that is severe enough to cause clinical disease in humans from low-level exposure is unlikely.

Intraperitoneal administration of 1,2-dibromoethane to male B6C3F1 mice induced hepatic DNA damage (genotoxicity) at doses lower than those that caused other signs of acute toxicity such as increased liver weights, elevated serum enzyme levels, or mortality (Storer and Conolly 1983). Thus, in vivo and in vitro studies suggest that there is a potential for humans to develop subcellular damage after exposure by various routes to low levels of 1,2-dibromoethane.

Renal Effects. The kidney is a target organ in humans for 1,2-dibromoethane toxicity (Letz et al. 1984; Olmstead 1960). In humans exposed acutely to toxic concentrations of 1,2-dibromoethane either by oral or dermal routes, renal damage was described, with one of the exposed individuals dying of acute renal failure despite attempts at hemodialysis. Results in humans are supported by animal studies. Renal effects occurred in male Fischer 344 rats exposed to 1,2-dibromoethane by intraperitoneal injection. Lesions were evenly distributed among renal proximal tubules and consisted of cellular swelling and cytoplasmic vacuolization but not necrosis (Kluwe et al. 1982). Nonprotein sulfhydryl levels were initially reduced, then increased; this is suggestive of changes in tubular glutathione levels. 1,2-Dibromoethane also acts as a renal mitogen in rats in the absence of tubular cell necrosis (Ledda-Columbano et al. 1987b).
2. HEALTH EFFECTS

Renal lesions or changes in renal function in humans chronically exposed to 1,2-dibromoethane have not been identified. Following chronic inhalation exposure to 1,2-dibromoethane, rats developed toxic nephropathy (NTP 1982).

1,2-Dibromoethane can be activated in the kidney of rodents by a glutathione-dependent pathway to toxic metabolites, as well as having such metabolites reach the kidney via the enterohepatic circulation (Rush et al. 1984; Working et al. 1986). Because similar metabolic pathways exist in humans, animal studies suggest that there is a possibility for adverse renal effects at a subcellular level to occur in humans exposed to low levels of 1,2-dibromoethane such as might occur near areas of former agricultural use or hazardous waste sites. Such low-level exposure is very unlikely to result in clinically detectable renal damage.

Dermal/Ocular Effects. Adverse dermal effects occur in humans following topical exposure of relatively high concentrations of 1,2-dibromoethane. These effects consist of inflammation, blister formation, and necrosis (Letz et al. 1984; Pflesser 1938). Effects were most severe when 1,2-dibromoethane applied to the skin was not allowed to evaporate (Pflesser 1938). Rapid absorption of 1,2-dibromoethane through the skin can also result in systemic toxicity (Letz et al. 1984). These results in humans are supported by studies in animals (Rowe et al. 1952). Humans exposed to low levels of 1,2-dibromoethane in contaminated water such as during bathing or swimming, are unlikely to have any local irritant effects but may be susceptible to absorption of the compound.

Ocular effects have not been reported in humans exposed dermally or orally to toxic doses of 1,2-dibromoethane. Animal studies have identified adverse ocular effects such as irritation and corneal damage after exposure to relatively high concentrations (NTP 1982; Rowe et al. 1952). While it appears that humans would be susceptible to development of ocular damage if a high concentration of 1,2-dibromoethane were splashed in the eyes, adverse ocular effects of exposure to low levels of environmental 1,2-dibromoethane would not be expected.

Immunological Effects. No studies were located that specifically investigated immunological effects in humans or animals after exposure to 1,2-dibromoethane.

Neurological Effects. Depression, disorientation, and collapse have been reported in humans with acute exposure to toxic doses of 1,2-dibromoethane by oral (Saraswat et al. 1986) or dermal (Letz et al. 1984) routes. Residues of 1,2-dibromoethane were detected in the brain tissue of one fatality (Letz et al. 1984). The fact that the nervous system is at risk when humans are acutely exposed to lethal doses is supported by animal studies (Rowe et al. 1952).
2. HEALTH EFFECTS

No neurological effects have been described in humans exposed in an occupational setting except for one report of nonspecific signs of headache and depression (Kochmann 1928). Neurologic signs were not reported in animals exposed by various routes and for intermediate and chronic durations. It is therefore unlikely that neurologic effects will occur in humans chronically exposed to low levels of 1,2-dibromoethane.

Neurological effects as evidenced by alterations in brain neurotransmitter enzymes occurred in the F1 progeny of male Fischer 344 rats exposed to 1,2-dibromoethane by intraperitoneal injection (Hsu et al. 1985). Choline acetyltransferase and acetylcholinesterase levels had reversible changes in various parts of the brain while glutamic acid decarboxylase levels remained depressed at 90 days post-partum. This study raises some concerns about the progeny of men with occupational exposure since adverse effects of 1,2-dibromoethane on spermatogenesis have been reported in humans. In addition, testicular binding and sperm damage in animals can occur by various routes of exposure.

Developmental Effects. Adverse effects on fetal development have not been documented in humans.

In rats and mice exposed to 1,2-dibromoethane by inhalation, most developmental effects have been observed at doses that produced maternal toxicity. This raises the possibility that the fetuses of pregnant women who were exposed to doses high enough to cause clinical illness would be at risk for development toxicity, depending on the trimester when exposure occurred.

Since overt toxicity would not be expected in pregnant women exposed to low environmental levels of 1,2-dibromoethane, fetuses would not appear to be at serious risk of developmental effects. However, the remote possibility that behavioral effects in the fetus could occur as a result of exposure of either the female or male parent to 1,2-dibromoethane should be considered. Although the possibility of behavioral effects has not been investigated in humans, this is a sensitive effect and would require a large study population to detect. One animal study suggesting this possibility is the previously discussed study of Hsu et al. (1985) in which the progeny of exposed male rats had alterations in brain neurotransmitter enzymes. Another study (Fanini et al. 1984) investigated the behavioral effects of paternal exposure to 1,2-dibromoethane in rat progeny. Male F344 rats injected intraperitoneally daily for 5 consecutive days with doses of 1,2-dibromoethane in saline ranging from 1.25 to 10 mg/kg were mated with untreated females 4 or 9 weeks following exposure. Pups fathered by males from the dosed groups and conceived at 4 or 9 weeks post-exposure showed dose-dependent impairment in an open-field activity test. Although the swimming performance of pups was significantly impaired, it was dependent upon the time of breeding and the particular component of swimming behavior analyzed.
Reproductive Effects. Antispermaticogenic effects and possible effects on fertility have been reported in humans occupationally exposed to 1,2-dibromoethane (Heinrichs 1983; Ratcliffe et al. 1987; Ter Haar 1980; Wong et al., 1979). However, many of these studies lacked sufficient statistical power to detect an association between parameters measured and exposure.

Adverse reproductive effects are supported by animal studies. However, in some of the oral and inhalation studies in animals, chemical toxicity and/or neoplasia made it difficult to ascribe testicular lesions to direct toxicity. In other studies, antispermatogenic effects of 1,2-dibromoethane were documented directly in bovines exposed via feed; these effects were reversible after chemical withdrawal (Amir and Ben-David 1973; Amir and Volcani 1965). Effects were more severe in adult bulls compared to young bulls (Amir 1975).

The effects on reproduction of 1,2-dibromoethane administered to animals by parenteral routes corroborate the findings of other investigations in animals conducted via inhalation and oral routes. Sperm damage occurred in rams after a single intratesticular injection of 1,2-dibromoethane (Amir et al. 1983). A dose-response was observed with less acute effects on spermatids noted at doses as low as 6.37 mg/kg. Some effects on morphology of sperm were reversible. Transient sperm abnormalities were reported in Columbian rams that received 12 consecutive, daily subcutaneous injections of 1,2-dibromoethane at various doses ranging from 7.8 to 13.5 mg/kg (Eljack and Hrudka 1979a). A dose-related decline in sperm motility and acrosome abnormalities were evident during the 5th week following initiation of treatment.

The mechanism of action for the antispermatogenic effects of 1,2-dibromoethane may be related to covalent binding of metabolites of 1,2-dibromoethane with thiol groups of nucleoproteins in nuclei of spermatozoa. Such adduct formation interferes with DNA, causing improper packing of the chromatin (Amir and Lavon 1976; Amir et al. 1977). Antispermatogenic effects in exposed workers and this preferential binding of 1,2-dibromoethane in the testis of rodents and ruminants suggest that similar effects on spermatozoa could occur in men exposed to low levels of 1,2-dibromoethane.

Genotoxic Effects. 1,2-Dibromoethane has been tested extensively to assess its genotoxic potential in prokaryotic, eukaryotic, and mammalian systems. Tables 2-7 and 2-8 present the results of in vivo and in vitro genotoxicity studies, respectively. The results of these studies indicate that 1,2-dibromoethane is a potent mutagen, producing a broad spectrum of mutations in various test systems.

In bacterial systems, 1,2-dibromoethane is a direct-acting mutagen and primarily causes mutations of the base-pair substitution type (Barber et
2. HEALTH EFFECTS

al. 1981; McCann et al. 1975; Moriya et al. 1983; Principe et al. 1981; Rosenkranz 1977). The mutagenicity of 1,2-dibromoethane in bacteria was not influenced by mammalian metabolizing systems in four out of five studies (Barber et al. 1981; Moriya et al. 1983; Principe et al. 1981; Stolzenberg and Hine 1980). However, detection of its mutagenic activity is influenced by the amount of glutathione present (Kerklaan et al. 1985; Zoetemelk et al. 1987). 1,2-Dibromoethane tested positive for mutagenicity with or without metabolic activation in fungi and mammalian cell lines in in vitro assay systems (Brimer et al. 1982; Clive et al. 1979; Crespi et al. 1985; Ferreri et al. 1983; Malling 1969; Principe et al. 1981; Tan and Hsie 1981). It has been tested for its ability to induce heritable mutations in vivo using fruit flies (Drosophila melanogaster), mice, and rats. 1,2-Dibromoethane caused heritable mutations in male fruit flies (Kale and Baum 1979, 1981, 1982, 1983; Vogel and Chandler 1974) but not in mice (Epstein et al. 1972; Teramoto et al. 1980) or rats (Teramoto et al. 1980).

Chromosomal abnormalities and sister chromatid exchanges have been observed in mice following intraperitoneal administration of 1,2-dibromoethane (Krishna et al. 1985). Such chromosomal aberrations were also detected in vitro using human lymphocytes (Tucker et al. 1984); however, in studies which use cells from animals and humans with prior exposure to 1,2-dibromoethane, these abnormalities were unreliable or were not detected (Krishna et al. 1985; Steenland et al. 1985, 1986).

1,2-Dibromoethane has been shown to bind covalently to DNA both in vitro (Banerjee and Van Duuren 1979, 1983; DiRenzo et al. 1982; Inskeep and Guengerich 1984; Koga et al. 1986; Ozawa and Guengerich 1983; Prodi et al. 1986) and in vivo (Hill et al. 1978; Inskeep et al. 1986; Koga et al. 1986; Prodi et al. 1986), forming a stable adduct. Such adducts have been observed in rat testicular cells following in vivo exposure to 1,2-dibromoethane (Hill et al. 1978) and DNA repair activity was increased in rat spermatocytes treated in vitro with 1,2-dibromoethane (Working et al. 1986). Preincubation of rat hepatocytes or spermatocytes with inhibitors of cytochrome P-450-mediated oxidation did not affect 1,2-dibromoethane-induced unscheduled DNA synthesis (UDS) in vitro. In contrast, depletion of cellular glutathione inhibited 1,2-dibromoethane-induced UDS in both cell types in vitro (Working et al. 1986). This observation indicates that conjugation of 1,2-dibromoethane to glutathione and its subsequent metabolism results in the formation of genotoxic metabolites.

Thus, interaction of 1,2-dibromoethane with DNA can result in a mutation that is passed on to offspring. In conclusion, sufficient evidence exists to indicate that 1,2-dibromoethane presents potential genotoxic risks for humans. These effects may occur in humans living in areas surrounding hazardous waste sites or areas of former agricultural use where they may be exposed to 1,2-dibromoethane.
<table>
<thead>
<tr>
<th>Species (test system)</th>
<th>End point</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Eukaryotic organisms:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Drosophila melanogaster</em>/inhalation exposure</td>
<td>Recessive lethal</td>
<td>+</td>
<td>Kale and Baum 1979, 1981,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1982, 1983</td>
</tr>
<tr>
<td><em>D. melanogaster</em>/dietary exposure</td>
<td>Recessive lethal</td>
<td>+</td>
<td>Vogel and Chandier 1974;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NTP 1989</td>
</tr>
<tr>
<td><strong>Mammalian cells:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse/oral exposure</td>
<td>Dominant lethal</td>
<td>-</td>
<td>Epstein et al. 1972</td>
</tr>
<tr>
<td>Mouse/oral exposure</td>
<td>Dominant lethal</td>
<td>-</td>
<td>Teramoto et al. 1980</td>
</tr>
<tr>
<td>Mouse/intraperitoneal administration</td>
<td>Dominant lethal</td>
<td>-</td>
<td>Epstein et al. 1972</td>
</tr>
<tr>
<td>Rat inhalation exposure</td>
<td>Dominant lethal</td>
<td>-</td>
<td>Short et al. 1979</td>
</tr>
<tr>
<td>Rat oral exposure</td>
<td>Dominant lethal</td>
<td>-</td>
<td>Teramoto et al. 1980</td>
</tr>
<tr>
<td>Mouse/intraperitoneal administration</td>
<td>Sister chromatid exchange</td>
<td>-</td>
<td>Krishna et al. 1985</td>
</tr>
<tr>
<td>Human/occupational exposure</td>
<td>Sister chromatid exchange</td>
<td>-</td>
<td>Steenland et al. 1985, 1986</td>
</tr>
<tr>
<td>Mouse/intraperitoneal administration</td>
<td>Micronuclear formation</td>
<td>-</td>
<td>Krishna et al. 1985</td>
</tr>
<tr>
<td>Mouse/intraperitoneal administration</td>
<td>Chromosomal aberrations</td>
<td>-</td>
<td>Krishna et al. 1985</td>
</tr>
<tr>
<td>Rat/intraperitoneal administration</td>
<td>Unscheduled DNA synthesis</td>
<td>-</td>
<td>Bentley and Working 1983</td>
</tr>
</tbody>
</table>

DNA = deoxyribonucleic acid; + = positive result; - = negative result
<table>
<thead>
<tr>
<th>Species (test system)</th>
<th>End point</th>
<th>With activation</th>
<th>Without activation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prokaryotic organisms:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Salmonella typhimurium</em> / plate incorporation</td>
<td>Reverse mutation</td>
<td>No data</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td></td>
<td>+</td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>S. typhimurium</em> / plate incorporation</td>
<td>Reverse mutation</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>S. typhimurium</em> / plate incorporation</td>
<td>Reverse mutation</td>
<td>-</td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td><em>Escherichia coli</em> (WP2 uvrA) / plate</td>
<td>Reverse mutation</td>
<td>+</td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td>incorporation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>E. coli</em> (WP2 har) / plate incorporation</td>
<td>Reverse mutation</td>
<td>+</td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td><em>S. typhimurium</em> / vapor exposure</td>
<td>Reverse mutation</td>
<td>+</td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td><em>S. typhimurium</em> / vapor phase</td>
<td>Reverse mutation</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td><em>S. typhimurium</em> / spot test</td>
<td>Reverse mutation</td>
<td>+</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td><em>S. typhimurium</em> / spot test</td>
<td>Reverse mutation</td>
<td>No data</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Serratia marcescens</em> (sz21) / host</td>
<td>Reverse mutation</td>
<td>-</td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td>mediated assay</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Bacillus subtilis</em> / spot test</td>
<td>Forward mutation</td>
<td>+</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td><em>E. coli</em> / spot test</td>
<td>Forward mutation</td>
<td>+</td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td><em>B. subtilis</em> / spot test</td>
<td>Forward mutation</td>
<td>No data</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td><em>E. coli</em> / spot test</td>
<td>DNA damage</td>
<td>No data</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>B. subtilis</em> / spot test</td>
<td>DNA damage</td>
<td>No data</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td><strong>Eukaryotic organisms:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Neurospora crassa</em> / liquid incubation</td>
<td>Recessive lethal</td>
<td>No data</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td><em>Streptomyces coelicolor</em> / plate incorporation</td>
<td>Forward mutation</td>
<td>No data</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td><em>Aspergillus niger</em> / plate incorporation</td>
<td>Forward mutation</td>
<td>No data</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td><em>S. coelicolor</em> / spot test</td>
<td>Forward mutation</td>
<td>No data</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td><em>A. niger</em> / spot test</td>
<td>Forward mutation</td>
<td>No data</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Species (test system)</td>
<td>End point</td>
<td>With activation</td>
<td>Without activation</td>
<td>Reference</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------</td>
<td>-----------------</td>
<td>--------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Mammalian cells:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chinese hamster ovary cells liquid media</td>
<td>Forward mutation</td>
<td>+</td>
<td>+</td>
<td>Tan and Hsie 1981; Brimer et al. 1982</td>
</tr>
<tr>
<td>Mouse lymphoma L5178Y/liquid media</td>
<td>Forward mutation</td>
<td>+</td>
<td>+</td>
<td>Clive et al. 1979; NTP 1989</td>
</tr>
<tr>
<td>Human epithelial cells liquid media</td>
<td>Forward mutation</td>
<td>No data</td>
<td>+</td>
<td>Ferreri et al. 1983</td>
</tr>
<tr>
<td>Human lymphoblasts Tk6</td>
<td>Forward mutation</td>
<td>No data</td>
<td>+</td>
<td>Crespi et al. 1985</td>
</tr>
<tr>
<td>Human lymphoblasts AAH-1</td>
<td>Forward mutation</td>
<td>No data</td>
<td>+</td>
<td>Crespi et al. 1985</td>
</tr>
<tr>
<td>Chinese hamster V79 cells: CH5</td>
<td>Sister chromatid exchange</td>
<td>+</td>
<td>+</td>
<td>Tezuka et al. 1980; NTP 1989</td>
</tr>
<tr>
<td>Chinese hamster V79 cells</td>
<td>Chromosomal aberrations</td>
<td>+</td>
<td>+</td>
<td>NTP 1989</td>
</tr>
<tr>
<td>Peripheral lymphocytes from oyster toadfish and American eel</td>
<td>Sister chromatid exchange</td>
<td>No data</td>
<td>+</td>
<td>Ellingham et al. 1986</td>
</tr>
<tr>
<td>Human peripheral lymphocytes</td>
<td>Sister chromatid exchange</td>
<td>+</td>
<td>No data</td>
<td>Tucker et al. 1984</td>
</tr>
<tr>
<td>Opossum lymphocytes</td>
<td>Unscheduled DNA synthesis</td>
<td>No data</td>
<td>+</td>
<td>Meneghini 1974</td>
</tr>
<tr>
<td>Primary rat hepatocytes</td>
<td>DNA repair</td>
<td>No data</td>
<td>+</td>
<td>Williams et al. 1982; Working et al. 1986</td>
</tr>
<tr>
<td>Human lymphocytes</td>
<td>DNA repair</td>
<td>+</td>
<td>-</td>
<td>Peroco and Prodi 1981</td>
</tr>
</tbody>
</table>

DNA = deoxyribonucleic acid; + = positive result; - = negative result
2. HEALTH EFFECTS

Cancer. There are no reports of cancer in humans associated with occupational exposure to 1,2-dibromoethane, although the negative epidemiologic studies have some limitations.

1,2-Dibromoethane has been positive in short-term tests in animals used to predict carcinogenic potential of a chemical (Milks et al. 1982; Moslen 1984). In addition, there is dramatic tissue-specific binding of metabolites in experimental animals. Radiolabeled 1,2-dibromoethane was administered parenterally (intravenously or intraperitoneally) to C57BL mice, Sprague-Dawley rats and F344 rats. Both species had binding of high levels of 1,2-dibromoethane metabolites in the epithelium of the entire respiratory tract, the upper gastrointestinal tract, the vagina, and subepithelial glands of the nasal olfactory mucosa. Lower levels of metabolites were bound in the liver, kidney, adrenal cortex, and testicular interstitium (Kowalski et al. 1985a). DNA synthesis in the nasal mucosa of mice was inhibited (Hellman and Brandt 1986). This tissue-specific metabolism correlates well with toxic and/or carcinogenic lesions observed in experimental studies of inhalation and oral exposure to 1,2-dibromoethane. The possibility exists that similar binding and metabolism could occur in humans.

1,2-Dibromoethane is a potent carcinogen in rats and mice, causing malignant and benign neoplasms of epithelial and mesenchymal origin in multiple organ systems when administered by inhalation, oral, or dermal routes. Cancer was also induced at initial point of contact with 1,2-dibromoethane—nasal cavity for inhalation exposure, forestomach for oral (gavage and drinking water) exposure, and skin for dermal exposure.

The weight of evidence for carcinogenicity of 1,2-dibromoethane includes induction of malignant neoplasms in two species of rodents and in multiple organ systems by inhalation, oral, and dermal exposure. In addition, 1,2-dibromoethane and a number of its metabolites are electrophiles, and form adducts with cell proteins and nucleic acid. Of two potential 1,2-dibromoethane metabolites tested in a drinking water study in mice, bromoethanol induced squamous papillomas of the forestomach in male and female mice while bromoacetaldehyde did not induce a significant incidence of tumors. Based on these findings, Van Duuren et al. (1985) determined that it was unlikely that bromoethanol or bromoacetaldehyde were the active carcinogenic metabolites of 1,2-dibromoethane. 1,2-Dibromoethane is a potent mutagen in numerous in vitro test systems. Based on these findings, exposure of humans to levels of 1,2-dibromoethane such as found in agricultural areas or near hazardous waste sites presents a potentially serious public health risk.

EPA has classified 1,2-dibromoethane in the Carcinogen Assessment Group's Group B2 (EPA 1987a). Group B2 includes chemicals for which evidence for carcinogenicity is adequate in animals but inadequate in humans. The q.*
value developed by EPA for humans exposed orally is $85 \text{ (mg/kg/day)}^{-1}$ based on data from the NCI (1978) gavage bioassay. For humans exposed by inhalation, the unit risk value is $2.2 \times 10^{-4} \text{ µg/m}^3$ based on data from the NTP (1982) inhalation bioassay (IRIS 1991).

### 2.5 BIOMARKERS OF EXPOSURE AND EFFECT

Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 1989).

A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance itself or substance-specific metabolites in readily obtainable body fluid(s) or excreta. However, several factors can confound the use and interpretation of biomarkers of exposure. The body burden of a substance may be the result of exposures from more than one source. The substance being measured may be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic compounds). Depending on the properties of the substance (e.g., biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the body by the time biologic samples can be taken. It may be difficult to identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as copper, zinc, and selenium). Biomarkers of exposure to 1,2-dibromoethane are discussed in Section 2.5.1.

Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an organism that, depending on magnitude, can be recognized as an established or potential health impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung capacity. Note that these markers are often not substance specific. They also may not be directly adverse, but can indicate potential health impairment (e.g., DNA adducts). Biomarkers of effects caused by 1,2-dibromoethane are discussed in Section 2.5.2.

A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability to respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic genetic or other characteristic or a preexisting disease that results in an increase in absorbed dose, biologically effective dose, or target tissue response. If
2. HEALTH EFFECTS

biomarkers of susceptibility exist, they are discussed in Section 2.7, "POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE."

2.5.1 Biomarkers Used to Identify and/or Quantify Exposure to 1,2-Dibromoethane

Primary biomarkers of exposure are the presence of 1,2-dibromoethane in blood or exhaled breath or excretion of specific metabolites in urine. In humans exposed to toxic levels of 1,2-dibromoethane (Letz et al. 1984), the parent compound was not measured in blood samples collected before death. However, two exposed individuals had elevated levels of serum bromide ions. This elevation is likely to have resulted from debromination of 1,2-dibromoethane during its metabolism. Elevated serum bromide is not specific to 1,2-dibromoethane exposure, but, rather, it is indicative of exposure to classes of brominated chemicals.

Because a proportion of unmetabolized 1,2-dibromoethane is excreted from the lungs of guinea pigs (Plotnick and Conner 1976), measurement of the chemical in exhaled breath of humans is another potential method of monitoring human exposure. This has been done in a study using university student volunteers from a petrochemical plant area and a nonindustrial area. 1,2-Dibromoethane in exhaled breath was not found in either group of volunteers (Wallace et al. 1982).

Rats exposed acutely by gavage to 110 mg/kg of 1,2-dibromoethane in olive oil had elevated concentrations of the parent compound in the blood up to 30 minutes after exposure. At 2 and 4 hours postexposure, only trace amounts were detected and by 13 hours after exposure, 1,2-dibromoethane concentrations were not detected in the blood. Serum bromide levels were not measured (Nachtomi and Alumot 1972). Metabolites of 1,2-dibromoethane in urine from rats receiving a comparable dose were characterized chromatographically (Nachtomi et al. 1965). Urine had increased concentrations of bromide ion, S(β-hydroxyethyl) mercapturic acid, and S(β-hydroxyl)cysteine. These latter two metabolites are formed via the cytosolic rather than the microsomal pathway and, therefore, may not be present as biomarkers for humans of 1,2-dibromoethane exposure. However, urine of exposed humans has not been tested for the metabolites listed, including bromide ion.

Two DNA adducts of 1,2-dibromoethane metabolites have been found in in vitro studies (Bolt et al. 1986; Ozawa and Guengerich 1983; Peterson et al. 1988). These adducts are S-[2-(N'-guanyl)ethyl]glutathione and S-[2-N'-guanyl]ethyl] cysteine. These adducts are potential biomarkers of exposure to 1,2-dibromoethane and could be tested for in biopsy or autopsy tissue specimens.

A less invasive procedure that could provide a indication of DNA adduct formation is measurement in the urine of the mercaptic acid S-[2-N'-guanyl]ethyl]-N-acetylcysteine. Excretion of this metabolite into the urine of
rats occurs in a dose-dependent, linear manner after intraperitoneal administration of 1,2-dibromoethane (Kim and Guengerich 1989). This biomarker has not been looked for to date in humans suspected to have exposure to 1,2-dibromoethane.

2.5.2 Biomarkers Used to Characterize Effects Caused by 1,2-Dibromoethane

The liver, kidney, and testis are the major visceral target organs for toxic effects of 1,2-dibromoethane.

Hepatocellular necrosis related to covalent binding of metabolites to cell and plasma proteins and to mitochondrial membrane damage results in release of intracellular enzymes into the bloodstream, providing biomarkers of liver cell damage. Biomarkers of hepatocellular necrosis are not specific to 1,2-dibromoethane but are a general indication of damage. Increased serum enzymes include aspartate aminotransferase (AST), glutamate oxalacetic transaminase (GOT), alanine aminotransferase (ALT), glutamate pyruvate transaminase (GPT), and lactate dehydrogenase (LDH) (Botti et al. 1986; Letz 1984) in humans and rats as well as leakage of LDH from exposed, isolated rodent hepatocytes (Albano et al. 1984; Van Iersel et al. 1988). Plasma prothrombin time was also measured by Rowe et al. (1952) in rodents exposed to 1,2-dibromoethane; this test, however, is of minimal diagnostic value in detection of mild hepatocellular dysfunction (Berkow 1987).

Kidney effects can range from mild tubular damage to life-threatening renal damage, i.e., tubular nephropathy. Severe toxic renal lesions can result in compromised renal function with changes in urinalysis, oliguria, or anuria (renal shutdown) and increases in blood urea nitrogen, serum creatinine, and uric acid. While biomarkers of renal damage have been identified in humans exposed to toxic doses of 1,2-dibromoethane by oral or dermal routes, these findings have not been duplicated in animal experiments.

Chemically-induced testicular damage can be recognized by changes in sperm concentration, sperm motility, and sperm morphology (Wyrobek 1984). Reduced fertility, a highly sensitive biomarker, may also be associated with chemical exposure of humans. For example, Ratcliffe et al. (1987) evaluated spermatogenic parameters in papaya fumigation industry employees exposed for an average length of 5 years to 1,2-dibromoethane and unexposed workers in the sugar industry. The route of exposure to 1,2-dibromoethane was primarily inhalation. They identified decreased sperm count per ejaculate, decreases in the percentage of viable and motile sperm, and increases in numbers of sperm with abnormal morphology in 1,2-dibromoethane-exposed workers. For additional discussion of the study, see Section 2.2.1.6.

An epidemiological study on 1,2-dibromoethane has identified equivocal effects of reduced fertility in exposed workers (Wong et al. 1979).
2. HEALTH EFFECTS

2.6 INTERACTIONS WITH OTHER CHEMICALS.

Disulfiram is the generic name for Antabuse, a drug used in the treatment of chronic alcoholism. Disulfiram potentiates the toxic and carcinogenic effects of 1,2-dibromoethane in experimental animals. Presumably, this occurs by blocking conversion of the aldehyde metabolite as with acetaldehyde from ethanol. There is no evidence that similar effects occur in humans. Based on animal data, however, Ayerst Laboratories, producers of Antabuse (disulfiram), recommended the following in the package insert: "Patients taking Antabuse tablets should not be exposed to ethylene dibromide or its vapors" (PDR 1991).

In rats treated with disulfiram prior to oral dosing with 1,2-dibromoethane (Plotnik et al. 1979), there was decreased clearance of radiolabeled 1,2-dibromoethane from the body with increased concentration in tissues (liver, kidney, spleen, testis, and brain). In the liver of the disulfiram-1,2-dibromoethane group, there was preferential uptake of labeled 1,2-dibromoethane in hepatocyte nuclei, indicative of DNA binding.

The mechanism of synergism between the compounds is not known. Slower clearance of 1,2-dibromoethane or increased tissue levels of a toxic intermediate metabolite (likely the aldehyde) in disulfiram-exposed individuals may be responsible for enhancement of toxic and neoplastic lesions in exposed rodents (Plotnik et al. 1979).

As discussed in Section 2.2.1 under the various systemic effects and cancer, rats exposed by inhalation to 1,2-dibromoethane and fed a diet containing 0.05% disulfiram (Wong et al. 1982), compared to rats exposed to 1,2-dibromoethane alone, had significantly elevated incidences of certain neoplastic and toxic lesions. Neoplasms elevated in the disulfiram-1,2-dibromoethane group were hepatocellular tumors, renal adenoma and adenocarcinoma, and thyroid follicular cell adenoma. Toxic lesions were testicular degeneration (atrophy) and splenic atrophy. Rats receiving the 1,2-dibromoethane-disulfiram regimen also had high mortality at a significantly earlier date compared to control rats, rats exposed to disulfiram alone, or rats exposed to 1,2-dibromoethane alone.

1,2-Dibromoethane did not potentiate the hepatotoxic effects of carbon tetrachloride in rats (Danni et al. 1988).
2. HEALTH EFFECTS

2.7 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE

Certain populations may have a higher risk for developing toxic effects from low-level 1,2-dibromoethane exposure.

A biological difference that could increase susceptibility of fetuses and premature or perinatal infants to 1,2-dibromoethane toxicity is developmental immaturity of the P-450 (microsomal enzyme) system. Biotransformation of xenobiotics occurs predominantly by glutathione conjugation (Benet and Sheiner 1985; Sipes and Gandolfi 1986). This pathway is known to generate a number of toxic intermediate metabolites of 1,2-dibromoethane. In addition, fetal mice have selective binding of 1,2-dibromoethane metabolites in epithelial lining of the upper alimentary tract and the entire respiratory tract after 1,2-dibromoethane was administered parenterally to pregnant females (Kowalski et al. 1986).

As discussed in Section 2.6, chronic alcoholics receiving Antabuse (disulfiram) therapy are potentially more susceptible to toxic and neoplastic effects of 1,2-dibromoethane. It also follows that individuals with compromised liver or renal function or with asthma or other chronic respiratory diseases may have increased susceptibility to the toxic effects of 1,2-dibromoethane; however, chemical-specific effects have not been identified.

2.8 MITIGATION OF EFFECTS

This section will describe clinical practice and research concerning methods for reducing toxic effects of exposure to 1,2-dibromoethane. However, because some of the treatments discussed may be experimental and unproven, this section should not be used as a guide for treatment of exposures to 1,2-dibromoethane. When specific exposures have occurred, poison control centers and medical toxicologists should be consulted for medical advice.

Human exposure to 1,2-dibromoethane may occur by inhalation, ingestion or by dermal contact. Mitigation approaches to reduce absorption of 1,2-dibromoethane have included general recommendations of separating contaminated food, water, air, clothing from the exposed individual. Externally, exposed eyes and skin are flushed with a clean neutral solution such as water or normal saline. Water or milk is administered after ingestion of 1,2-dibromoethane to wash residual chemical through the esophagus if the patient can swallow (Bronsten and Currance 1988). Residual chemical remaining in the stomach is removed by gastric lavage after precautions have been taken to protect the respiratory tract from aspiration of gastric contents. Activated charcoal is administered to bind unabsorbed chemical that has passed out of the stomach and into the lower gastrointestinal tract. Administration of a cathartic is thought to be unnecessary since diarrhea frequently follows ingestion of this agent.
2. HEALTH EFFECTS

Once absorbed, 1,2-dibromoethane is rapidly metabolized. Its metabolism may induce effects by either of two systems, the microsomal monooxygenase system or the cytosolic activation system. Animal research has shown that seventy percent of 1,2-dibromoethane is excreted in the urine and feces within 48 hours. The lack of persistent metabolites in the tissues indicate that 1,2-dibromoethane is readily removed from the body. Methods for reducing body burden were not found.

Two reactive intermediates are formed through 1,2-dibromoethane metabolism, 2-bromoacetaldehyde and S-(2-bromoethyl) glutathione. The 2-bromoacetaldehyde causes tissue damage by covalent binding to cellular macromolecules. The S-(2-bromoethyl) glutathione is responsible for genotoxic effects and possibly its carcinogenic effect observed in laboratory animals.

No specific antidote has been shown to be effective in treating 1,2-dibromoethane intoxication once absorption into the bloodstream has occurred (Ellenhorn and Barceloux 1988). Intravenous infusions of glucose may limit the hepatotoxicity of 1,2-dibromoethane (EPA 1989b). During the recovery phase, a diet rich in vitamin B and carbohydrates may limit liver damage (Dreisbach and Robertson 1987; Lawrence and Michaels 1984). Hemodialysis may be needed to regulate extracellular fluid and electrolyte balance and to remove metabolic waste products if renal failure occurs (EPA 1989b).

Clinical or experimental methods to interfere with the mechanisms of action for 1,2-dibromoethane are not well understood. Using P-450 inhibitors may be possible to prevent the formation of the reactive metabolites, however this may not be feasible since it would not be specific for 1,2-dibromoethane and it would also affect the detoxification of other substances. Also, for this approach to work the glutathione pathway must also be inhibited. Otherwise, carcinogenicity would be increased due to the diversion of 1,2-dibromoethane from the oxidative pathway to the conjugative pathway, which forms S-(2-bromoethyl) glutathione, a more potent mutagen and carcinogen (EPA, 1985).

The carcinogenic and mutagenic effects of 1,2-dibromoethane is due to its ability to bind to DNA and RNA with metabolic activation. The mechanism of action for the antispermatogenic effects is probably related to the removal of sulphur from cysteine in the nucleus of the spermatozoa. Clinical intervention to interfere with these mechanisms has yet to be developed.

2.9 ADEQUACY OF THE DATABASE

Section 104(i)(5) of CERCLA as amended directs the Administrator of ATSDR (in consultation with the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate information on the health effects of 1,2-dibromoethane is available. Where adequate information is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the initiation of a program of research designed
2. HEALTH EFFECTS

to determine the health effects (and techniques for developing methods to
determine such health effects) of 1,2-dibromoethane.

The following categories of possible data needs have been identified by
a joint team of scientists from ATSDR, NTP, and EPA. They are defined as
substance-specific informational needs that, if met, would reduce or eliminate
the uncertainties of human health assessment. In the future, the identified
data needs will be evaluated and prioritized, and a substance-specific
research agenda will be proposed.

2.9.1 Existing Information on Health Effects of 1,2-Dibromoethane

The existing data on health effects of inhalation, oral, and dermal
exposure of humans and animals to 1,2-dibromoethane are summarized in
Figure 2-4. The purpose of this figure is to illustrate the existing
information concerning the health effects of 1,2-dibromoethane. Each dot in
the figure indicates that one or more studies provide information associated
with that particular effect. The dot does not imply anything about the
quality of the study or studies. Gaps in this figure should not be
interpreted as "data needs" information (i.e., data gaps that must necessarily
be filled).

Figure 2-4 graphically depicts the information that currently exists on
the health effects of 1,2-dibromoethane in humans and animals by various
routes of exposure. The vast majority of literature reviewed concerning the,
health effects of 1,2-dibromoethane in humans described case reports and
longer-term studies of pesticide workers and case reports of accidental or
intentional ingestion of 1,2-dibromoethane. The predominant route of exposure
in the occupational studies is believed to be inhalation, with dermal exposure
also implied. In a case report of fatalities, dermal exposure was considered
the primary route (Letz et al. 1984). The information on human exposure is
limited in that the possibility of concurrent exposure to other pesticides or
other toxic substances cannot be excluded, and the duration and level of
exposure to 1,2-dibromoethane generally cannot be quantified from the
information presented in these reports.

The database for the health effects of 1,2-dibromoethane after
inhalation and ingestion in experimental animals is substantial. However, as
can be seen in Figure 2-4, only limited information is available on the
effects of dermal exposure to 1,2-dibromoethane in animals. Furthermore, the
health effects associated with intermediate and chronic exposure durations are
more fully characterized than those associated with acute exposure.
2. HEALTH EFFECTS

FIGURE 2-4. Existing Information on Health Effects of 1,2-Dibromoethane

- Inhalation
- Oral
- Dermal

HUMAN

- Inhalation
- Oral
- Dermal

ANIMAL

● Existing Studies
2. HEALTH EFFECTS

2.9.2 Data Needs

**Acute-Duration Exposure.** The toxic effects of inhalation exposure to 1,2-dibromoethane have been investigated in various species of animals but no data are available in humans. Acute inhalation of 1,2-dibromoethane has been shown to cause lethal effects in rats, rabbits, guinea pigs, and monkeys which result primarily from respiratory and cardiac failure (Akamine 1952; Short et al. 1978; Rowe et al. 1952). The lungs, liver, kidney, and spleen are the target organs of inhaled 1,2-dibromoethane (Rowe et al. 1952). Central nervous system (CNS) effects are more pronounced at high vapor concentrations (Rowe et al. 1952). However, behavioral effects have been reported in rats and mice at lower exposure concentrations (Rowe et al. 1952). Acute oral exposures have resulted in death in humans and animals (Olmstead 1960; Rowe et al. 1952; Saraswat et al. 1986; Schlinke 1969). Hepatotoxicity has been the primary effect in both humans and animals (Olmstead 1960; Rowe et al. 1952; Saraswat et al. 1986). The limited data from human studies show that dermal exposure causes blisters and death (Letz et al. 1984); similar effects occur in animals (Rowe et al. 1952). Thus, acute effects of 1,2-dibromoethane in animals have been characterized, and additional studies do not appear to be necessary at this time.

**Intermediate-Duration Exposure.** Effects of repeated exposures in humans have not been investigated. The animal studies described predominantly renal, respiratory, hepatic, gastrointestinal tract, developmental, and reproductive or dermal/ocular effects (Amir 1975; Amir et al. 1977; Nitschke et al. 1981; NTP 1982; Rowe et al. 1952; Saraswat et al. 1986). Little or no reliable information on cardiovascular, hematological, musculoskeletal, neurological, and immunological effects in animals is available. Since all three routes (inhalation, oral, and dermal) are significant means of exposure for individuals living near hazardous waste sites, more information on the health effects (specifically neurological, immunological, hematological, and cardiac effects) associated with repeated-dose, low-level exposure to 1,2-dibromoethane would be useful.

**Chronic-Duration Exposure and Cancer.** Limited epidemiological studies have been conducted involving occupational exposure in workers, primarily by the respiratory route (Ratcliffe et al. 1987; Takahashi et al. 1981; Ter Haar 1980; Wong et al. 1979). These studies did not identify chronic adverse effects in organ systems other than the male reproductive system (refer to the subsequent discussion on reproductive toxicity). Chronic bioassays have been conducted in animals via the inhalation, oral, and dermal routes of exposure (NCI 1978; NTP 1982; Van Duuren et al. 1979, 1985, 1986; Wong et al. 1982). These studies have found predominantly respiratory, forestomach, hepatic, renal, and testicular effects. Thus, the chronic effects of 1,2-dibromoethane in animals appear to be characterized, and additional studies do not appear to be necessary. Because the use of 1,2-dibromoethane has diminished...
2. HEALTH EFFECTS

Dramatically since its registration was canceled in 1984, there is lower potential for additional long-term exposure. However, based on the Wong et al. (1982) study, additional chronic studies on the interactions between 1,2-dibromoethane and other chemicals may be warranted.

Limited epidemiological studies have been conducted involving occupational exposure in workers, primarily by the respiratory route (Ratcliffe et al. 1987; Takahashi et al. 1981; Ter Haar 1980; Wong et al. 1979). These studies neither confirm nor refute the possibility of 1,2-dibromoethane as a human carcinogen. Carcinogenicity bioassays have been conducted in animals via the inhalation, oral, and dermal routes of exposure (NCI 1978; NTP 1982; Van Duuren et al. 1979, 1985, 1986; Wong et al. 1982). These studies have found cancer in multiple organ systems in two species of rodents. Thus, the carcinogenic effects of 1,2-dibromoethane appear to be well characterized, and additional studies are not necessary. Because the use of 1,2-dibromoethane has diminished considerably since its registration was canceled in 1984, the potential for additional long-term exposure is lower.

Genotoxicity. 1,2-Dibromoethane has been tested for mutagenic activity in a battery of in vitro and in vivo assay systems. It is mutagenic in bacteria, fungi, fruit flies, and cultured mammalian cells (Ames and Yanofsky 1971; Barber 1981; Brimer et al. 1982; Crespi et al. 1985; Moriya et al. 1983; NTP 1989; Principe et al. 1981; Shiau et al. 1980). In the dominant lethal assay, 1,2-dibromoethane failed to elicit a positive response (Epstein et al. 1972; Short et al. 1979; Teratomo et al. 1980). In addition, there is limited evidence that it may cause sister chromatid exchanges and chromosomal aberrations (Ellingham et al. 1986; NTP 1989; Tezuka et al. 1980; Tucker et al. 1984). However, conflicting results have been reported for chromosomal aberration studies in human lymphocytes from exposed workers and in human and animal cell lines treated with 1,2-dibromoethane in vitro (Krishna et al. 1985; Steenland et al. 1985, 1986). A number of in vitro and in vivo studies demonstrate that 1,2-dibromoethane can interact with DNA resulting in genotoxic events (Bentley and Working 1988; Meneghini 1974; Peroco and Prodi 1981; Williams et al. 1982; Working et al. 1986). In view of the limited and somewhat conflicting evidence for the carcinogenicity of 1,2-dibromoethane in exposed human populations, data on the clastogenic and genotoxic effects in humans could offer insight into potential human health risks from 1,2-dibromoethane.

Reproductive Toxicity. Epidemiologic evidence concerning antispermatogenic and antifertility effects of inhalation exposure to 1,2-dibromoethane has been documented in the literature (Heinrichs 1983; Ratcliffe et al. 1987; Ter Haar 1980; Wong et al. 1979). However, results of these studies are limited by the small sample size and confounding factors. In rats, inhalation exposure results in impaired reproductive performance (NTP 1982; Short et al. 1979). Although no information on the reproductive toxicity of 1,2-dibromoethane is available in humans by oral exposure,
2. HEALTH EFFECTS

Antispermatogenic effects have been well demonstrated in various animal species including the bull, rat, and mouse following oral exposure (Amir 1973; Amir and Ben-David 1973; Amir and Lavon 1976; Amir and Volcani 1965; Amir et al. 1983; NCI 1978). No studies are available in humans or animals to assess reproductive toxicity resulting from the dermal route of exposure. The toxicokinetic data indicate that 1,2-dibromoethane is absorbed through the skin (Jakobson et al. 1982; Letz et al. 1984). Therefore, additional information on the effects via the dermal route of exposure would be useful.

**Developmental Toxicity.** The developmental effects of inhalation exposure to 1,2-dibromoethane have not been investigated in humans. The studies in animals clearly indicate that fetotoxic and behavioral effects occur in mice and/or rats at concentrations that are toxic to maternal welfare as well (Fanini et al. 1984; Hsu et al. 1985; Short et al. 1978). No data are available for humans or animals regarding developmental toxicity resulting from oral and dermal routes of exposure. Since human exposure to 1,2-dibromoethane can occur via inhalation and dermal exposures at hazardous waste sites and also from ingestion of contaminated drinking water, additional epidemiological studies in populations around hazardous waste sites to investigate the developmental hazard posed by 1,2-dibromoethane would be useful. Such studies would also be useful in areas where groundwater was contaminated by 1,2-dibromoethane from prior use of the pesticide in agriculture.

**Immunotoxicity.** No information on specific immunological effects of 1,2-dibromoethane is available for humans or animals exposed via inhalation, oral, or dermal routes. Some effect on the immune system can be inferred from a report of lymphoid neoplasia associated with exposure of workers to various chemicals including 1,2-dibromoethane (Alavanja et al. 1988). Epidemiological and animal studies would be useful to investigate the immunotoxic potential of 1,2-dibromoethane. Furthermore, if 1,2-dibromoethane proves to be a potential immunosuppressant, further research into this area could help identify populations at higher risk because of pre-existing permanent immunosuppression.

**Neurotoxicity.** Evidence for neurological effects in humans and experimental animals after oral or inhalation exposure is limited. Acute inhalation exposure of a worker resulted in transient depression (Kochmann 1928). Animal data show that acute inhalation of high concentrations causes CNS depression in animals (Rowe et al. 1952). Behavioral effects have been reported in offspring following inhalation exposure of rats during gestation (Fanini et al. 1984; Hsu et al. 1985). Acute oral exposures have been reported to cause death and brain lesions in humans (Saraswat et al. 1986) and stiffness, prostration, and anorexia in animals (Schlinke 1969). No information is available to assess neurological effects resulting from dermal exposure to 1,2-dibromoethane in humans and animals. Further studies of
2. HEALTH EFFECTS

neurological effects following inhalation and/or dermal exposure in both the newborn and adult would be valuable, as there are so few data available.

Epidemiological and Human Dosimetry Studies. Most of the available information on the effects of 1,2-dibromoethane in humans comes from cases of acute poisoning following accidental or intentional ingestion and from occupational exposures in agricultural industries (Alavanja et al. 1988; Kochmann 1928; Letz et al. 1984; Olmstead 1960; Ott et al. 1980; Ratcliffe et al. 1987; Saraswat et al. 1986; Takahashi et al. 1981; Ter Haar 1980; Turner and Barry 1979; Wong et al. 1979). Limitations inherent in these studies include unquantified exposure concentrations and durations, small sample size, as well as concomitant exposure to other pesticides and marijuana use. In addition, developmental and systemic effects following inhalation, oral, and dermal exposures in humans have not been studied. Well-controlled epidemiological studies that focused on exposure levels and health effects (e.g., systemic effects, developmental and immunological effects, genotoxicity, and cancer) of persons living in areas near hazardous waste sites would be useful in monitoring other affected populations. A common problem in such studies is acquisition of reliable dosimetry data on the exposed populations. For this reason, efforts to improve estimates of past exposure and to define more accurately current exposure levels to 1,2-dibromoethane would be valuable. Follow-up of exposed workers would be useful.

Biomarkers of Exposure and Effect. There appears to be no biological indicator for 1,2-dibromoethane toxicity that is entirely adequate when considered alone. Biomarkers of acute exposure to potentially toxic levels are residues of 1,2-dibromoethane in target tissues such as liver and brain, elevated serum bromide levels, and the presence of bromide ions and certain metabolites of 1,2-dibromoethane in urine (Letz et al. 1984; Nachtomi et al. 1965). Tissue specimens also could be examined for the presence of 1,2-dibromoethane metabolites covalently bound to protein or DNA (Bolt et al. 1986; Ozawa and Guengerich 1983; Peterson et al. 1988).

Results of studies in humans and animals suggest that sperm abnormalities, evidence of DNA damage such as chromosomal anomalies, and tests for liver and kidney dysfunction may serve as biomarkers of the effects of 1,2-dibromoethane (Ellingham et al. 1986; Heinrichs 1983; NTP 1982, 1989; Ratcliffe et al. 1987; Rowe et al. 1952; Ter Haar 1980; Wong et al. 1979). More quantitative data on chronically exposed individuals would provide a good database for use with screening protocols. These data could include tests of urine for 1,2-dibromoethane metabolites, monitoring of serum and urinary bromide ions, periodic monitoring of semen samples for abnormalities in sperm concentration, motility and morphology, and serum aspartate aminotransferase for liver cell damage.
2. HEALTH EFFECTS

Absorption, Distribution, Metabolism, and Excretion. Quantitative evidence on the absorption of 1,2-dibromoethane in humans is not available. However, it is known that workers exposed to 1,2-dibromoethane experience toxic effects following inhalation, oral, and dermal exposure (Alavanja et al. 1988; Kochmann 1928; Letz et al. 1984; Ott et al. 1980; Ratcliffe et al. 1987; Takahashi et al. 1981; Ter Haar 1980; Turner and Barry 1979; Wong et al. 1979). Animal studies clearly indicate that 1,2-dibromoethane is absorbed (Botti et al. 1982; Jakobson et al. 1982; Letz et al. 1984; Rowe et al. 1952). Reports that specifically evaluate the compound's rate or extent of absorption would be useful.

No studies were located regarding the distribution of 1,2-dibromoethane in humans. Animal studies regarding its distribution following oral absorption are available (Plotnick et al. 1979; Wong et al. 1982). Based on similar pathologic findings in humans and animals, the distribution in humans seems to be similar. Studies that investigate the distribution of 1,2-dibromoethane following inhalation or dermal exposures would be useful in order to evaluate whether 1,2-dibromoethane behaves similarly across all routes of exposure. Information was not available regarding the metabolism of 1,2-dibromoethane following inhalation, oral, or dermal exposure in humans. Its metabolism in humans probably occurs via the microsomal monooxygenase system because glutathione conjugation is less prominent in man. Metabolism of 1,2-dibromoethane in animals has been investigated via oral exposure (Lawrence and Michaels 1984; Tamura et al. 1986; Van Duuren et al. 1985). Mercapturic acids are identified as the primary metabolites of microsomal oxidation (Kirby et al. 1980; Nachtomi 1970; Nachtomi et al. 1965). The reactive metabolites formed by the microsomal oxidation or glutathione conjugation of 1,2-dibromoethane may bind to protein or DNA, producing either cytotoxicity or genotoxicity, respectively (Ozawa and Guengerich 1983; Van Bladeren 1983; White et al. 1983). Quantitative information regarding the metabolites formed would suggest which biodegradation pathways are favored and would also provide insight into the enzyme kinetics. Information regarding the overall rate of metabolism and rates of specific reaction following inhalation and dermal exposures would be useful, as well as how metabolism is affected by chemical interactions.

No studies in humans were found regarding excretion of 1,2-dibromoethane. Animal studies regarding the excretion of 1,2-dibromoethane following inhalation and dermal exposures are unavailable, but information is available for excretion following oral exposures (Plotnick et al. 1979). Since metabolites may contribute to the toxic effects attributed to 1,2-dibromoethane, it would be beneficial to conduct studies that would establish elimination rates for each metabolite or similar metabolic products. In addition, such studies may also provide information to facilitate the rapid removal of 1,2-dibromoethane and its metabolites in exposed people.
2. HEALTH EFFECTS

Comparative Toxicokinetics. Generally, target organs and adverse effects of 1,2-dibromoethane exposure are similar across species. Toxicokinetic studies have been performed in rats, mice, and guinea pigs. There are no major differences in distribution patterns. Humans would be expected to metabolize 1,2-dibromoethane in a manner qualitatively similar to animals. However, the disposition of 1,2-dibromoethane in humans remains to be determined.

Mitigation of Effects. Data are needed on mechanisms that may be used to decrease the effects of 1,2-dibromoethane once it has entered the bloodstream. Currently, the only available data are regarding treatment of clinical effects of 1,2-dibromoethane intoxication. Data are also needed on the chronic effects of low-level exposure to 1,2-dibromoethane to assess its long-term effects in humans.

2.9.3 On-going Studies

A recent abstract reported an excessive mortality from non-Hodgkin's lymphoma during the 1970s and 1980s in grain millers in the grain processing industry (Alavanja et al. 1988). Such workers had been exposed to 1,2-dibromoethane as well as aluminum phosphide, ethylene dichloride, malathion, and methyl bromide.

Additional on-going studies regarding the health effects of 1,2-dibromoethane were reported in the Directory of On-Going Research in Cancer Epidemiology (Parkin and Wahrendorf 1987). T. Meinhardt (NIOSH, Cincinnati, Ohio) is conducting epidemiological studies to investigate carcinogenic and cytogenetic changes in two separate populations exposed occupationally to 1,2-dibromoethane. J. Ratcliffe, formerly of NIOSH, was investigating cytogenetic and reproductive effects of exposure to 1,2-dibromoethane during occupational exposure to workers engaged in fumigating papaya.
3. CHEMICAL AND PHYSICAL INFORMATION

3.1 CHEMICAL IDENTITY

The chemical formula, structure, synonyms, and identification numbers for 1,2-dibromoethane are listed in Table 3-1.

3.2 PHYSICAL AND CHEMICAL PROPERTIES

Important physical and chemical properties of 1,2-dibromoethane are listed in Table 3-2.
3. CHEMICAL AND PHYSICAL INFORMATION

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Information</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical name</td>
<td>1,2-Dibromoethane</td>
<td>Windholz 1983</td>
</tr>
<tr>
<td>Synonyms</td>
<td>Ethylene dibromide; dibromooethane; ethylene bromide; ethane, 1,2-dibromo-; EDB; α-, β-dibromoethane; sym-dibromoethane; glycol bromide; glycol dibromide; 1,2-dibromoethano (Italian); bomoro el etile (Italian); 1,2-dibroomethaan (Dutch); althylenbromid (German); dibromure d'ethylen (French); dwubromoetan (Polish)</td>
<td>HSDB 1989;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Weiss 1986;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Windholz 1983</td>
</tr>
<tr>
<td>Trade names</td>
<td>Bromofume; Dowfume W85; Dowfume EDB; Dowfume 40, W-10, W-15, W-40; Dowfume MC-2; Isocrome D; ENT 15, 349; Netis; Pestmaster EDB-85; Santryuum; Unifume; EDB-85; Fumogas; Icopfume soilbrom-85; soilfume</td>
<td>HSDB 1989;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Weiss 1986;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Windholz 1983</td>
</tr>
<tr>
<td>Chemical Formula</td>
<td>C$_2$H$_4$Br$_2$</td>
<td>Windholz 1983</td>
</tr>
<tr>
<td></td>
<td>BrCH$_2$CH$_2$Br</td>
<td>Windholz 1983</td>
</tr>
<tr>
<td>Chemical structure</td>
<td>H H</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Br—C—C—Br</td>
<td></td>
</tr>
<tr>
<td></td>
<td>H H</td>
<td></td>
</tr>
</tbody>
</table>
3. CHEMICAL AND PHYSICAL INFORMATION

TABLE 3-1 (Continued)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Information</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Identification numbers:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAS registry</td>
<td>106-93-4</td>
<td>Weiss 1986</td>
</tr>
<tr>
<td>NIOSH RTECS</td>
<td>NIOSH/KH 9275000</td>
<td>NIOSH 1985</td>
</tr>
<tr>
<td>EPA hazardous waste</td>
<td>U067</td>
<td>HSDB 1989</td>
</tr>
<tr>
<td>OHM/TADS</td>
<td>7216716</td>
<td>HSDB 1989</td>
</tr>
<tr>
<td>DOT/UN/NA/IMCO shipping</td>
<td>DOT 1605; UN 1605; IMO 6.1</td>
<td>HSDB 1989</td>
</tr>
<tr>
<td>HSDB</td>
<td>536</td>
<td>HSDB 1989</td>
</tr>
<tr>
<td>NCI</td>
<td>CO0522</td>
<td>HSDB 1989</td>
</tr>
</tbody>
</table>

CAS = Chemical Abstracts Services; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency; HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; RTECS = Registry of Toxic Effects of Chemicals Substances
### 3. CHEMICAL AND PHYSICAL INFORMATION

#### TABLE 3-2. Physical and Chemical Properties of 1,2-Dibromoethane

<table>
<thead>
<tr>
<th>Property</th>
<th>Information</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight</td>
<td>187.86</td>
<td>Weiss 1986</td>
</tr>
<tr>
<td></td>
<td>187.88</td>
<td>Windholz 1983</td>
</tr>
<tr>
<td></td>
<td>188.0</td>
<td>NIOSH 1985</td>
</tr>
<tr>
<td>Color</td>
<td>Colorless</td>
<td>Weiss 1986</td>
</tr>
<tr>
<td>Physical state at</td>
<td>Liquid</td>
<td>Weiss 1986</td>
</tr>
<tr>
<td>15°C, 1 atm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melting point (centigrade)</td>
<td>10°C</td>
<td>NIOSH 1978</td>
</tr>
<tr>
<td>Boiling point (centigrade)</td>
<td>131°-132°C</td>
<td>Windholz 1983</td>
</tr>
<tr>
<td>Density at 25°C</td>
<td>2.172 g/cm³</td>
<td>Windholz 1983</td>
</tr>
<tr>
<td>Odor</td>
<td>Mild sweet odor, like chloroform</td>
<td>Weiss 1986</td>
</tr>
<tr>
<td>Odor threshold:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td>Air</td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td>Solubility:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water at 20°C</td>
<td>0.4 g/100 g water</td>
<td>NIOSH 1978</td>
</tr>
<tr>
<td>Water at 25°C</td>
<td>0.429 g/100 g water</td>
<td>Parrish 1983</td>
</tr>
<tr>
<td>Organic solvents</td>
<td>Miscible with alcohol, ether</td>
<td>Windholz 1983</td>
</tr>
<tr>
<td>Partition coefficients:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Octanol/water</td>
<td>86</td>
<td>Steinberg et al. 1987</td>
</tr>
<tr>
<td>$K_{oc}$</td>
<td>66</td>
<td>Rogers and McFarlane 1981</td>
</tr>
<tr>
<td>Vapor pressure at 25°C</td>
<td>11 mmHg</td>
<td>Windholz 1983</td>
</tr>
<tr>
<td>Henry's law constant:</td>
<td>8.2x10⁻⁴ atm m³/mol</td>
<td>Rathbun and Tai 1986</td>
</tr>
<tr>
<td>at 20°C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autoignition temperature</td>
<td>Not flammable</td>
<td>Weiss 1986</td>
</tr>
<tr>
<td>Flashpoint</td>
<td>Not flammable</td>
<td>Weiss 1986</td>
</tr>
<tr>
<td>Flammability limits</td>
<td>Not flammable</td>
<td>Weiss 1986</td>
</tr>
<tr>
<td>Conversion factors</td>
<td>No data</td>
<td>Weiss 1986</td>
</tr>
<tr>
<td>Explosive limits</td>
<td>No data</td>
<td>Weiss 1986</td>
</tr>
</tbody>
</table>
4. PRODUCTION, IMPORT, USE, AND DISPOSAL

4.1 PRODUCTION

1,2-Dibromoethane is a halogenated aliphatic hydrocarbon produced when gaseous ethylene comes in contact with bromine. The mixing of ethylene and bromine is accomplished in a variety of ways. One of the more common manufacturing processes involves a liquid-phase bromination of ethylene at 35°C-85°C. After the bromination of ethylene, the mixture is neutralized to free acid and then purified by distillation. Other methods of 1,2-dibromoethane formation include the hydrobromination of acetylene and a reaction of 1,2-dibromoethane with water (Fishbein 1980; HSDB 1989).

In the 1970s, production of 1,2-dibromoethane in the United States remained stable, averaging 280 million pounds per year; production peaked in 1974 at 332.1 million pounds. In 1979, the production volume averaged to 285.9 million pounds (Santodonato et al. 1985). Since then, production has consistently decreased. This decrease was primarily due to increased government regulation and restriction on products using 1,2-dibromoethane. Consequently, by 1982, the U.S. production of 1,2-dibromoethane reached a low of 169.8 million pounds (Santodonato et al. 1985). Data on production of 1,2-dibromoethane are not available after 1984.

1,2-Dibromoethane production constitutes one of the largest single uses of bromine; as a result, 1,2-dibromoethane production plants are generally located near major sources of bromine, such as in Arkansas (Fishbein 1980). Current facilities that manufacture or process 1,2-dibromoethane are listed in Table 4-1.

4.2 IMPORT/EXPORT

The U.S. import levels of 1,2-dibromoethane fluctuated between 1977 and 1981, reaching a peak in 1980 of 0.861 million pounds and a low in 1979 of 0.079 million pounds (Santodonato et al. 1985). Worldwide producers of 1,2-dibromoethane include the United Kingdom, Benelux, France, Spain, Italy, and Switzerland; collectively they produce 10-66 million pounds per year (Fishbein 1980).

A major market for U.S. 1,2-dibromoethane production has been overseas, although export levels have been declining. The U.S. export level of 1,2-dibromoethane in 1981 was 29.8 million pounds. This was substantially lower than in 1978 when the U.S. export level was 84.8 million pounds (Santodonato et al. 1985).

4.3 USE

1,2-Dibromoethane has been and is still used in a variety of ways. The main use is as an additive in leaded gasoline where 1,2-dibromoethane acts as a "scavenger" that converts lead oxides in cars to lead halides; these are
<table>
<thead>
<tr>
<th>Facility</th>
<th>Location</th>
<th>Maximum Amount (lbs)</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Great Lakes Chemical Co. El Dorado Main Plant</td>
<td>El Dorado, AR</td>
<td>1,000,000-9,999,999</td>
<td>Produce; for sale/distribution</td>
</tr>
<tr>
<td>Great Lakes Chemical Corp. South Plant</td>
<td>El Dorado, AR</td>
<td>100,000-999,999</td>
<td>As a reactant</td>
</tr>
<tr>
<td>Ethyl Corporation</td>
<td>Magnolia, AR</td>
<td>1,000,000-9,999,999</td>
<td>Produce; for sale/distribution</td>
</tr>
<tr>
<td>Texaco Ref. 7 Mktg., Inc.</td>
<td>Bakersfield, CA</td>
<td>10,000-99,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Exxon Co. USA. Benicia Refinery</td>
<td>Benicia, CA</td>
<td>No Data</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Arco Products Company Los Angeles Refinery</td>
<td>Carson, CA</td>
<td>10,000-99,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Shell Oil Company</td>
<td>Carson, CA</td>
<td>10,000-99,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Shell Oil Company</td>
<td>Carson, CA</td>
<td>10,000-99,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Tosco Corporation</td>
<td>El Segundo, CA</td>
<td>10,000-99,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Chevron Research Company Richmond Research Center</td>
<td>Martinez, CA</td>
<td>10,000-99,999</td>
<td>As a formulation component; in ancillary or other uses</td>
</tr>
<tr>
<td>Chevron U.S.A. Inc. Richmond Refinery</td>
<td>Richmond, CA</td>
<td>1,000-9,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Mobil Oil Corporation Torrance Refinery</td>
<td>Torrance, CA</td>
<td>1,000-9,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Texaco Ref. &amp; Mktg., Inc.</td>
<td>Wilmington, CA</td>
<td>10,000-99,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Chevron U.S.A. Inc. Hawaiian Refinery</td>
<td>Ewa Beach, HI</td>
<td>100,000-999,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Shell Oil Company</td>
<td>Roxana, IL</td>
<td>10,000-99,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Rock Island Refining Corporation</td>
<td>Indianapolis, IN</td>
<td>10,000-99,999</td>
<td>As a formulation component; in reprocessing</td>
</tr>
<tr>
<td>Ethyl Process Development Center</td>
<td>Baton Rouge, LA</td>
<td>100-999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Exxon Baton Rouge Refinery</td>
<td>Baton Rouge, LA</td>
<td>100,000-999,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Alliance Refinery - Bp America</td>
<td>Belle Chasse, LA</td>
<td>100-999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Tenneco Oil Company</td>
<td>Chalmette, LA</td>
<td>10,000-99,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Marathon Petroleum Company</td>
<td>Garyville, LA</td>
<td>1,000-9,999</td>
<td>Import; as a formulation component</td>
</tr>
<tr>
<td>Plessid Refining Company</td>
<td>Port Allen, LA</td>
<td>1,000-9,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Marathon Petroleum Company</td>
<td>Detroit, MI</td>
<td>1,000-9,999</td>
<td>In ancillary or other uses</td>
</tr>
<tr>
<td>Koch Refining Company</td>
<td>Saint Paul, MN</td>
<td>1,000-9,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Chevron U.S.A. Inc. Pascagoula Refinery</td>
<td>Pascagoula, MS</td>
<td>100,000-999,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Du Pont Chambers Works</td>
<td>Deepwater, NJ</td>
<td>1,000,000-9,999,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Dyes Chemical Corporation</td>
<td>Holley, NY</td>
<td>10,000-99,999</td>
<td>As a byproduct; as a reactant</td>
</tr>
<tr>
<td>Facility</td>
<td>Location</td>
<td>Maximum Amount on site (lbs)</td>
<td>Use</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>---------------------</td>
<td>------------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Shell Chemical Company</td>
<td>Belpre, OH</td>
<td>10,000-99,999</td>
<td>As a reactant</td>
</tr>
<tr>
<td>Sun Refinery And Marketing Co.</td>
<td>Oregon, OH</td>
<td>10,000-99,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Sun Refining And Marketing Co.</td>
<td>Tulsa, OK</td>
<td>1,000-9,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Kerr-McGee Refining Corp.</td>
<td>Wynnewood, OK</td>
<td>1,000-9,999</td>
<td>Import; as a formulation component</td>
</tr>
<tr>
<td>Chevron U.S.A. Inc.</td>
<td>Philadelphia, PA</td>
<td>10,000-99,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Exxon Baytown Refinery</td>
<td>Baytown, TX</td>
<td>10,000-99,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Du Pont Beaumont Works</td>
<td>Beaumont, TX</td>
<td>10,000-99,999</td>
<td>In re-packaging</td>
</tr>
<tr>
<td>Chevron U.S.A. Inc. El Paso Refinery</td>
<td>El Paso, TX</td>
<td>0-99</td>
<td>As an impurity</td>
</tr>
<tr>
<td>Ethyl Corporation Houston Plant</td>
<td>Pasadena, TX</td>
<td>100,000-999,999</td>
<td>As a formulation component; in repackaging</td>
</tr>
<tr>
<td>Chevron U.S.A. Inc. Port Arthur Refinery</td>
<td>Port Arthur, TX</td>
<td>10,000-99,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Diamond Shamrock Refining And Marketing Co.</td>
<td>Sunray, TX</td>
<td>10,000-99,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Phillips 66 Company Sweeny Refinery And Petrochemical</td>
<td>Sweeny, TX</td>
<td>10,000-99,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Marathon Petroleum Company</td>
<td>Texas City, TX</td>
<td>10,000-99,999</td>
<td>As a formulation component</td>
</tr>
<tr>
<td>Diamond Shamrock Refining And Marketing Co.</td>
<td>Three Rivers, TX</td>
<td>10,000-99,999</td>
<td>As a formulation component</td>
</tr>
</tbody>
</table>

*Derived from TRI87 1989
4. PRODUCTION, IMPORT, USE, AND DISPOSAL

released more easily with engine exhaust (Fishbein 1980; Stenger 1978). In 1978, 90% of the 1,2-dibromoethane produced went into leaded gasoline for this purpose (Santodonato et al. 1985). Due to the increased regulation of leaded gasoline, the production and consumption of 1,2-dibromoethane has been and will continue to decrease in the future (Fishbein 1980; Santodonato et al. 1985).

In the 1970s and early 1980s, the second largest application of 1,2-dibromoethane was as a soil fumigant to protect against insects, pests, and nematodes in citrus, vegetable, and grain crops and as a fumigant for turf, particularly on golf courses (HSDB 1989). However, in 1984, EPA banned the use of 1,2-dibromoethane as a soil and grain fumigant, thus eliminating this market for 1,2-dibromoethane manufacturers (Santodonato et al. 1985). Currently, other minor applications include treatment of felled logs for bark beetles, termite control, control of wax moths in beehives, spot treatment of milling machinery, Japanese beetle control in ornamental plants, and as a chemical intermediate for dyes, resins, waxes, and gums (HSDB 1989).

4.4 DISPOSAL

Disposal methods of 1,2-dibromoethane fall under the general regulation for organic pesticide disposal developed by EPA. The two main methods of disposal are incineration and burial. Incineration is the preferred method; disposal by burial, in a specially designated landfill, is used only if no appropriate incineration facilities are available. All emissions of the incineration process must meet the requirements of the Clean Air Act of 1970 relating to gaseous emissions. Similarly, combustible containers of organic pesticides should be disposed of in a pesticide incinerator or be buried in a specially designated landfill. The noncombustible containers should be triple-rinsed and then returned to the manufacturer to be recycled. Residues and rinse liquids should be used in conjunction with the 1,2-dibromoethanecontaining product where possible, otherwise they should be disposed of as described above (HSDB 1989).
5. POTENTIAL FOR HUMAN EXPOSURE

5.1 OVERVIEW

1,2-Dibromoethane has historically been released to the environment mainly as a result of its use as a gasoline additive and fumigant. 1,2-Dibromoethane partitions to the atmosphere and groundwater. The compound can be transported over long distances in the atmosphere, and is very mobile in soils. 1,2-Dibromoethane is transformed in the atmosphere by reaction with hydroxyl radicals and in soils by biodegradation. As a result of its high water solubility, the compound is not expected to bioconcentrate or biomagnify in food chains. Residual 1,2-dibromoethane bound to soil micropores is relatively immobile and resistant to degradation. This material is present in ppb concentrations and may be slowly leached from soil micropores over years to contaminate groundwater. If the micropores are disturbed and crushed, there is a greater likelihood of releasing the bound 1,2-dibromoethane. The compound persists in soils and groundwater.

The most important route of exposure to 1,2-dibromoethane for most members of the general population is ingestion of contaminated drinking water. Individuals living in the vicinity of hazardous waste sites contaminated with 1,2-dibromoethane may be exposed to higher concentrations of the compound.

EPA has identified 1,177 NPL sites. 1,2-Dibromoethane has been found at 9 of the total number of sites evaluated for that compound. We do not know how many of the 1,177 sites have been evaluated for 1,2-dibromoethane. As more sites are evaluated by EPA; this number may change (View 1989). The frequency of these sites within the United States can be seen in Figure 5-1.

5.2 RELEASES TO THE ENVIRONMENT

1,2-Dibromoethane has been widely released to the environment mainly as a result of the historical use of the compound as a gasoline additive and a fumigant (Fishbein 1979). The compound has also been released from industrial processing facilities. For example, 1,2-dibromoethane was found in air, water, soil, and sediment samples taken near industrial bromine facilities in El Dorado and Magnolia, Arkansas, in 1977 (Pellizzari et al. 1978).

According to the SARA Section 313 Toxics Release Inventory (TRI), an estimated total of at least 152,634 pounds of 1,2-dibromoethane were released to the environment from manufacturing and processing facilities in the United States in 1987 (see Table 5-1). This total includes an estimated 44 pounds that were released through underground injection. The TRI data should be used with caution since the 1987 data represent first-time reporting by these facilities. Only certain types of facilities were required to report. This is not an exhaustive list.
<table>
<thead>
<tr>
<th>Facility</th>
<th>Location</th>
<th>Air</th>
<th>Underground injection</th>
<th>Water</th>
<th>Land</th>
<th>Environment</th>
<th>POTHb transfer</th>
<th>Off-site transfer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Great Lakes Chemical Co.</td>
<td>El Dorado, AR</td>
<td>9,700</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>9,700</td>
<td>0</td>
<td>14,000</td>
</tr>
<tr>
<td>El Dorado-Main Plant</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Great Lakes Chemical</td>
<td>El Dorado, AR</td>
<td>3,700</td>
<td>44</td>
<td>0</td>
<td>0</td>
<td>3,744</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Corp. South Plant</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethyl Corporation</td>
<td>Magnolia, AR</td>
<td>18,100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>18,100</td>
<td>0</td>
<td>23,100</td>
</tr>
<tr>
<td>Texaco Ref. 7 Mktg., Inc.</td>
<td>Bakersfield, CA</td>
<td>150</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>150</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Exxon Co. USA, Benicia Refinery</td>
<td>Benecia, CA</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Arco Products Company</td>
<td>Carson, CA</td>
<td>60</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>60</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Los Angeles Refinery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shell Oil Company</td>
<td>Carson, CA</td>
<td>145</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>145</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Shell Oil Company</td>
<td>Carson, CA</td>
<td>71</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>71</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Chevron U.S.A. Inc.</td>
<td>El Segundo, CA</td>
<td>13</td>
<td>0</td>
<td>90</td>
<td>250</td>
<td>353</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Tosco Corporation</td>
<td>Martinez, CA</td>
<td>500</td>
<td>No Data</td>
<td>250</td>
<td>250</td>
<td>1,000</td>
<td>No Data</td>
<td>0</td>
</tr>
<tr>
<td>Chevron Research Company</td>
<td>Richmond, CA</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Richmond Research Center</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chevron U.S.A. Inc.</td>
<td>Richmond, CA</td>
<td>500</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>500</td>
<td>No Data</td>
<td>0</td>
</tr>
<tr>
<td>Richmond Refinery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mobil Oil Corporation</td>
<td>Torrance, CA</td>
<td>500</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>500</td>
<td>250</td>
<td>0</td>
</tr>
<tr>
<td>Torrence Refinery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Texaco Ref. &amp; Mktg., Inc.</td>
<td>Wilmington, CA</td>
<td>50</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>52</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Chevron U.S.A. Inc.</td>
<td>Ewa Beach, HI</td>
<td>500</td>
<td>No Data</td>
<td>250</td>
<td>0</td>
<td>750</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Hawaiian Refinery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shell Oil Company</td>
<td>Roxana, IL</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Rock Island Refining Corporation</td>
<td>Indianapolis, IN</td>
<td>250</td>
<td>0</td>
<td>0</td>
<td>250</td>
<td>500</td>
<td>0</td>
<td>250</td>
</tr>
<tr>
<td>Ethyl Process Development Center</td>
<td>Baton Rouge, LA</td>
<td>5,500</td>
<td>0</td>
<td>250</td>
<td>0</td>
<td>5,750</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Exxon Baton Rouge Refinery</td>
<td>Baton Rouge, LA</td>
<td>18</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>18</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
TABLE 5-1 (Continued)

<table>
<thead>
<tr>
<th>Facility</th>
<th>Location</th>
<th>Air</th>
<th>Underground Injection</th>
<th>Water</th>
<th>Land</th>
<th>Environment</th>
<th>POTM&lt;sup&gt;b&lt;/sup&gt; Transfer</th>
<th>Off-site Transfer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alliance Refinery - Bp America</td>
<td>Belle Chasse, LA</td>
<td>750</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>750</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Tenneco Oil Company</td>
<td>Chalmette, LA</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>No Data</td>
<td>0</td>
</tr>
<tr>
<td>Marathon Petroleum Company</td>
<td>Garyville, LA</td>
<td>750</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>750</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Placid Refining Company</td>
<td>Port Allen, LA</td>
<td>4</td>
<td>No Data</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Marathon Petroleum Company</td>
<td>Detroit, MI</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Koch Refining Company</td>
<td>Saint Paul, MN</td>
<td>12</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>12</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Chevron U.S.A. Inc.</td>
<td>Pascagoula, MS</td>
<td>500</td>
<td>0</td>
<td>92</td>
<td>250</td>
<td>842</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Pascagoula Refinery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Du Pont Chambers Works</td>
<td>Deepwater, NJ</td>
<td>6,060</td>
<td>0</td>
<td>0</td>
<td>700</td>
<td>6,760</td>
<td>No Data</td>
<td>1,700</td>
</tr>
<tr>
<td>Diaz Chemical Corporation</td>
<td>Holley, NY</td>
<td>500</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>500</td>
<td>0</td>
<td>250</td>
</tr>
<tr>
<td>Shell Chemical Company</td>
<td>Belpre, OH</td>
<td>13,000</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>13,000</td>
<td>0</td>
<td>360</td>
</tr>
<tr>
<td>Sun Refinery And Marketing Co.</td>
<td>Oregon, OH</td>
<td>250</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>250</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Sun Refining And Marketing Co.</td>
<td>Tulsa, OK</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Kerr-Mcgee Refining Corp.</td>
<td>Wynnewood, OK</td>
<td>250</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>250</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Chevron U.S.A. Inc.</td>
<td>Philadelphia, PA</td>
<td>500</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>500</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Exxon Baytown Refinery</td>
<td>Baytown, TX</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Du Pont Beaumont Works</td>
<td>Beaumont, TX</td>
<td>400</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>No Data</td>
<td>400</td>
<td>No Data</td>
</tr>
<tr>
<td>Chevron U.S.A. Inc. El Paso Refinery</td>
<td>El Paso, TX</td>
<td>250</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>250</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ethyl Corporation Houston Plant</td>
<td>Pasadena, TX</td>
<td>1,200</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1,200</td>
<td>0</td>
<td>250</td>
</tr>
<tr>
<td>Chevron U.S.A. Inc. Port Arthur Refinery</td>
<td>Port Arthur, TX</td>
<td>250</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>250</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Diamond Shamrock Refining And Marketing Company</td>
<td>Sunray, TX</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Facility</td>
<td>Location</td>
<td>Air</td>
<td>Underground injection</td>
<td>Water</td>
<td>Land</td>
<td>Environment</td>
<td>POTW&lt;sup&gt;b&lt;/sup&gt; transfer</td>
<td>Off-site transfer</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>-------------------</td>
<td>-----</td>
<td>-----------------------</td>
<td>-------</td>
<td>------</td>
<td>-------------</td>
<td>-----------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Phillips 66 Company</td>
<td>Sweeny, TX</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>37</td>
</tr>
<tr>
<td>Sweeny Refinery And Petrochemical Company</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marathon Petroleum Company</td>
<td>Texas City, TX</td>
<td>1,300</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1,300</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Diamond Shamrock Refining And Marketing Company</td>
<td>Three Rivers, TX</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td><strong>Totals</strong></td>
<td></td>
<td>65740</td>
<td>44</td>
<td>934</td>
<td>1702</td>
<td>68420</td>
<td>503</td>
<td>40100</td>
</tr>
</tbody>
</table>

*Derived from TRI87 1989

<sup>b</sup>POTW -- publicly owned treatment works
FIGURE 5–1. FREQUENCY OF NPL SITES WITH 1,2-DIBROMOETHANE CONTAMINATION

* Derived from View 1989
5. POTENTIAL FOR HUMAN EXPOSURE

Class and Ballschmitter (1988) suggested that 1,2-dibromoethane may be produced naturally in sea water from a dibromomethane precursor via a halogen exchange reaction. The dibromomethane is produced by brown algae via haloperoxidase enzymes and released to sea water.

5.2.1 Air

1,2-Dibromoethane releases to the atmosphere historically have been due to fugitive emissions from leaded gasolines, automobile exhaust, and the former use of the compound as a fumigant (Fishbein 1979).

An estimated total of at least 149,854 pounds of 1,2-dibromoethane was released to the atmosphere from manufacturing and processing facilities in the United States in 1987 (TR187 1989) (see Table 5-1).

5.2.2 Water

The use of 1,2-dibromoethane as a solvent and chemical intermediate has led to release of the compound to surface waters in industrial process effluents (Fishbein 1979).

An estimated total of at least 1,034 pounds of 1,2-dibromoethane was released to surface waters from manufacturing and processing facilities in the United States in 1987 (TR187 1989) (see Table 5-1).

1,2-Dibromoethane has been detected in an estimated 0.23% of the groundwater samples analyzed for the 2,783 hazardous waste sites participating in the Contract Laboratory Program (CLP); a positive geometric mean concentration value was not reported. 1,2-Dibromoethane has not been detected in surface water samples taken at hazardous waste sites (CLPSD 1988). Note that the CLP Statistical Database (CLPSD) includes data from both NPL and non-NPL sites.

5.2.3 Soil

The main sources of 1,2-dibromoethane release to soils appear to be the historical use of the compound as a soil fumigant and land disposal of wastes containing the compound.

An estimated total of at least 1,702 pounds of 1,2-dibromoethane was released to soils from manufacturing and processing facilities in the United States in 1987 (TR187 1989) (see Table 5-1).

1,2-Dibromoethane has been detected in an estimated 0.12% of the soil samples collected from the 2,783 hazardous waste sites that have had samples analyzed by the CLP; a positive geometric concentration value was not reported (CLPSD 1988). Note that the CLPSD includes data from both NPL and non-NPL sites.
5. POTENTIAL FOR HUMAN EXPOSURE

5.3 ENVIRONMENTAL FATE

5.3.1 Transport and Partitioning

The vapor pressure (11 mmHg at 25°C) of 1,2-dibromoethane suggests that the compound readily partitions to the atmosphere following release to surface water and soils. As the data in Section 5.4.1 indicate, 1,2-dibromoethane can be transported for long distances in the atmosphere before removal in wet and dry deposition or degradation.

Volatilization is the most important removal process for 1,2-dibromoethane released to surface waters. Volatilization half-lives of 1-16 days have been estimated for flowing and standing surface waters. Sorption to sediment or suspended particulate material is not expected to be an important process (EPA 1987a, 1987b; HSDB 1989).

As a result of its low sorption potential, high vapor pressure, and high water solubility, 1,2-dibromoethane is rapidly lost from soils by volatilization to the atmosphere or leaching to surface water and groundwater (EPA 1987a). In studies with two silty clay loam soils and cation saturated montmorillonite clays, a maximum of only 4% of applied 1,2-dibromoethane was found to be sorbed to soil particulates; an experimental soil sorption coefficient (Koc) value of 66 was reported (Rogers and McFarlane 1981). However, Steinberg et al. (1987) have reported that a small fraction of 1,2-dibromoethane released to soils (that is not rapidly volatilized, leached, or degraded) is sorbed strongly to soil micropores where it persists for long periods of time, resistant to mobilization and degradation. This residual 1,2-dibromoethane may slowly leach (half-life = years) from micropore sites to contaminate groundwater.

As a result of its high water solubility, 1,2-dibromoethane is not expected to bioconcentrate or biomagnify in terrestrial and aquatic food chains.

5.3.2 Transformation and Degradation

5.3.2.1 Air

Direct photolysis of 1,2-dibromoethane in the troposphere is not expected to occur (Jaber et al. 1984). 1,2-Dibromoethane reacts with hydroxyl radicals in the atmosphere; the half-life for the reaction has been estimated to be about 40 days (EPA 1987a).

5.3.2.2 Water

Biotic and abiotic degradation of 1,2-dibromoethane in surface waters is slow relative to volatilization of the compound to the atmosphere (EPA 1987b). 1,2-Dibromoethane is resistant to hydrolysis (Jaber et al. 1984); the
5. POTENTIAL FOR HUMAN EXPOSURE

hydrolytic half-life of the compound has been reported to range from 2.5 years (Vogel and Reinhard 1982) to 13.2 years (HSDB 1989). As a result of its hydrolytic stability and the limited biological activity in subsurface soils, 1,2-dibromoethane leached to groundwater is expected to persist for years.

5.3.2.3 Soil

1,2-Dibromoethane undergoes biodegradation in aerobic surface soils; the rate has been reported to decrease with increasing concentrations of the compound (Pignatello 1986). Biodegradation appears to be limited under anaerobic conditions (Bouwer and McCarty 1983). Residual 1,2-dibromoethane sorbed to soil micropores is resistant to biodegradation, chemical transformation, and mobilization; Steinberg et al. (1987) detected the compound in a surface soil 19 years after 1,2-dibromoethane had been applied for the last time as a fumigant.

5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT

As a result of its persistence in soil and groundwater, and past Widespread use as a gasoline additive and fumigant, 1,2-dibromoethane has been detected in ambient air, soils, groundwater, and food. However, most of the monitoring data reported in this section, although the latest available, are not current. Volatilization is the most important removal process for 1,2-dibromoethane released to surface waters. Since only a small fraction of the compound is sorbed to soil, sorption to sediment and subsequent persistence in sediment is not expected to be an important process in the removal of 1,2-dibromoethane from the environment. The data may reflect ambient concentrations of a decade or more ago, but because of the phaseout of the use of leaded gasoline and the ban on fumigant uses of 1,2-dibromoethane, current ambient media concentrations, with the potential exception of groundwater concentrations, are expected to be much lower than the levels reported here.

5.4.1 Air

1,2-Dibromoethane has been detected in ambient air samples collected at a number of sites in the United States. In a review of available monitoring data for volatile organic compounds, Brodzinsky and Singh (1983) reported the following median concentrations of 1,2-dibromoethane in ambient air samples in the United States: rural and remote areas--less than detection limit; urban and suburban areas--2.6 parts per trillion (ppt); and source-dominated areas--1.9 ppt. Typical daily concentrations at four sites in the metropolitan Los Angeles area in 1983 were reported to range from less than 5 ppt to 17 ppt (Kowalski et al. 1985b). Ambient air concentrations for other metropolitan areas in the United States in 1980 were reported by Singh et al. (1981) as follows:
5. POTENTIAL FOR HUMAN EXPOSURE

1,2-Dibromoethane (ppt)

<table>
<thead>
<tr>
<th>Location</th>
<th>Mean</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Houston, TX</td>
<td>59</td>
<td>10-368</td>
</tr>
<tr>
<td>St. Louis, MO</td>
<td>16</td>
<td>8-26</td>
</tr>
<tr>
<td>Denver, CO</td>
<td>31</td>
<td>10-78</td>
</tr>
<tr>
<td>Riverside, CA</td>
<td>22</td>
<td>10-47</td>
</tr>
</tbody>
</table>

1,2-Dibromoethane has also been detected in ambient air samples collected at two hazardous waste sites in New Jersey at geometric mean concentrations of 20-50 ppt; the maximum value reported was 6,710 ppt (La Regina et al. 1986).

Long-range transport of 1,2-dibromoethane from industrialized areas may have been the source of the compound found in ambient air samples collected in the Arctic by Rasmussen and Khalil (1984). 1,2-Dibromoethane concentrations in the 1983 study were reported to range from 1.0 to 1.9 ppt.

Natural production was speculated to be the source of 1,2-dibromoethane found in ambient air samples collected from open areas of the North and South Atlantic Ocean by Class and Ballschmitter (1988); concentration levels were reported to be less than 0.001-0.003 ppt.

5.4.2 Water

As a result of its volatility, 1,2-dibromoethane has been detected at only low levels in surface water samples collected in the United States. Ewing et al. (1977) reported that 1,2-dibromoethane was detected (i.e., concentrations greater than 1,000 ppt) in only 2 of 204 surface water samples collected near heavily industrialized sites throughout the country. 1,2-Dibromoethane was detected at a maximum concentration of 200 ppt in 11 of 175 surface water samples collected in New Jersey from 1977 to 1979 (Page 1981). However, the compound has been widely detected in groundwater samples collected in the United States. States with reported 1,2-dibromoethane groundwater contamination problems include Wisconsin (Krill et al. 1986), Hawaii (Oki and Giambelluca 1987), New Jersey (maximum concentration of 48,800 ppt in 34 of 421 samples) (Page 1981), and Georgia (1,000-94,000 ppt) (Marti et al. 1984). According to the interim data available in the Pesticides in Ground Water Data Base, 1,2-dibromoethane detection in groundwater has been confirmed in six states: California, Connecticut, Georgia, Massachusetts, New York, and Washington. The median and maximum concentrations reported were 900 and 14,000 ppt, respectively (Williams et al. 1988).
5. POTENTIAL FOR HUMAN EXPOSURE

Class and Ballschmitter (1988) suggested that brown algae may be the source of the <0.01-0.03 ppt of 1,2-dibromoethane found in the marine water samples collected from the North and South Atlantic Oceans.

5.4.3 Soil

No information was found in the literature regarding current ambient concentrations of 1,2-dibromoethane in surface soils in the United States.

5.4.4 Other Environmental Media

1,2-Dibromoethane residues in foods have decreased since the use of the compound as a fumigant was banned by EPA. For example, Daft (1989) reported finding 1,2-dibromoethane in only 2 of 549 samples of fatty and nonfatty foods analyzed for fumigant residues in a recent survey. 1,2-Dibromoethane was detected in samples of peanut butter and whiskey at a mean concentration of 7 µg/g (range 2-11 ng/g). Historical foodstuff residue levels have been reviewed by EPA (1983).

5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE

Current human exposure to 1,2-dibromoethane for most members of the general population appears to be limited to ingestion of low levels of the compound in contaminated drinking water. According to EPA (1985), daily intake from drinking water has been estimated to range from 0 to 16 µg/kg/day. Ingestion of contaminated foodstuffs does not appear to be an important source of exposure; EPA (1983) estimated that the maximum intake of 1,2-dibromoethane from contaminated foods was 0.09 µg/kg/day. Average inhalation of ambient air also appears to be of less importance than ingestion of groundwater, although the available data are not current and variable. Daily respiratory intake was estimated by EPA (1985) to range from 0 to 79 µg/kg/day. Average inhalation exposures in four metropolitan areas of the United States in 1980 were estimated by Singh et al. (1981) to range from 2.8 to 9.9 µg/day (or 0.04-0.14 µg/kg/day for a 70-kg human). However, inhalation of 1,2-dibromoethane released to indoor air from contaminated groundwater (e.g., during showering) may be an important source of human exposure. For example, McKone (1987) modeled the mass transfer of several volatile organic compounds, including 1,2-dibromoethane, from water to air and calculated a maximum concentration of 1,2-dibromoethane in household air of 2.4x10^-4 mg/L, assuming a tap water concentration of 1 mg/L.

Exposure of the general population to higher concentrations of 1,2-dibromoethane may result from contact with contaminated hazardous waste site media, principally soils and groundwater. No information was found in the available literature regarding the size of the human population potentially exposed to 1,2-dibromoethane through contact with contaminated waste site media.
5. POTENTIAL FOR HUMAN EXPOSURE

In occupational settings, current exposures are expected to be substantially reduced from historical levels (Santodonato et al. 1985). The large numbers of people exposed to 1,2-dibromoethane in the workplace through its manufacture and use as a gasoline additive and fumigant have decreased as these uses of the compound have been limited. NIOSH (1977) estimated that as many as 108,000 workers were potentially exposed to 1,2-dibromoethane during production and fumigant related uses, and an additional 875,000 workers were exposed to lower levels of the compound through its use in leaded gasoline. Current exposure levels are also expected to be substantially reduced from the historical inhalation and dermal exposures reported in manufacturing and processing facilities by Rumsey and Tanita (1978) and in fumigation operations reviewed by EPA (1983).

5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES

Members of the general population with potentially high exposure to 1,2-dibromoethane include individuals living near the nine NPL sites currently known to be contaminated with the compound. The size of the population and the concentrations of 1,2-dibromoethane in all of the contaminated media to which these people are potentially exposed have not been completely characterized. Other populations with potentially high exposures to 1,2-dibromoethane include individuals in the six states with confirmed groundwater contamination, and workers involved in the manufacture and continued use of 1,2-dibromoethane.

5.7 ADEQUACY OF THE DATABASE

Section 104(i)(5) of CERCLA as amended directs the Administrator of ATSDR (in consultation with the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate information on the health effects of 1,2-dibromoethane is available. Where adequate information is not available, ATSDR, in conjunction with the NTP, is required to assure the initiation of a program of research designed to determine the health effects (and techniques for developing methods to determine such health effects) of 1,2-dibromoethane.

The following categories of possible data needs have been identified by a joint team of scientists from ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that, if met, would reduce or eliminate the uncertainties of human health assessment. In the future, the identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be proposed.
5. POTENTIAL FOR HUMAN EXPOSURE

5.7.1 Data Needs

**Physical and Chemical Properties.** The physical/chemical properties of 1,2-dibromoethane, described in Table 3-2, are sufficiently well characterized to enable assessment of the environmental fate of the compound.

**Production, Import/Export, Use, and Disposal.** According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required to submit chemical release and off-site transfer information to the EPA. The Toxic Release Inventory (TRI), which contains this information for 1987, became available in May of 1989. This database will be updated yearly and should provide a list of industrial production facilities and emissions.

Although 1,2-dibromoethane is currently produced and used in the United States, increased government regulation and restriction on products containing the compound probably have decreased the potential for exposure of the U.S. population (Fishbein 1980; Santodonato et al. 1985). The most recent information on the annual U.S. production of 1,2-dibromoethane is for 1982 (169.8 million pounds); this is lower than the average for the 1970s (280 million pounds) (Santodonato et al. 1985). The most recent import and export data are for 1980 (0.861 million pounds) and 1981 (29.8 million pounds), respectively; import volumes reportedly fluctuated between 1977 and 1981 and the 1981 export volume is substantially lower than that for 1978 (84.8 million pounds) (Santodonato et al. 1985). 1,2-Dibromoethane may be found in air and water as a result of its use, e.g., as a chemical intermediate, although its uses as a lead scavenger in gasoline and as a soil and grain fumigant have been decreased or eliminated by governmental regulation (Fishbein 1979, 1980; HSDB 1989; Santodonato et al. 1985; Stenger 1978). In addition, the general regulations governing organic pesticide disposal developed by EPA are applicable to 1,2-dibromoethane. It is disposed of mainly by incineration and by burial; however, the amounts disposed of by each method are not reported (HSDB 1989). Therefore, more recent production, import, export, use, and disposal volumes of 1,2-dibromoethane would be useful in assessing the potential for the release of, and exposure to, this chemical.

Information regarding the various modes of production, use, and disposal of 1,2-dibromoethane is well documented. However, more recent data describing present domestic production levels, the proportions of 1,2-dibromoethane consumed by the various uses, as well as data on export levels and the countries to which these exports are made would be helpful in providing a broader, more up-to-date picture of the U.S. 1,2-dibromoethane industry as a whole.

**Environmental Fate.** 1,2-Dibromoethane partitions to the atmosphere and groundwater (Windolz 1983). It is transported in the atmosphere where it undergoes degradation by hydroxyl radicals (EPA 1987a). 1,2-Dibromoethane is
mobile and biodegradable in soils, although 1,2-dibromoethane sorbed to soil micropores is immobile and persistent (Pignatello 1986; Steinberg et al. 1987). 1,2-Dibromoethane is volatilized from surface waters before it can undergo degradation (EPA 1987b). Additional information is needed on the persistence of 1,2-dibromoethane in groundwater and sorbed to soil micropores. This information will be helpful in establishing the half-life of the compound in the media of most concern for human exposure.

**Bioavailability from Environmental Media.** 1,2-Dibromoethane can be absorbed by inhalation of contaminated ambient air, dermal contact, and ingestion of contaminated drinking water and foodstuffs (EPA 1983; Jakobson et al. 1982; Letz et al. 1984; Rowe et al. 1952; Saraswat et al. 1986; Stott and McKenna 1984). Ingestion of contaminated groundwater is the exposure route of concern at hazardous waste sites. Additional information is needed on the absorption of 1,2-dibromoethane from soil following ingestion or dermal contact. This information will be useful in determining the abioavailability of residual 1,2-dibromoethane in soils.

**Food Chain Bioaccumulation.** 1,2-Dibromoethane is not expected to bioconcentrate in plants, aquatic organisms, or animals, or biomagnify in terrestrial or aquatic food chains as a result of its high water solubility (NIOSH 1978; Parrish 1983). Additional information is needed on bioconcentration and biomagnification of the compound to confirm this predicted environmental behavior.

**Exposure Levels in Environmental Media.** 1,2-Dibromoethane has been detected in ambient air, groundwater, soils, and foodstuffs (Brodzinsky and Singh 1983; EPA 1983; Ewing et al. 1977; Daft 1989; Page 1981; Pellizzari et al. 1978; Singh et al. 1981; Williams et al. 1988). However, the monitoring data for these media are not current. Estimates of human intake have been made on the basis of these older data. Additional information is needed on the current levels of 1,2-dibromoethane in ambient air, soils, and groundwater and on human intake levels, particularly at the nine hazardous waste sites known to be contaminated with the compound. This information will be helpful in estimating human exposure to the compound via contact with contaminated media.

**Exposure Levels in Humans.** 1,2-Dibromoethane can be measured in blood and metabolites can be detected in urine (Letz et al. 1984; Nachtomi et al. 1965). However, since the compound is rapidly and extensively metabolized in mammals, and 1,2-dibromoethane metabolites do not persist in tissues, these biomarkers have not been useful in identifying or quantifying human exposure to the compound.

**Exposure Registries.** No exposure registries for 1,2-dibromoethane were located. This compound is not currently one of the compounds for which a subregistry has been established in the National Exposure Registry. The
5. POTENTIAL FOR HUMAN EXPOSURE

compound will be considered in the future when chemical selection is made for subregistries to be established. The information that is amassed in the National Exposure Registry facilitates the epidemiological research needed to assess adverse health outcomes that may be related to the exposure to this compound.

5.7.2 On-going Studies

As part of the Third National Health and Nutrition Evaluation Survey (NHANES III), the Environmental Health Laboratory Sciences Division of the National Center for Environmental Health and Injury Control, Centers for Disease Control, will be analyzing human blood samples for 1,2-dibromoethane and other volatile organic compounds. These data will give an indication of the frequency of occurrence and background levels of these compounds in the general population.

On-going remedial investigations and feasibility studies conducted at the nine NPL sites known to be contaminated with 1,2-dibromoethane will add to the available database on exposure levels in environmental media, exposure levels in humans, and exposure registries.
6. ANALYTICAL METHODS

The purpose of this chapter is to describe the analytical methods that are available for detecting and/or measuring and monitoring 1,2-dibromoethane in environmental media and in biological samples. The intent is not to provide an exhaustive list of analytical methods that could be used to detect and quantify 1,2-dibromoethane. Rather, the intention is to identify well established methods that are used as the standard methods of analysis. Many of the analytical methods used to detect 1,2-dibromoethane in environmental samples are the methods approved by federal agencies such as EPA and the National Institute for Occupational Safety and Health (NIOSH). Other methods presented in this chapter are those that are approved by groups such as the Association of Official Analytical Chemists (AOAC) and the American Public Health Association (APHA). Additionally, analytical methods are included that refine previously used methods to obtain lower detection limits, and/or to improve accuracy and precision.

6.1 BIOLOGICAL MATERIALS

Gas chromatography (GC) equipped with a flame ionization detector has been employed for measuring the concentration of 1,2-dibromoethane in the tissues of two workers following exposure (Letz et al. 1984). A detection limit of 0.5 µg of 1,2-dibromoethane per gram of tissue was achieved. In the same report, Letz et al. (1984) detected ppm (mg/L) levels of bromide ion (a metabolite of 1,2-dibromoethane) in the serum and whole blood before and after the death of two individuals, respectively. Detection limits of 50 mg of bromide ion per liter of serum and 8 mg of bromide ion per liter of whole blood were obtained using gold chloride calorimetry and high-performance liquid chromatography, respectively. GC has also been used for quantifying ppm levels of 1,2-dibromoethane in blood and liver of rats and chicks (Nachtomi and Alumot 1972). See Table 6-1 for details.

6.2 ENVIRONMENTAL SAMPLES

High-resolution GC equipped with an appropriate detector is the most common analytical technique for determining the concentrations of 1,2-dibromoethane in air, water, wastewater, soil, leaded gasoline, and various foods (e.g., grains, grain-based foods, beverages, and fruits). The choice of a particular detector will depend on the nature of the sample matrix, the detection limit, and the cost of the analysis. Because volatile organic compounds in environmental samples may exist as complex mixtures or at very low concentrations, concentrations of these samples prior to quantification are usually necessary.

Gas purging and trapping is the most commonly used method for the preconcentration of 1,2-dibromoethane from water, waste water, soil, and various foods. This method also provides a preliminary separation of 1,2-dibromoethane from other less volatile and nonvolatile components in the
<table>
<thead>
<tr>
<th>Sample matrix</th>
<th>Preparation method</th>
<th>Analytical method</th>
<th>Sample detection limit</th>
<th>Percent recovery</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biological tissues</td>
<td>Add water to tissue sample (at 50°C) and homogenise; extract with carbon disulfide and analyze</td>
<td>Gas chromatography flame ionisation detector</td>
<td>0.5 µg/g</td>
<td>No data</td>
<td>Letz et al. 1984</td>
</tr>
<tr>
<td>Bromide ion in serum (before death of workers)</td>
<td>No data</td>
<td>Gold chloride colorimetry</td>
<td>50 mg/L</td>
<td>No data</td>
<td>Letz et al. 1984</td>
</tr>
<tr>
<td>Bromide ion in whole-blood (after death of workers)</td>
<td>No data</td>
<td>High-performance liquid chromatography</td>
<td>8 mg/L</td>
<td>3.6% coefficient of variation</td>
<td>Letz et al. 1984</td>
</tr>
<tr>
<td>Blood and liver (rats and chicks)</td>
<td>No data</td>
<td>Gas chromatography</td>
<td>ppm levels</td>
<td>No data</td>
<td>Nachtomi and Alumot 1972</td>
</tr>
</tbody>
</table>
samples, thereby alleviating the need for extensive separation of the components by a chromatographic column prior to quantification.

The best sensitivity for 1,2-dibromoethane quantification is obtained by either electron capture detector (ECD) or Hall electrolytic conductivity detector (HECD) in the halide detection mode, since these detectors are relatively insensitive to nonhalogenated species and very sensitive to halogenated species. Another common detection device is a mass spectrometer (MS) connected to a GC. The GC/MS combination provides unequivocal identification of 1,2-dibromoethane in samples containing multiple components having similar GC elution characteristics (see Table 6-2). To date, GC equipped with either ECD or HECD has provided the greatest sensitivity for detecting 1,2-dibromoethane. However, GC/MS employing the techniques of selective ion monitoring and isotope dilution have produced sensitivities in the parts-per-quadrillion range for some organic pollutants (Patterson et al. 1987), and could be used for 1,2-dibromoethane analysis.

The primary method of analyzing 1,2-dibromoethane in air is by adsorption on a solid phase (i.e., activated charcoal tube or Tenax adsorbent followed by thermal or solvent elution for subsequent quantification. GC/ECD and GC/MS are the most commonly used analytical techniques for 1,2-dibromoethane after elution from the solid phase (Clark et al. 1982; Collins and Barker 1983; Erikson and Pellizzari 1978; Girish and Kumar 1975; NIOSH 1987; Scott et al. 1987). NIOSH has recommended GC/ECD (method 1008) for determining 1,2-dibromoethane in air (NIOSH 1987). The range of quantification is 0.3–1,000 ppb for a 25-L air sample.

1,2-Dibromoethane is usually isolated from aqueous media by the purge-and-trap method or liquid-liquid extraction. GC/ECD or GC/MS is the technique employed for measuring 1,2-dibromoethane in water and waste water at ppt levels (Kroneld 1985; Marti et al. 1984; Simmonds 1984). GC/ECD is also the technique (method 8011) recommended by the EPA Office of Solid Waste and Emergency Response for determining 1,2-dibromoethane in drinking water and groundwater at ppt levels (EPA 1987b).

1,2-Dibromoethane can be isolated from soil samples by liquid-liquid extraction and subsequent quantification by GC/MS (Sawhney et al. 1988). Low ppb levels of 1,2-dibromoethane in soil were reported using this technique. Sample collection and preparation for the analysis of 1,2-dibromoethane in foods includes the purge-and-trap method, headspace gas analysis, liquid-liquid extraction, and steam distillation (Alleman et al. 1986; Anderson et al. 1985; Bielorai and Alumot 1965, 1966; Cairns et al. 1984; Clower et al. 1985; Pranoto-Soetardhi et al. 1986; Scudamore 1985). GC equipped with either ECD or HECD is the technique used for measuring 1,2-dibromoethane in foodstuffs at ppt levels (Clower et al. 1985; Entz and Hollifield 1982; Heikes and Hopper 1986; Page et al. 1987; Van Rillaer and Beernaert 1985).
<table>
<thead>
<tr>
<th>Sample matrix</th>
<th>Preparation method</th>
<th>Analytical method</th>
<th>Sample detection limit</th>
<th>Percent recovery</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Air</td>
<td>Adsorb air sample onto charcoal tube; extract sample and analyze</td>
<td>GC/ECD</td>
<td>0.0003-1 ppm (for a 25-L air sample)</td>
<td>No data</td>
<td>NIOSH 1987 (Method 1008)</td>
</tr>
<tr>
<td>Air</td>
<td>Collect air sample on Tenax adsorbent; desorb thermally and analyze</td>
<td>GC/ECD or GC/FID</td>
<td>No data</td>
<td>1.4% RSD</td>
<td>Clark et al. 1982</td>
</tr>
<tr>
<td>Water</td>
<td>No data</td>
<td>GC/FID</td>
<td>0.019 ppm</td>
<td>No data</td>
<td>Dumas and Bond 1982</td>
</tr>
<tr>
<td>Water</td>
<td>Purge and cryotrap on adsorbent</td>
<td>GC/ECD</td>
<td>0.01-0.004 μg/L</td>
<td>12.1% RSD</td>
<td>Simmonds 1984</td>
</tr>
<tr>
<td>Water</td>
<td>Purge and trap on adsorbent</td>
<td>GC/MS</td>
<td>0.05 μg/L</td>
<td>95%</td>
<td>Marti et al. 1984</td>
</tr>
<tr>
<td>Water and waste water</td>
<td>Add sodium chloride to sample and extract with hexane</td>
<td>GC/ECD</td>
<td>0.01 μg/L</td>
<td>95%-114%</td>
<td>EPA 1987b (Method 8011)</td>
</tr>
<tr>
<td>Water and waste water</td>
<td>Purge and trap on adsorbent</td>
<td>GC/MS</td>
<td>1 μg/L (drinking water)</td>
<td>68%</td>
<td>Michael et al. 1988</td>
</tr>
<tr>
<td>Soil</td>
<td>Extract sample with methanol</td>
<td>GC/MS</td>
<td>≤0.0018 μg/g</td>
<td>No data</td>
<td>Sawhney et al. 1988</td>
</tr>
<tr>
<td>Soil</td>
<td>Decompose 1,2-dibromoethene in sample by distillation and cooling in acetone:isooctane (1:1); analyze resulting hydrogen bromide at 376 nm</td>
<td>MEC</td>
<td>&lt;0.5 μg/g</td>
<td>&gt;96%</td>
<td>Abdel-Kader et al. 1979</td>
</tr>
<tr>
<td>Leaded gasoline</td>
<td>Derivatize 1,2-dibromoethene in sample with silica-supported silver picrate column; analyze derivative</td>
<td>HPLC/ED</td>
<td>0.28 μg/L</td>
<td>No data</td>
<td>Colgan et al. 1986</td>
</tr>
<tr>
<td>Sample matrix</td>
<td>Preparation method</td>
<td>Analytical method</td>
<td>Sample detection limit</td>
<td>Percent recovery</td>
<td>Reference</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------------</td>
<td>-------------------</td>
<td>------------------------</td>
<td>-----------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Various foods (e.g., grains, grain-based foods, fruits, and beverages)</td>
<td>Ground sample in water (water-soluble foods or sulfuric acid (water-immiscible foods) and introduce in headspace analyzer</td>
<td>GC/MS</td>
<td>&lt;0.001 µg/g (water-soluble foods) 0.01-0.05 µg/g (lipid-containing foods)</td>
<td>901-100%</td>
<td>Entz and Hollifield 1982</td>
</tr>
<tr>
<td></td>
<td>Ground sample in water or sulfuric acid and introduce in headspace analyzer</td>
<td>GC/ECD</td>
<td>0.001 µg/g</td>
<td>701-82%</td>
<td>Pranoto-Soetardhi et al. 1986</td>
</tr>
<tr>
<td></td>
<td>Extract 1,2-dibromoethane from sample by steam distillation</td>
<td>GC/ECD</td>
<td>0.0005-0.1 µg/g</td>
<td>95.11-117%</td>
<td>Page et al. 1987; Van Rillaar and Beernaert 1985</td>
</tr>
<tr>
<td></td>
<td>Add isooctane and sodium chloride solution to sample and shake; extract with methanol and analyze</td>
<td>GC/ECD or HEDC</td>
<td>0.002 µg/g</td>
<td>62%</td>
<td>Daft 1988</td>
</tr>
<tr>
<td></td>
<td>Extract sample by soaking in acetone: water (5:1) and dry (calcium chloride)</td>
<td>GC/ECD</td>
<td>low ng/g levels</td>
<td>901-100%</td>
<td>Daft 1988</td>
</tr>
<tr>
<td></td>
<td>Purge-and-trap on adsorbent</td>
<td>GC/ECD or HEDC</td>
<td>0.0009 µg/g</td>
<td>821-99%</td>
<td>Heikes and Hopper 1986</td>
</tr>
<tr>
<td></td>
<td>Extract with acetone-water, or by triple hexane codistillation</td>
<td>GC/ECD</td>
<td>0.0004-0.005 µg/g</td>
<td>941-106%</td>
<td>Clover et al. 1985</td>
</tr>
</tbody>
</table>

ECD = electron capture detector; ED = electrochemical detector; FID = flame ionization detector; GC = gas chromatography; HEDC = Hall's electrolytic conductivity detector; HPLC = high performance liquid chromatography; MEC = molecular emission cavity analysis; MS = mass spectrometry; FID = photo-ionization detector
A highly sensitive and specific liquid chromatographic method for determining 1,2-dibromoethane in leaded gasoline has been developed by Colgan et al. (1986). The method involves the reaction between silver picrate adsorbed on silica gel and 1,2-dibromoethane to form 1-bromo-2-(picryloxy)ethane and/or 1,2-bis(picryloxy)ethane. The derivatives formed were analyzed by high-performance liquid chromatography (HPLC) equipped with an oxidative electrochemical detector (ED). A detection limit of 280 ppt of 1,2-dibromoethane was reported (Colgan et al. 1986).

6.3 ADEQUACY OF THE DATABASE

Section 104(i)(5) of CERCLA as amended directs the Administrator of ATSDR (in consultation with the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate information on the health effects of 1,2-dibromoethane is available. Where adequate information is not available, ATSDR, in conjunction with the NTP, is required to assure the initiation of a program of research designed to determine the health effects (and techniques for developing methods to determine such health effects) of 1,2-dibromoethane.

The following categories of possible data needs have been identified by a joint team of scientists from ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that, if met, would reduce or eliminate the uncertainties of human health assessment. In the future, the identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be proposed.

6.3.1 Data Needs

Methods for Determining Biomarkers of Exposure and Effect. GC, HPLC, and gold chloride calorimetry have been used for measuring low ppt levels of 1,2-dibromoethane and bromide ion. These techniques are sensitive for measuring background levels of 1,2-dibromoethane in the population (Letz et al. 1984). However, it is not known whether these techniques are sensitive for measuring levels of 1,2-dibromoethane at which health effects may begin to occur. Although analytical methods are available to detect exposures to 1,2-dibromoethane, it is difficult to monitor for exposure to 1,2-dibromoethane in humans. This is because 1,2-dibromoethane is volatile and has a short half-life in biological materials (Plotnick et al. 1979; Windholz 1983). Monitoring for bromide ion in biological media is also problematic in that the presence of this metabolite may result from the metabolism of other brominated hydrocarbons (see Chapter 2). Furthermore, information on the precision and accuracy of the gas chromatographic technique would be useful for interpreting monitoring data in biological tissues and fluids.
Biochemical assays have been employed to measure changes in enzyme levels (e.g., aspartate aminotransferase, lactic dehydrogenase) as an indication of exposure to 1,2-dibromoethane in humans and animals (Albano et al. 1984; Botti et al. 1989; Letz et al. 1984; Van Iersel et al. 1988). Decreased sperm counts per ejaculate and increased numbers of sperm with abnormal morphology have also been identified in workers following exposure to 1,2-dibromoethane (Ratcliffe et al. 1987; Wyrobek 1984). In general, these techniques are nonspecific for 1,2-dibromoethane exposure (see Chapter 2). There are no data to indicate whether a biomarker, if available, would be preferred over chemical analysis for monitoring exposure to 1,2-dibromoethane.

Methods for Determining Parent Compounds and Degradation Products in Environmental Media. GC equipped with either ECD, HECD, or MS and HPLC/ED are the analytical techniques used for measuring low levels of 1,2-dibromoethane in air, water, waste water, soil, leaded gasoline, and foodstuffs (Colgan et al. 1986; Daft 1988; EPA 1987b; Marti et al. 1984; Michael et al. 1988; NIOSH 1987; Sawhney et al. 1988; Simmonds 1984). The media of most concern for potential human exposure to 1,2-dibromoethane are drinking water, air, and foodstuffs. Gas chromatographic techniques are sensitive for measuring background levels of 1,2-dibromoethane in these media and levels of 1,2-dibromoethane at which health effects might begin to occur. GC/ECD is the technique (method 8011) recommended by EPA for measuring ppt levels of 1,2-dibromoethane in water (EPA 1987b). NIOSH has also recommended GC/ECD as the method (method 1008) for measuring low-ppm to sub-ppb levels of 1,2-dibromoethane in air (NIOSH 1987). GC/HECD or ECD has been employed for detecting 1,2-dibromoethane in various foodstuffs at low- to sub-ppb levels. No additional analytical methods for measuring 1,2-dibromoethane in environmental media appear to be necessary at this time.

6.3.2 On-going Studies

The Environmental Health Laboratory Sciences Division of the National Center for Environmental Health and Injury Control, Centers for Disease Control, is developing methods for the analysis of 1,2-dibromoethane and other volatile organic compounds in blood. These methods use high resolution gas chromatography and magnetic sector mass spectrometry which gives detection limits in the low parts-per-trillion range.
7. REGULATIONS AND ADVISORIES

1,2-Dibromoethane is on the list of chemicals appearing in "Toxic Chemicals Subject to Section 313 of the Emergency Planning and Community Right-to-Know Act of 1986" (EPA 1987f).

The international, national, and state regulations and guidelines regarding 1,2-dibromoethane in air, water, and other media are summarized in Table 7-1.
7. REGULATIONS AND ADVISORIES

<table>
<thead>
<tr>
<th>Agency</th>
<th>Description</th>
<th>Information</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INTERNATIONAL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IARC</td>
<td>Carcinogenic classification</td>
<td>Group 2A*</td>
<td>IARC 1987</td>
</tr>
<tr>
<td><strong>NATIONAL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regulations:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Air:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSHA (Transitional Values)</td>
<td>PEL TWA (8 hr)</td>
<td>20 ppm</td>
<td>OSHA 1974 (29 CFR 1910.1000)</td>
</tr>
<tr>
<td></td>
<td>Ceiling level (CL)</td>
<td>30 ppm</td>
<td>OSHA 1974 (29 CFR 1910.1000)</td>
</tr>
<tr>
<td></td>
<td>Acceptable maximum peak above CL (5 min for 8 hr shift)</td>
<td>50 ppm</td>
<td>OSHA 1974 (29 CFR 1910.1000)</td>
</tr>
<tr>
<td></td>
<td>STEL (15 min)</td>
<td>0.5 ppm</td>
<td>EPA 1987a</td>
</tr>
<tr>
<td>b. Water:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPA OSW</td>
<td>Monitoring for organic chemicals: Groundwater monitoring requirement for EDB if the state determines they are vulnerable to EDB contamination</td>
<td>Yes</td>
<td>EPA 1987a (40 CFR 141.40)</td>
</tr>
<tr>
<td></td>
<td>NPDES permit application requirements: Toxic pollutants and hazardous substances to be identified by existing discharges if expected to be present</td>
<td>Yes</td>
<td>EPA 1983 (40 CFR 122, Appendix D)</td>
</tr>
<tr>
<td>c. Other:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DOT</td>
<td>Label</td>
<td>Poison</td>
<td>DOT 1980 (49 CFR 172.102)</td>
</tr>
<tr>
<td>EPA OERR</td>
<td>CERCLA reportable quantity</td>
<td>1000 lbs (454 kg)</td>
<td>EPA 1986 (40 CFR 117.31)</td>
</tr>
<tr>
<td>EPA OPP</td>
<td>Decision and emergency order suspending registrations of pesticide products containing 1,2-dibromoethane for use as a grain and spot milling fumigant</td>
<td></td>
<td>EPA 1984b</td>
</tr>
<tr>
<td>EPA OSW</td>
<td>Designation of hazardous substances</td>
<td>Yes</td>
<td>EPA 1978 (40 CFR 116.4)</td>
</tr>
<tr>
<td></td>
<td>Listing as toxic waste from specific sources: Wastewater from the reactor vent gas scrubber in the production of EDB via bromination of ethane; spent adsorbent solids and still bottoms from purification of EDB in its production via bromination of ethane</td>
<td>Yes</td>
<td>EPA 1981b (40 CFR 261.32)</td>
</tr>
<tr>
<td>EPA OSW</td>
<td>Listing as toxic waste: Discarded commercial chemical products off-specifications species container residues, and spill residues thereof</td>
<td>Yes</td>
<td>EPA 1988a</td>
</tr>
<tr>
<td></td>
<td>Listing as hazardous waste constituent</td>
<td>Yes</td>
<td>EPA 1988b (40 CFR 261, Appendix VIII)</td>
</tr>
<tr>
<td></td>
<td>Groundwater monitoring list</td>
<td>Yes</td>
<td>EPA 1987a (40 CFR 264, Appendix IX)</td>
</tr>
</tbody>
</table>
7. REGULATIONS AND ADVISORIES

### TABLE 7-1 (Continued)

<table>
<thead>
<tr>
<th>Agency</th>
<th>Description</th>
<th>Information</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NATIONAL</strong> (Cont.)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPA OTS</td>
<td>Toxic chemical release reporting; Community right-to-know (proposed)</td>
<td>Yes</td>
<td>EPA 1987f</td>
</tr>
<tr>
<td>OSHA</td>
<td>Meets criteria for OSHA medical records rules</td>
<td>Yes</td>
<td>OSHA 1980 (29 CFR 1910.20)</td>
</tr>
<tr>
<td>RCRA</td>
<td>Handling and record/reportkeeping requirements--limit</td>
<td>1000 kg</td>
<td>CESARS 1989</td>
</tr>
<tr>
<td>USDA</td>
<td>Removal of provisions that mangoes be treated with EDB before entry into the United States</td>
<td>Yes</td>
<td>USDA 1988</td>
</tr>
</tbody>
</table>

**Guidelines:**

- **a. Air:**
  - ACGIH
    - Carcinogenicity: \( A_2^b \)
    - Skin designation: Yes
  - NIOSH
    - REL TWA (8-hr): 0.045 ppm
    - CL (15-min): 0.13 ppm (1.0 mg/m³)
    - Designated as NIOSH occupational carcinogen: Yes

- **b. Water:**
  - EPA ODW
    - Health Advisories:
      - 1-day: 8.0 μg/L
      - 10-day: 8.0 μg/L

- **c. Other:**
  - EPA
    - Carcinogen classification: \( B_2^c \)
    - Unit risk (air): \( 2.2 \times 10^{-4} \) μg/m³
    - Unit risk (water): \( 2.5 \times 10^{-3} \) μg/L
    - Oral cancer potency factor: 85 mg/kg/day

**STATE**

- **Regulations and Guidelines:**
  - **a. Air:**
    - Acceptable ambient air concentrations (μg/m³)
      - Connecticut: 8-hr 755
      - Indiana: 8-hr 720
      - North Carolina: 24-hr 1.90
      - Pennsylvania (Philadelphia): 1-yr 2.47
      - Virginia: 24-hr 1500

    - Point source emissions limits for BACT: No data
      - North Dakota
      - Wisconsin
        - 250.0 lbs/yr

      - Rydell 1990
        - State of Wisconsin Department of Natural Resources 1988a
### 7. REGULATIONS AND ADVISORIES

#### TABLE 7-1 (Continued)

<table>
<thead>
<tr>
<th>Agency</th>
<th>Description</th>
<th>Information</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>STATE (Cont.)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Water:</td>
<td>Drinking water quality standards and guidelines (μg/L)</td>
<td></td>
<td>FSTRAC 1988</td>
</tr>
<tr>
<td>Arizona</td>
<td>0.010</td>
<td></td>
<td></td>
</tr>
<tr>
<td>California</td>
<td>0.02</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Connecticut</td>
<td>0.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kansas</td>
<td>0.005</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Massachusetts</td>
<td>0.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maine</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minnesota</td>
<td>0.008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td>0.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Washington</td>
<td>0.02</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vermont</td>
<td>0.01</td>
<td></td>
<td>State of Vermont Agency of Natural Resources</td>
</tr>
<tr>
<td>Wisconsin</td>
<td>Public health groundwater quality standards (μg/L)</td>
<td>0.5</td>
<td>State of Wisconsin Department of Natural Resources</td>
</tr>
<tr>
<td>Wisconsin</td>
<td>Enforcement standard</td>
<td>0.010</td>
<td>Natural Resources 1988b</td>
</tr>
<tr>
<td>Wisconsin</td>
<td>Preventive action limit</td>
<td>0.001</td>
<td></td>
</tr>
</tbody>
</table>

*Group 2A: Inadequate evidence of carcinogenicity in humans; sufficient evidence in animals

*A2: Suspected human carcinogen

*B2: Probable human carcinogen

ACGIH = American Conference of Governmental Industrial Hygienists; BACT = Best Available Control Technology; CERCLA = Comprehensive Environmental Response, Compensation, and Liability Act; CL = Ceiling Level; DOT = Department of Transportation; EDB = 1,2-Dibromoethane; EPA = Environmental Protection Agency; NIOSH = National Institute for Occupational Safety and Health; NPDES = National Pollutant Discharge Elimination System; ODW = Office of Drinking Water; OERR = Office of Emergency and Remedial Response; OPP = Office of Pesticide Programs; OSHA = Occupational Safety and Health Administration; OSW = Office of Solid Wastes; OTS = Office of Toxic Substances; OWRS = Office of Water Regulations and Standards; PEL = Permissible Exposure Limit; RCRA = Resource Conservation Recovery Act; REL = Recommended Exposure Limit; TWA = Time-Weighted Average; USDA = United States Department of Agriculture.
8. REFERENCES


* Cited in text


8. REFERENCES


8. REFERENCES


Clark AI, McIntyre AE, Perry R, et al. 1984. Monitoring and assessment of ambient atmospheric concentrations of aromatic and halogenated hydrocarbons at urban, rural, and motorway locations. Environmental Pollution (Series B) 7:141-158.


8. REFERENCES


8. REFERENCES


8. REFERENCES


*EPA. 1987f. US Environmental Protection Agency. Federal Register 52:21152


8. REFERENCES


8. REFERENCES


8. REFERENCES


8. REFERENCES


IARC. 1977. Ethylene dibromide. IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: Some fumigants, the herbicides 2,4-D and 2,4,5-T, chlorinated dibenzodioxins and miscellaneous industrial chemicals, Vol. 15. International Agency for Research on Cancer., 195-209.


8. REFERENCES


8. REFERENCES


*Kochmann VM. 1928. [Possible industrial poisonings with ethylene dibromide]. Munchener Medizinische Wochenschrift 75:1334-1336. (German).

8. REFERENCES


8. REFERENCES


8. REFERENCES


McKenry MV. 1974. The behavior of pesticides containing 1,3-dichloropropene and 1,2-dibromoethene in soils. Diss Abstr Int 34:3034B.


8. REFERENCES


8. REFERENCES


NIOSH. 1978. NIOSH Current intelligence bulletin reprints; Bulletins 1 through 18. US National Institute for Occupational Safety and Health,. Cincinnati, OH: Surveillance Hazard Evaluations, and Field Studies, NIOSH. PB83-105080


8. REFERENCES


8. REFERENCES


*Pfleesser G. 1938. [Skin-damaging effect of ethylene dibromide, a constituent of the liquid from remote water gauges]. Archiv fuer Gewerbepathologie und Gewerbehygiene 8:591-600. (German).


8. REFERENCES


8. REFERENCES


*Rydell, CD. 1990. Written communication (March 27) to Barry L. Johnson. Agency for Toxic Substances and Disease Registry, regarding North Dakota Air Contaminant Limits. North Dakota State Department of Health and Consolidated Laboratories, Bismarck, ND.


8. REFERENCES


8. REFERENCES


8. REFERENCES


8. REFERENCES


8. REFERENCES

Tokoro R, Osteryoung J. 1982. [Study of the reduction mechanism of 1,2-dibromothane by reverse pulse polarography]. An Sim Bras Eletroquim Eletroanal 1:307-316. (Spanish)


8. REFERENCES


REFERENCES


8. REFERENCES


9. GLOSSARY

**Acute Exposure** -- Exposure to a chemical for a duration of 14 days or less, as specified in the Toxicological Profiles.

**Adsorption Coefficient (K_{oc})** -- The ratio of the amount of a chemical adsorbed per unit weight of organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.

**Adsorption Ratio (K_{d})** -- The amount of a chemical adsorbed by a sediment or soil (i.e., the solid phase) divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or sediment.

**Bioconcentration Factor (BCF)** -- The quotient of the concentration of a chemical in aquatic organisms at a specific time or during a discrete time period of exposure divided by the concentration in the surrounding water at the same time or during the same period.

**Cancer Effect Level (CEL)** -- The lowest dose of chemical in a study, or group of studies, that produces significant increases in the incidence of cancer (or tumors) between the exposed population and its appropriate control.

**Carcinogen** -- A chemical capable of inducing cancer.

**Ceiling Value** -- A concentration of a substance that should not be exceeded, even instantaneously.

**Chronic Exposure** -- Exposure to a chemical for 365 days or more, as specified in the Toxicological Profiles.

**Developmental Toxicity** -- The occurrence of adverse effects on the developing organism that may result from exposure to a chemical prior to conception (either parent), during prenatal development, or postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point in the life span of the organism.

**Embryotoxicity and Fetotoxicity** -- Any toxic effect on the conceptus as a result of prenatal exposure to a chemical; the distinguishing feature between the two terms is the stage of development during which the insult occurred. The terms, as used here, include malformations and variations, altered growth, and in utero death.

**EPA Health Advisory** -- An estimate of acceptable drinking water levels for a chemical substance based on health effects information. A health advisory is not a legally enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
**Immediately Dangerous to Life or Health (IDLH)** -- The maximum environmental concentration of a contaminant from which one could escape within 30 min without any escape-impairing symptoms or irreversible health effects.

**Intermediate Exposure** -- Exposure to a chemical for a duration of 15-364 days, as specified in the Toxicological Profiles.

**Immunologic Toxicity** -- The occurrence of adverse effects on the immune system that may result from exposure to environmental agents such as chemicals.

**In Vitro** -- Isolated from the living organism and artificially maintained, as in a test tube.

**In Vivo** -- Occurring within the living organism.

**Lethal Concentration (le) (LC_{le})** -- The lowest concentration of a chemical in air which has been reported to have caused death in humans or animals.

**Lethal Concentration (se) (LC_{se})** -- A calculated concentration of a chemical in air to which exposure for a specific length of time is expected to cause death in 50% of a defined experimental animal population.

**Lethal Dose (le) (LD_{le})** -- The lowest dose of a chemical introduced by a route other than inhalation that is expected to have caused death in humans or animals.

**Lethal Dose (se) (LD_{se})** -- The dose of a chemical which has been calculated to cause death in 50% of a defined experimental animal population.

**Lethal Time (se) (LT_{se})** -- A calculated period of time within which a specific concentration of a chemical is expected to cause death in 50% of a defined experimental animal population.

**Lowest-Observed-Adverse-Effect Level (LOAEL)** -- The lowest dose of chemical in a study, or group of studies, that produces statistically or biologically significant increases in frequency or severity of adverse effects between the exposed population and its appropriate control.

**Malformations** -- Permanent structural changes that may adversely affect survival, development, or function.

**Minimal Risk Level** -- An estimate of daily human exposure to a chemical that is likely to be without an appreciable risk of deleterious effects (noncancerous) over a specified duration of exposure.
9. GLOSSARY

Mutagen -- A substance that causes mutations. A mutation is a change in the genetic material in a body cell. Mutations can lead to birth defects, miscarriages, or cancer.

Neurotoxicity -- The occurrence of adverse effects on the nervous system following exposure to chemical.

No-Observed-Adverse-Effect Level (NOAEL) -- The dose of chemical at which there were no statistically or biologically significant increases in frequency or severity of adverse effects seen between the exposed population and its appropriate control. Effects may be produced at this dose, but they are not considered to be adverse.

Octanol-Water Partition Coefficient (K<sub>ow</sub>) -- The equilibrium ratio of the concentrations of a chemical in n-octanol and water, in dilute solution.

Permissible Exposure Limit (PEL) -- An allowable exposure level in workplace air averaged over an 8-hour shift.

q1* -- The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the multistage procedure. The q1* can be used to calculate an estimate of carcinogenic potency, the incremental excess cancer risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and pg/m³ for air).

Reference Dose (RFD) -- An estimate (with uncertainty spanning perhaps an order of magnitude) of the daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious effects during a lifetime. The RFD is operationally derived from the NOAEL (from animal and human studies) by a consistent application of uncertainty factors that reflect various types of data used to estimate RfDs and an additional modifying factor, which is based on a professional judgment of the entire database on the chemical. The RfDs are not applicable to nonthreshold effects such as cancer.

Reportable Quantity (RQ) -- The quantity of a hazardous substance that is considered reportable under CERCLA. Reportable quantities are (1) 1 lb or greater or (2) for selected substances, an amount established by regulation either under CERCLA or under Sect. 311 of the Clean Water Act. Quantities are measured over a 24-hour period.

Reproductive Toxicity -- The occurrence of adverse effects on the reproductive system that may result from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related endocrine system. The manifestation of such toxicity may be noted as alterations in sexual behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of this system.
9. GLOSSARY

**Short-Term Exposure Limit (STEL)** -- The maximum concentration to which workers can be exposed for up to 15 min continually. No more than four excursions are allowed per day, and there must be at least 60 min between exposure periods. The daily TLV-TWA may not be exceeded.

**Target Organ Toxicity** -- This term covers a broad range of adverse effects on target organs or physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited exposure to those assumed over a lifetime of exposure to a chemical.

**Teratogen** -- A chemical that causes structural defects that affect the development of an organism.

**Threshold Limit Value (TLV)** -- A concentration of a substance to which most workers can be exposed without adverse effect. The TLV may be expressed as a TWA, as a STEL, or as a CL.

**Time-Weighted Average (TWA)** -- An allowable exposure concentration averaged over a normal 8-hour workday or 40-hour workweek.

**Toxic Dose (TD50)** -- A calculated dose of a chemical, introduced by a route other than inhalation, which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.

**Uncertainty Factor (UF)** -- A factor used in operationally deriving the RfD from experimental data. UFs are intended to account for (1) the variation in sensitivity among the members of the human population, (2) the uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using LOAEL data rather than NOAEL data. Usually each of these factors is set equal to 10.
Chapter 1

Public Health Statement

This chapter of the profile is a health effects summary written in nontechnical language. Its intended audience is the general public especially people living in the vicinity of a hazardous waste site or substance release. If the Public Health Statement were removed from the rest of the document, it would still communicate to the lay public essential information about the substance.

The major headings in the Public Health Statement are useful to find specific topics of concern. The topics are written in a question and answer format. The answer to each question includes a sentence that will direct the reader to chapters in the profile that will provide more information on the given topic.

Chapter 2

Tables and Figures for Levels of Significant Exposure (LSE)

Tables (2-1, 2-2, and 2-3) and figures (2-1 and 2-2) are used to summarize health effects by duration of exposure and endpoint and to illustrate graphically levels of exposure associated with those effects. All entries in these tables and figures represent studies that 'provide reliable, quantitative estimates of No-Observed-Adverse-Effect Levels (NOAELs), Lowest-Observed-Adverse-Effect Levels (LOAELs) for Less Serious and Serious health effects, or Cancer Effect Levels (CELS). In addition, these tables and figures illustrate differences in response by species, Minimal Risk Levels (MRLs) to humans for noncancer end points, and EPA's estimated range associated with an upper-bound individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. The LSE tables and figures can be used for a quick review of the health effects and to locate data for a specific exposure scenario. The LSE tables and figures should always be used in conjunction with the text. The legends presented below demonstrate the application of these tables and figures. A representative example of LSE Table 2-1 and Figure 2-1 are shown. The numbers in the left column of the legends correspond to the numbers in the example table and figure.

LEGEND

See LSE Table 2-1

(1). Route of Exposure One of the first considerations when reviewing the toxicity of a substance using these tables and figures should be the relevant and appropriate route of exposure. When sufficient data exist,
three LSE tables and two LSE figures are presented in the document. The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE Table 2-1, 2-2, and 2-3, respectively). LSE figures are limited to the inhalation (LSE Figure 2-1) and oral (LSE Figure 2-2) routes.

(2). Exposure Duration Three exposure periods: acute (14 days or less); intermediate (15 to 364 days); and chronic (365 days or more) are presented within each route of exposure. In this example, an inhalation study of intermediate duration exposure is reported.

(3). Health Effect The major categories of health effects included in LSE tables and figures are death, systemic, immunological, neurological, developmental, reproductive, and cancer. NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. Systemic effects are further defined in the "System" column of the LSE table.

(4). Key to Figure Each key number in the LSE table links study information to one or more data points using the same key number in the corresponding LSE figure. In this example, the study represented by key number 18 has been used to define a NOAEL and a Less Serious LOAEL (also see the two "181:" data points in Figure 2-1).

(5). Species The test species, whether animal or human, are identified in this column.

(6). Exposure Frequency/Duration The duration of the study and the weekly and daily exposure regimen are provided in this column. This permits comparison of NOAELs and LOAELs from different studies. In this case (key number 18), rats were exposed to [substance x] via inhalation for 13 weeks, 5 days per week, for 6 hours per day.

(7). System This column further defines the systemic effects. These systems include: respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems. In the example of key number 18, one systemic effect (respiratory) was investigated in this study.

(8). NOAEL A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure level at which no harmful effects were seen in the organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system which was used to derive an intermediate exposure, inhalation MKL of 0.005 ppm (see footnote "c").

(9). LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the Lowest exposure level used in the study that caused a harmful health effect. LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help readers identify the levels of exposure at which adverse health effects first appear and the gradation of effects with increasing dose. A brief description of the specific end point used to
quantify the adverse effect accompanies the LOAEL. The "Less Serious" respiratory effect reported in key number 18 (hyperplasia) occurred at a LOAEL of 10 ppm.

(10). **Reference** The complete reference citation is given in Chapter 8 of the profile.

(11). **CEL** A Cancer Effect Level (CEL) is the lowest exposure level associated with the onset of carcinogenesis in experimental or epidemiological studies. CELs are always considered serious effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report doses which did not cause a measurable increase in cancer.

(12). **Footnotes** Explanations of abbreviations or reference notes for data in the LSE tables are found in the footnotes. Footnote "c" indicates the NOAEL of 3 ppm in key number 18 was used to derive an MRL of 0.005 ppm.

**LEGEND**

**See LSE Figure 2-1**

LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the reader quickly compare health effects according to exposure levels for particular exposure duration.

(13). **Exposure Duration** The same exposure periods appear as in the LSE table. In this example, health effects observed within the intermediate and chronic exposure periods are illustrated.

(14). **Health Effect** These are the categories of health effects for which reliable quantitative data exist. The same health effects appear in the LSE table.

(15). **Levels of Exposure** Exposure levels for each health effect in the LSE tables are graphically displayed in the LSE figures. Exposure levels are reported on the log scale "y" axis. Inhalation exposure is reported in mg/m$^3$ or ppm and oral exposure is reported in mg/kg/day.

(16). **NOAEL** In this example, 18r NOAEL is the critical end point for which an intermediate inhalation exposure MRL is based. As you can see from the LSE figure key, the open-circle symbol indicates a NOAEL for the test species (rat). The key number 18 corresponds to the entry in the LSE table. The dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see entry 18 in the Table) to the MRL of 0.005 ppm (see footnote "b" in the LSE table).

(17). **CEL** Key number 38r is one of three studies for which Cancer Effect Levels (CELs) were derived. The diamond symbol refers to a CEL for the test species (rat). The number 38 corresponds to the entry in the LSE table.
(18). **Estimated Upper-Bound Human Cancer Risk Levels** This is the range associated with the upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived from EPA's Human Health Assessment Group's upper-bound estimates of the slope of the cancer dose response curve at low dose levels (q_l\(^*\)).

(19). **Key to LSE Figure** The Key explains the abbreviations and symbols used in the figure.
# TABLE 2-1. Levels of Significant Exposure to [Chemical X] - Inhalation

## Key to figure:
- **Species**
- **Exposure frequency/duration**
- **System**
- **NOAEL (ppm)**
- **LOAEL (effect)**

<table>
<thead>
<tr>
<th>Key to figure</th>
<th>Species</th>
<th>Exposure frequency/duration</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL (effect)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>INTERMEDIATE EXPOSURE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Systemic</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
</tr>
<tr>
<td>4</td>
<td>18 Rat</td>
<td>13 wk</td>
<td>Resp</td>
<td>3(^b)</td>
<td>10 (hyperplasia)</td>
<td>Nitschke et al. 1981</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5d/wk</td>
<td>6hr/d</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## CHRONIC EXPOSURE

<table>
<thead>
<tr>
<th>Key to figure</th>
<th>Species</th>
<th>Exposure frequency/duration</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL (effect)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>Cancer</td>
<td>38 Rat</td>
<td>18 mo</td>
<td></td>
<td>20 (CEL, multiple organs)</td>
<td>Wong et al. 1982</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5d/wk</td>
<td>7hr/d</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Rat</td>
<td>89-104 wk</td>
<td>5d/wk</td>
<td>6hr/d</td>
<td>10 (CEL, lung tumors, nasal tumors)</td>
<td>NTP 1982</td>
</tr>
<tr>
<td>40</td>
<td>Mouse</td>
<td>79-103 wk</td>
<td>5d/wk</td>
<td>6hr/d</td>
<td>10 (CEL, lung tumors, hemangiosarcomas)</td>
<td>NTP 1982</td>
</tr>
</tbody>
</table>

\(^a\) The number corresponds to entries in Figure 2-1.

\(^b\) Used to derive an intermediate inhalation Minimal Risk Level (MRL) of $5 \times 10^{-3}$ ppm; dose adjusted for intermittent exposure and divided by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).

CEL = cancer effect level; d = day(s); h = hour(s); LOAEL = lowest-observed-adverse-effect level; mo = month(s); NOAEL = no-observed-adverse-effect level; Resp = respiratory; wk = week(s)
FIGURE 2-1. Levels of Significant Exposure to [Chemical X]—Inhalation
Chapter 2 (Section 2.4)

Relevance to Public Health

The Relevance to Public Health section provides a health effects summary based on evaluations of existing toxicological, epidemiological, and toxicokinetic information. This summary is designed to present interpretive, weight-of-evidence discussions for human health end points by addressing the following questions.

1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous waste sites?

The section discusses health effects by end point. Human data are presented first, then animal data. Both are organized by route of exposure (inhalation, oral, and dermal) and by duration (acute, intermediate, and chronic). In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered in this section. If data are located in the scientific literature, a table of genotoxicity information is included.

The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer potency or perform cancer risk assessments. MRLs for noncancer end points if derived, and the end points from which they were derived are indicated and discussed in the appropriate section(s).

Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public health are identified in the Identification of Data Needs section.

Interpretation of Minimal Risk Levels

Where sufficient toxicologic information was available, MRLs were derived. MRLs are specific for route (inhalation or oral) and duration (acute, intermediate, or chronic) of exposure. Ideally, MRLs can be derived from all six exposure scenarios (e.g., Inhalation – acute, -intermediate, -chronic; Oral – acute, -intermediate, - chronic). These MRLs are not meant to support regulatory action, but to acquaint health professionals with exposure levels at which adverse health effects are not expected to occur in humans. They should help physicians and public health officials determine the safety of a community living near a substance emission, given the concentration of a contaminant in air or the estimated daily dose received via food or water, MRLs are based largely on toxicological studies in animals and on reports of human occupational exposure.
MRL users should be familiar with the toxicological information on which the number is based. Section 2.4, "Relevance to Public Health," contains basic information known about the substance. Other sections such as 2.6, "Interactions with Other Chemicals" and 2.7, "Populations that are Unusually Susceptible" provide important supplemental information.

MRL users should also understand the MRL derivation methodology. MRLs are derived using a modified version of the risk assessment methodology used by the Environmental Protection Agency (EPA) (Barnes and Dourson, 1988; EPA 1989a) to derive reference doses (RfDs) for lifetime exposure.

To derive an MRL, ATSDR generally selects the end point which, in its best judgement, represents the most sensitive human health effect for a given exposure route and duration. ATSDR cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available for all potential effects (e.g., systemic, neurological, and developmental). In order to compare NOAELs and LOAELs for specific end points, all inhalation exposure levels are adjusted for 24hr exposures and all intermittent exposures for inhalation and oral routes of intermediate and chronic duration are adjusted for continuous exposure (i.e., 7 days/week). If the information and reliable quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive species (when information from multiple species is available) with the highest NOAEL that does not exceed any adverse effect levels. The NOAEL is the most suitable end point for deriving an MRL. When a NOAEL is not available, a Less Serious LOAEL can be used to derive an MRL, and an uncertainty factor (UF) of 10 is employed. MRLs are not derived from Serious LOAELs. Additional uncertainty factors of 10 each are used for human variability to protect sensitive subpopulations (people who are most susceptible to the health effects caused by the substance) and for interspecies variability (extrapolation from animals to humans). In deriving an MRL, these individual uncertainty factors are multiplied together. The product is then divided into the adjusted inhalation concentration or oral dosage selected from the study. Uncertainty factors used in developing a substance-specific MRL are provided in the footnotes of the LSE Tables.
APPENDIX B
ACRONYMS, ABBREVIATIONS, AND SYMBOLS

ACGIH Conference of Governmental Industrial Hygienists
ADME Absorption, Distribution, Metabolism, and Excretion
ATSDR Agency for Toxic Substances and Disease Registry
BCF bioconcentration factor
BSC Board of Scientific Counselors
CDC Centers for Disease Control
CEL Cancer Effect Level
CERCLA Comprehensive Environmental Response, Compensation, and Liability
CFR Code of Federal Regulations
CLP Contract Laboratory Program
cm centimeter
CNS central nervous system
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DOL Department of Labor
ECG electrocardiogram
EPA Environmental Protection Agency
EKG electroencephalogram
FEMA Federal Emergency Management Agency
FAO Food and Agricultural Organization of the United Nations
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
f1 first generation
ft feet per minute
fr foot
GC Federal Register
HPLC gram
hr gas chromatography
IDLH High performance liquid chromatography
IARC hour
ILO Immediately Dangerous to Life and Health
In International Agency for Research on Cancer
Kd International Labor Organization
kg inch
Koc adsorption ratio
Kow kilogram
L octanol-soil partition coefficient
LC octanol-water partition coefficient
LC50 liquid chromatography
LD50 lethal concentration low
LD50 lethal concentration 50 percent kill
LD10 lethal dose low
American lethal dose 50 percent kill
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>lowest-observed-adverse-effect level</td>
</tr>
<tr>
<td>LSE</td>
<td>Levels of Significant Exposure</td>
</tr>
<tr>
<td>m</td>
<td>meter</td>
</tr>
<tr>
<td>mg</td>
<td>milligram</td>
</tr>
<tr>
<td>min</td>
<td>minute</td>
</tr>
<tr>
<td>mL</td>
<td>milliliter</td>
</tr>
<tr>
<td>mm</td>
<td>millimeters</td>
</tr>
<tr>
<td>mmol</td>
<td>millimole</td>
</tr>
<tr>
<td>mppcf</td>
<td>millions of particles per cubic foot</td>
</tr>
<tr>
<td>MRL</td>
<td>minimal risk level</td>
</tr>
<tr>
<td>MS</td>
<td>mass spectroscopy</td>
</tr>
<tr>
<td>NIEHS</td>
<td>National Institute of Environmental Health Sciences</td>
</tr>
<tr>
<td>NIOSH</td>
<td>National Institute for Occupational Safety and Health</td>
</tr>
<tr>
<td>NIOSHTIC</td>
<td>NIOSH's Computerized Information Retrieval System</td>
</tr>
<tr>
<td>nm</td>
<td>nanometer</td>
</tr>
<tr>
<td>ng</td>
<td>nanogram</td>
</tr>
<tr>
<td>NHANES</td>
<td>National Health and Nutrition Examination Survey</td>
</tr>
<tr>
<td>nmol</td>
<td>nanomole</td>
</tr>
<tr>
<td>NOAEL</td>
<td>no-observed-adverse-effect level</td>
</tr>
<tr>
<td>NOES</td>
<td>National Occupational Exposure Survey</td>
</tr>
<tr>
<td>NOHS</td>
<td>National Occupational Hazard Survey</td>
</tr>
<tr>
<td>NPL</td>
<td>National Priorities List</td>
</tr>
<tr>
<td>NRC</td>
<td>National Research Council</td>
</tr>
<tr>
<td>NTIS</td>
<td>National Technical Information Service</td>
</tr>
<tr>
<td>NTP</td>
<td>National Toxicology Program</td>
</tr>
<tr>
<td>OSHA</td>
<td>Occupational Safety and Health Administration</td>
</tr>
<tr>
<td>PEL</td>
<td>permissible exposure limit</td>
</tr>
<tr>
<td>pg</td>
<td>picogram</td>
</tr>
<tr>
<td>pmol</td>
<td>picomole</td>
</tr>
<tr>
<td>PHS</td>
<td>Public Health Service</td>
</tr>
<tr>
<td>PMR</td>
<td>proportional mortality ratio</td>
</tr>
<tr>
<td>ppb</td>
<td>parts per billion</td>
</tr>
<tr>
<td>ppm</td>
<td>parts per million</td>
</tr>
<tr>
<td>ppt</td>
<td>parts per trillion</td>
</tr>
<tr>
<td>REL</td>
<td>recommended exposure limit</td>
</tr>
<tr>
<td>RfD</td>
<td>Reference Dose</td>
</tr>
<tr>
<td>RTECS</td>
<td>Registry of Toxic Effects of Chemical Substances</td>
</tr>
<tr>
<td>sec</td>
<td>second</td>
</tr>
<tr>
<td>SCE</td>
<td>sister chromatid exchange</td>
</tr>
<tr>
<td>SIC</td>
<td>Standard Industrial Classification</td>
</tr>
<tr>
<td>SMR</td>
<td>standard mortality ratio</td>
</tr>
<tr>
<td>STEL</td>
<td>short-term exposure limit</td>
</tr>
<tr>
<td>STORET</td>
<td>STORAGE and RETRIEVAL</td>
</tr>
<tr>
<td>TLV</td>
<td>threshold limit value</td>
</tr>
<tr>
<td>TSCA</td>
<td>Toxic Substances Control Act</td>
</tr>
<tr>
<td>TRI</td>
<td>Toxic Release Inventory</td>
</tr>
<tr>
<td>TWA</td>
<td>time-weighted average</td>
</tr>
<tr>
<td>U.S.</td>
<td>United States</td>
</tr>
</tbody>
</table>
APPENDIX B

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>UF</td>
<td>uncertainty factor</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>&gt;</td>
<td>greater than</td>
</tr>
<tr>
<td>≥</td>
<td>greater than or equal to</td>
</tr>
<tr>
<td>=</td>
<td>equal to</td>
</tr>
<tr>
<td>&lt;</td>
<td>less than</td>
</tr>
<tr>
<td>≤</td>
<td>less than or equal to</td>
</tr>
<tr>
<td>%</td>
<td>percent</td>
</tr>
<tr>
<td>α</td>
<td>alpha</td>
</tr>
<tr>
<td>β</td>
<td>beta</td>
</tr>
<tr>
<td>δ</td>
<td>delta</td>
</tr>
<tr>
<td>γ</td>
<td>gamma</td>
</tr>
<tr>
<td>µm</td>
<td>micron</td>
</tr>
<tr>
<td>µg</td>
<td>microgram</td>
</tr>
</tbody>
</table>
APPENDIX C

PEER REVIEW

A peer review panel was assembled for 1,2-dibromoethane. The panel consisted of the following members: Dr. Donald Hill, Southern Research Institute, Birmingham, Alabama; Dr. Herbert Rosenkrantz, Professor and Chairman of Department of Environmental Health Sciences, Case Western Reserve University, Cleveland, Ohio; and Dr. John Egle, Jr., Associate Professor of Pharmacology, Medical College of Virginia, Richmond, Virginia. These experts collectively have knowledge of 1,2-dibromoethane's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

A second peer review panel was assembled to review mitigation of effects (Section 2.8) for 1,2-dibromoethane. The panel consisted of the following members: Dr. Brent Burton, Medical Director, Oregon Poison Center, Oregon Health Sciences University, Portland, Oregon; Dr. Alan Hall, Private Consulting and Medical Translating Services, Evergreen, Colorado; and Dr. Alan Woolf, Director of Clinical Pharmacology, and Toxicology, Massachusetts Poison Control System, The Children's Hospital, Boston, Massachusetts. All reviewers were selected under the same conditions mentioned above.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.